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ABSTRACT
The main objectives of the work presented in this thesis were to develop an assay 
to subtype viruses circulating in Uganda and to study virological and 
immunological factors that might be important in HIV-1 vaccine development in 
East Africa.
Development of an antibody binding assay for serological subtyping revealed a 
complex pattern of cross-reactivity, and led to further investigation of these 
responses. Competitive inhibition and adsorption studies identified a spectrum of 
antibodies in the human antisera, possibly due to multiple immune responses to 
more than one viral epitope or to one inimunodorninant epitope. Neutralizing 
antibodies to specific V3 loop peptides were raised in rabbits; MN and U31 
peptides were good immunogens, but Ugandan consensus sequence peptides 
raised antisera with weak peptide reactivities. Antibody binding assay of partial 
V3 loop peptides indicated that most Ugandan antisera recognised an epitope(s) 
in the C-terminal region of the V3 loop, not at the apex.
Virus samples from the UVRI clinic and the Natural History cohort in rural SW 
Uganda were isolated and characterized. Comparison of primary isolates in 
PBMC cultures and cell adapted variants indicated that SI and NSI variants may 
be present within a primary isolation culture.
Neutralizing antibody titres were compared between cell line adapted viruses 
and primary isolates: Differences found led to the use of low passaged primary 
isolates for this investigation. Cross-clade neutralizing antibodies were present in 
most antisera, many with high neutralization titres (>640); suggesting a shared 
immunogenic epitope, which could be important in vaccine design. Analysis of
sequential serum samples revealed no decrease in neutralizing titres with time. 
One sequential virus isolate (3029), re-isolated after 2 years, was more resistant to 
neutralization by heterologous antisera. No correlation was established between 
antibody binding and neutralization by human or rabbit antisera.
Comparison of clinical data with neutralization data was inconclusive.
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1. INTRODUCTION
1.1 The Epidemic of AIDS
Human Immunodeficiency Virus Types 1 and 2 (HIV-1 and HIV-2) are the 
causative agents of Acquired Immune Deficiency Syndrome (AIDS). This 
syndrome was first recognised in 1981 in the United States of America when 
homosexual men presented with a variety of diseases, especially Kaposi's 
sarcoma and Pneumocystis carinii pneumonia which were attributed to a form of 
immunodeficiency (Center for Disease Control, 1981). At this time the life style 
of these predominantly young men was thought to be responsible for their 
immunodeficiency. However, by 1982 reports of AIDS were registered in other 
groups, including intravenous drug users and haemophiliacs (Center for 
Disease Control, 1982). In 1983 a similar syndrome was reported in African 
people living in Europe (Brunet et al., 1983) soon followed by the first reports of 
African AIDS in Rwanda and Zaire (Riot et al, 1984). This emerging pattern of 
disease launched the search for an infectious agent. Clinical examination of 
infected Americans revealed a reduced T helper lymphocyte level with 
increased suppressor T cells. In 1981 human T cell lymphotropic virus (HTLV-1) 
had been discovered by Gallo: this retrovirus, which causes adult T cell 
leukaemia, was the first virus shown to infect human T cells. Methods of T 
lymphocyte culture devised by Gallo and his colleagues were invaluable in the 
race that ensued to identify the causative agent of AIDS. In France, Barré- 
Sinoussi, Chermann and Montagnier discovered lymphadenopathy-associated 
virus (LAV) (Barre-Sinoussi et al, 1983) and in America, Gallo's team isolated a 
virus they designated human T cell lymphotropic virus III (HTLV-III) (Gallo et 
al, 1984). Both of these new retroviruses were isolated from AIDS patients' 
lymphoid tissue and were propagated on CD4+ immortalised T cell lines 
(Heymann et al, 1993). In 1986 it was agreed to rename these retroviruses HIV-1 
(Coffin, 1986; Coffin et al, 1986).
A second human immunodeficiency virus (HIV-2) was isolated by Clavel and 
colleagues in 1986 from two West ATrican AIDS patients who had repeatedly
tested negative for antibodies to HIV-1 by an enzyme-linked immunosorbent 
assay (ELISA) (Clavel et ah, 1986). Gel electrophoresis and RNA hybridization 
experiments revealed that this new retrovirus was similar to HIV-1, but was 
possibly even more closely related to a simian immunodeficiency virus, SIVmac, 
the etiological agent of simian AIDS in macaques. Differences between HIV-1 
and HIV-2 are highlighted by the fact that natural infection with one HIV type 
does not prevent infection with the other. Dual infections with HIV-1 and HIV-2 
are common on the Ivory Coast, a part of West Africa where both viruses are 
prevalent (George et al., 1992).
By the end of 1984, South Africa, Rwanda and the Central African Republic had 
reported cases of AIDS to the World Health Organization. At which time the 
global number of cases had reached 12,030. This figure doubled in 1985 with 
cases of AIDS reported to the WHO by 33 American and 20 European, 6 African 
and 9 Asian/Oceanian countries. By June 1988 this number had climbed to 
100,410 reported cases of AIDS in 138 countries, including 29 African nations 
(Red cross, 1988). AIDS is a truly international disease with incident reports of 
AIDS from nearly every country. To date the WHO estimates that there are 34 to 
46 million cases of HTV infection in the world, 14 million in Africa (UNAIDS 
and WHO, 2003).
In the USA there have been 1.2 million cases of HIV infection (UNAIDS and 
WHO, 2003). In 1992 AIDS became the leading cause of death in men aged 25 to 
44 years and the fourth leading cause of death in women in the same age group. 
In 1993 the number of AIDS cases among women increased by 151% and among 
men by 105% (Quinn, 1995). The incidence of HIV infection in women in the 
USA is still increasing. Heterosexual transmission accounted for 22% of all new 
cases of HIV infection diagnosed in 2001/2002 (UNAIDS and WHO, 2002a). 
Perinatal transmission is decreasing mainly due to maternal use of Zidovudine 
(UNAIDS and WHO, 2002a). Phylogenetic analysis of regions of the envelope 
glycoprotein of viruses from infected injecting drug users (IDU) and 
homosexual men in America and Northern Europe has revealed that HIV-1 
found in the European IDU group originated in the USA. The envelope amino
acid sequences of the European IDU viruses clustered with the American IDU 
viral sequences and not with the viral sequences of European homosexuals 
(Lukashov et ai, 1996).
In the European Union, a union of thirteen countries (Austria, Belgium, 
Denmark, France, Germany, Greece, Ireland, Italy, The Netherlands, Portugal, 
Spain, Sweden and the United Kingdom), there is estimated to be a total of 
520000 to 680000 HIV infected people (UNAIDS and WHO, 2003), with 30000 -  
40000 new cases in 2003 (UNAIDS and WHO, 2004). Among these HIV infected 
persons three main groups have emerged; 42% were injecting drug users, 25% 
were homosexual or bisexual men and 18% were heterosexually infected. 
Estimates of the incidence of AIDS in the European Union suggested an overall 
annual increase of 24%, with the largest increases in the heterosexually infected 
group (Downs et al, 1997).
In India a high level of HIV infection was first observed in prostitutes in Goa 
and in a STD clinic in Bombay where 38.5% of patients were found to be HIV 
seropositive. In both of these groups, 20% of the infected persons were reactive 
to both HIV-1 and HIV-2. Genetic analysis of the env gene of HIV-1 isolates from 
both Bombay and Goa showed them to be subtype C and closely related to the 
South African strain H IV -I nof (Dietrich et ah, 1993). By the end of 2002 between
3.8 and 4.6 million people in India were infected with HIV and in some areas 
HIV prevalence had reached 1% in pregnant women (UNAIDS and WHO,
2003).
In Thailand, the AIDS epidemic has exploded in two distinct groups; in the 
injecting drug users seroincidence increased at a rate of 3% to 5% per month 
with a seroprevalence in 1988 of 32-43% and seroprevalence among prostitutes 
was 5% in the Thai provinces and 44% in the northern Chiang Mai province 
(Pau et al, 1993). The pattern of HIV spread throughout Asia is predicted to 
follow that seen in India and Thailand with heterosexual transmission becoming 
the major route of infection (Quinn, 1995).
By 2002 the number of people with HIV/  AIDS in China was estimated to be 
820000. At this ecirly stage of the Chinese epidemic HIV transmission is mainly
in urban areas within the sex worker and injecting drug user populations 
(UNAIDS and WHO, 2002a and 2003). The World Health Organization 
estimate that there are already between 4.6 and 8.2 million HIV infected persons 
in South Asia (UNAIDS and WHO, 2003).
In the mid-1990s the number of reported cases of AIDS in Indonesia was 67, but 
this was thought to be due to the lack of an HIV surveillance program and the 
number of infected Indonesians was estimated at around 50000. Genetic analysis 
of the Indonesian viruses revealed that they were closely related to the Thai 
viruses of subtypes E and B (Porter et al, 1997). Since 1997 the HIV 
seroprevalence has increased sharply and by 2001 0.015% of blood donations 
were HIV positive (UNAIDS and WHO, 2002b). In 2000-2001 HIV 
seroprevalence of sex workers varied from 0% to 26.5% in different areas of 
Indonesia and the seroprevalence of IDUs was as high as 53% in Surabaya 
(UNAIDS and WHO, 2002c).
In Central and South America since 1985 the number of HIV infected persons 
has risen steadily from about 400000 to nearly 2 million cases: with 610000 
cases in Brazil and 150000 cases in Mexico (UNAIDS and WHO, 2002a). In Haiti 
the national HIV prevalence is 5.6%; 13% in the north west and 2% in the south. 
The Bahamas and Trinidad and Tobago have an HIV prevalence of 3% 
(UNAIDS and WHO, 2004b).
In Oceania the incidence is lower than in other areas of the world with 12000 to 
18000 AIDS cases (UNAIDS and WHO, 2003). Of these 12000 were in Australia, 
and by the end of lune 2000 719 AIDS cases and 1456 cases of HIV infection 
had been reported in New Zealand (UNAIDS and WHO, 2002a).
Appendix I shows the number of persons living with HIV infection or AIDS 
estimated by the World Health Organization at the end of 2003 (UNAIDS and 
WHO, 2003).
1.2 HIV-1 in sub-Saharan Africa
The emergence of AIDS in sub-Saharan Africa took a different pattern to that 
seen in America. A wasting disease, known locally as "slim disease", first 
appeared in East Africa in the Ugandan district of Rakai and since the first 
reports 19 years ago (Serwadda et ah, 1985) the epidemic in Uganda had 
escalated so that by 1995 at 46,000 Uganda had the highest number of reported 
AIDS patients of any African country (World Health Organization, 1995b). HIV- 
1 seroprevalence in adults reached 8.2% in the rural district of Masaka (Wagner 
et al., 1993) and in the capital city of Kampala, antenatal clinics recorded 
seroprevalence as high as 30-40% (Mulder, 1995). In south western Uganda, in 
the Rakai district (See Appendix II - Map of Uganda showing these areas) 8% of 
the people in agricultural villages were seropositive and in the main road 
trading centres up to 47% of women were infected with HIV-1 (Wawer et al., 
1991). Since the mid-1990s studies carried out in rural south western Uganda 
have indicated a decline in the overall seroprevalence of HIV-1 (Kamali et al., 
2000; Whitworth et al., 2002). In 2000 Kamali et al. reported a decline in 
seroprevalence from 8.2% to 6.9% over 7 years, but no corresponding decline in 
seroincidence (Kamali et al., 2000). In 2002 seroprevalence had continued to drop 
to 6.4% (Whitworth et al., 2002). From this rural cohort early indications are that 
the HIV-1 epidemic in Uganda may have at last reached a plateau. However the 
earlier pattern of escalating HIV infection in Uganda has been echoed in many 
sub-Saharan African nations since 1985 as outlined by the following 
seroprevalence studies.
In 1992 5000 new antenatal patients attending the Langata clinic in Nairobi, 
Kenya were screened for HIV-1 seroreactivity. HIV-1 seroprevalence was 13% in 
the group, suggesting a rapidly increasing annual incidence rate of 3 -  4% 
among pregnant women in Nairobi (Temmerman et al., 1992).
In 1987 HIV-1 and HIV-2 seroprevalence was investigated at a rural hospital in 
north western Tanzania. In order to avoid any bias 253 consecutive patients 
were examined and the total HIV seroprevalence was 4.4%. HIV-1 antigen or 
antibodies to HIV-1 were present in 3.6% of the study group, 0.8% had
antibodies to HIV-2 and 0.4% had antibodies to both. In the nearby town of 
Bukoba 16% of pregnant women and 13.9% of blood donors were found to be 
HIV-1 seropositive. Risk assessment was carried out and an association was 
established between HIV infection and a history of gonorrhoea. Contact with 
people from Rwanda and Uganda was also associated with an increased 
likelihood of HIV infection (Schmutzhard et ah, 1989). In 1989/90 Shao et al. 
carried out a population-based study of HIV-1 in 4086 subjects in northwest 
Tanzania. Four study groups were identified and seroprevalence were assessed; 
in the high risk group seroprevalence was 13%, in the urban group 8.8%, in the 
peri-urban group 6.5% and in the rural group 2.6% (Shao et al., 1994).
In 1988 500 consecutive patients attending a STD clinic in Addis Ababa were 
tested for FIIV-l antibodies: 12% of these patients were found to be HIV-1 
seropositive. The seroprevalence of this group of patients did not reflect that of 
the general population of Ethiopia, because they were attending a STD clinic. It 
did however show that HIV-1 infection may be associated with other STDs and 
that in 1988 HIV-1 had recently reached Ethiopia (Kefenie et ah, 1991). In 1994 
13000 AIDS cases had been reported in Ethiopia (World Health Organization, 
1995a). A few years later a survey in Addis Ababa estimated that seroprevalence 
in the general population was between 10% and 27%, and in commercial sex 
workers was as high as 47% to 59% (Abebe et al., 1997).
The overall trend in the late 1990s across East Africa has been a gradual decline 
in HIV-1 prevalence which has levelled off at about 8.5% (Asamoah-Odei et al.,
2004). This gradual decline may be due to changes in sexual behaviour, better 
and more widespread treatment of STDs and use of condoms, or simply due 
to a naturally occurring plateau in the epidemic.
In Central Africa the overall prevalence of HIV-1 has levelled off at around 5%, 
but it is important to realise that regional seroprevalence rates may differ from 
this figure (Asamoah-Odei et ah, 2004).
HIV-1 seropositivity and mortality were studied in Kinshasa, The Democratic 
Republic of tire Congo in 1987. Seroprevalence in the general population of
Kinshasa were reported at between 3% and 7%, and AIDS accounted for 43% of 
500 consecutive adult deaths at the University hospital (Nelson et ah, 1991). In 
1994 a seroepidemiological study of HIV in the north western region of The 
Democratic Republic of the Congo revealed HIV-1 seroprevalence at 48.5% and 
HIV-2 seroprevalence at 4.5% (Bernal et ah, 1994).
A study in 1992/93 of 1233 pregnant women attending antenatal clinics in 
Kigali (Rwanda) revealed that 34% were HIV-1 seropositive (Leroy et ah, 1995). 
During the same period of time in southern Rwanda 1150 women enrolled in 
a 2 year survey of HIV-1 seroincidence: over the study period HIV-1 incidence 
was 2.7% overall with a peak incidence of 10.5% in teenagers (Bulterys et ah, 
1994).
In the Central African Republic HIV-1 is highly divergent and subgroups A, C, 
D and E have been identified (Murphy et ah, 1993). In a house to house study 
carried out in 1986 the seroprevalence of men was 1.4% and the seroprevalence 
of women was found to be 5.5%. In 1989 a study of workers at 22 companies m 
Bangui found that seroprevalence ia men was 11% and women 2.2%. These 
varying results may be partially explained by the different sample groups 
covered by the two studies: Working men, such as those in the 1989 study, are 
thought to have more sexual partners than unemployed men. Women who are 
unemployed, like those in the home-based 1986 study, may increase their 
income through prostitution. These activities are likely to increase the HIV-1 
seroprevalence in these groups (Mathiot et ah, 1990).
Sero-surveillance carried out in Gabon in the 1990s showed that seroprevalence 
in the general population had remained low and stable at 2%. This pattern was 
also seen in Cameroon and is in contrast to that seen in the other African nations 
reporting HTV infection. Genetic analysis of the isolates in these two countries 
has shown there to be 6 different group M subtypes and group O: in Yaoundé, 
Cameroon less than 10% of HIV-1 infected persons were infected with group O 
viruses (Zekeng et ah, 1994).
This central African pattern of high genetic diversity and low rate of 
transmission of HIV-1 has yet to be explained (Delaporte et ah, 1996).
West African studies of women attending antenatal clinics have indicated that 
HIV-1 prevalence has remained constant at about 4% in this part of Africa since 
1997 (Asamoah-Odei eta l, 2004).
In the Gambia, HIV-2 has been found to be more prevalent than HIV-1; in 1991 
26% of prostitutes were found to be infected with HIV-2. In the same group 
2.1% were seropositive for HIV-1 and 2.5% were dually infected (Pepin et al, 
1991).
In a study of over 5000 hospital admissions in Abidjan, the Ivory Coast 66% of 
deaths were due to AIDS, with an HIV-1 to HIV-2 ratio of 10:1 in these AIDS, 
mortalities (Lucas et ah, 1993). This ratio of HIV-1 to HIV-2 perhaps highlights 
the slower rate of disease progression or the reduced pathologic effects of HIV- 
2, as suggested by other researchers (Kanki et ah, 1994). Kanki et ah studied 
retrovirus prevalence in West Africa since 1985 and concluded that HIV-2 was 
more common than HIV-1, but less pathogenic. HIV-2 has a slower heterosexual 
spread than HIV-1, leading to a prevalence plateau at approximately 11% of the 
population (Kanki et al., 1987, 1994). In a community based study in Guinea 
Bassau HIV-2 seroprevalence in 100 randomly selected households (649 adults 
and 680 children) was 9% in 15 to 40 year olds and 20% in those over 40. The 
survey reported 4 HIV-2 seropositive children but these infections were hospital 
acquired and there was no evidence of vertical transmission of HIV-2 (Poulsen 
et ah, 1989).
Since the early 1990s the heterosexually transmitted HIV-1 epidemic in Southern 
Africa increased. In 1996 HIV-1 prevalence in Malawi and Botswana was up to 
30% (Abdool Karim and Abdool Karim, 1999). HIV-1 prevalence in women 
attending antenatal clinics in Blantyre (Malawi) and Lusaka (Zambia) were 
16% and 20% respectively (UNAIDS and WHO, 2003).
In South Africa HIV seroprevalence has risen rapidly since 1990 from 0.76% to 
22.8% in 1998. Seroincidence peaked in 1997 at 11.9% in young women aged 
15 to 30 years old (Abdool Karim and Abdool Karim, 1999). In the 1980s HIV-
1 infection in South Africa led to a predominantly homosexually transmitted 
disease of the white population. By 1990 this first epidemic was in decline and 
the second epidemic was underway. In this second, and more widespread 
epidemic, infection w ith HIV-1 leads to a heterosexually transmitted disease 
of black Africans, who make up 77% of the total population and of whom 45% 
are less than 20 years old (Gilbert and Walker, 2002). In a huge and on going 
national survey of women attending 400 antenatal clinics over 16500 women 
have been tested anonymously and the seroprevalence in 2002 was 26% and 
still increasing. Levels peaked at 37% in KwaZulu Natal where AIDS caused 
48% of all adult deaths (Hosegood et al, 2004).
In a general population study carried out involving 2596 male factory workers 
in Harare, Zimbabwe between March 1993 and March 1995 19.3% were 
seropositive at enrolment into the cohort. Seroincidence during the study was 
3.2%, and peaked at 4.5% in the age group 21-25 years. HIV seroincidence risk 
factors were investigated, and men reporting sexually transmitted diseases 
during the follow-up period of the study were more likely to seroconvert. 
Increased numbers of sexual partners and sex with prostitutes also increased the 
likelihood of seroconversion (Mbizvo et al, 1996). A study of the prevalence of 
HIV-1 has been carried out in two rural districts of Zimbabwe, the Rusitu Valley 
and the slightly less remote Honde Valley (Gregson et al, 1997). A total of 487 
pregnant women were tested for HIV-1 infection. The HIV prevalence in the 
Rusitu Valley was 14% and in the Honde Valley was 24%. Despite the rural 
remoteness of these two locations, the HIV-1 epidemic seems to have become 
wide spread throughout this part of Africa (Gregson et al, 1997).
Vertical transmission of HIV-1 occurs from infected mothers to their children 
during pregnancy and at birth, and transmission from mother to infant during 
breast-feeding is another important route of HIV infection (Stiehm & Vink, 1991; 
Kampinga et ah, 1997). In South Africa mother to child transmission is estimated 
at between 30 and 34% of pregnancies of infected mothers (Bobat et ah, 1996, 
Wtilkinson ct al, 2000). Vertical transmission of HIV-1 in Uganda was recorded
at 26% from two study groups (Mugerwa et al., 1996). In a study carried out in 
Addis Ababa, Ethiopia of 92 pregnant mothers infected with HIV-1 and their 
infants over a 2 year follow up period 68% of the children became infected by 
the time they were 18 months old (Chamiso, 1996).
However in sub-Saharan Africa heterosexual intercourse represents the main 
mode of transmission of HIV-1 (Latif et al., 1989; Bernal et al., 1994; Gilbert and 
Walker, 2002). Heterosexual transmission of HIV-1 is exacerbated by the 
presence of other sexually transmitted diseases (Hudson et al., 1988; Latif et al., 
1989; Schmutzhard et al., 1989). Over the last 15 years HIV-1 has emerged as a 
major cause of adult death in many areas of Africa including Rwanda, the Ivory 
Coast, Uganda, The Democratic Republic of the Congo and KwaZulu Natal (De 
Cock et al., 1990; Nelson et al., 1991; Gregson et al., 1994; Mulder et al., 1994; 
Hosegood et al., 2004).
Appendix III shows the HIV-1 prevalence among women attending antenatal 
clinics in Africa and was compiled from surveys carried out between 2001 and 
2002 (UNAIDS and WHO, 2002d).
1.3 Clinical
HIV infection almost inevitably leads to AIDS, which for the purpose of accurate 
disease surveillance has been described in detail by the WHO and the American 
Center for Disease Control (CDC). A clinical case definition was established in 
1985 with a proviso that this might in time need to be adapted to suit disease in 
different countries (World Health Organization, 1986). AIDS in adults was 
defined by the presence of two of the major signs and at least one of the minor 
signs as detailed below;
Major signs:
i /  10% or greater loss of body weight, 
i i/  chronic diarrhoea (longer than 1 month), 
iii/ prolonged fever (longer than 1 month).
Minor signs:
i /  persistent cough (longer than 1 month).
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ii/ generalized pruritic dermatitis, 
iii/ recurrent herpes zoster, 
iv / oral candidiasis, 
v /  progressive herpes simplex, 
v i/ generalized lymphadenopathy.
Kaposi's sarcoma or cryptococcal meningitis alone also are definitive for AIDS 
diagnosis. A slightly different definition was detailed for paediatric AIDS.
This clinical case definition of AIDS was revised by the CDC in 1987 (Centers for 
Disease Control, 1987). In this revision of the clinical case definition in the 
absence of laboratory evidence for HIV infection more diseases indicative of 
AIDS were added; these included cryptosporidiosis, cytomegalovirus, primary 
brain lymphoma, Pneumocystis carinii pneumonia, Mycobacterium disseminated 
disease, multifocal leukoencephalopathy and toxoplasmosis of the brain. A 
detailed list of infections with confirmed HTV infection was also listed in the 
CDC updated case definition. A further revision of the AIDS case definition was 
made by the CDC in 1991; when pulmonary tuberculosis, invasive cervical 
cancer and recurrent pneumonia were added to the list of indicative diseases. 
Both the original and the CDC's revisions of the AIDS case definition were 
appropriate for the identification of AIDS in the USA and other developed 
countries, but were not consistent in the developing countries where the 
facilities for diagnosis of the AIDS indicator infections might not be available. 
Clinical presentation of AIDS in Africa differs from that seen in developed 
countries this is mainly due to the different microbial environment in which the 
HIV positive persons are living. The opportunistic infections in tropical 
locations are associated with the common pathogens present (Biggar, 1986). 
Enteropathic AIDS, also known as "slim disease", is common in many African 
countries and was investigated by Sewankambo in Uganda. The symptoms of 
this disease are substantial weight loss and chronic diarrhoea: the causative 
agents of the diarrhoea have been identified as cryptosporidiosis and 
isosporiasis (Sewankambo et al, 1987).
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To enable the clinical case definition to be used in developing countries various 
revisions have been made in different continents and countries. These revisions 
are weighted towards the predominating local infections that are indicative of 
AIDS and that can be readily identified with perhaps limited medical facilities. 
The Caracas case definition used in South America incorporates a point system 
which weights certain diseases and requires HIV seropositivity for AIDS 
definition (Buehler et al, 1993).
In Uganda the WHO clinical case definition for Africa was introduced in 1987 
and there were educational meetings to teach the district medical officers how to 
apply the definition (Berkley et al, 1989). Modifications have been made to this 
African case definition to increase its efficiency in Uganda. A TB cough was 
excluded from the minor signs and amenorrhea was added (Widy-Wirski et al, 
1988).
1.4 Viral Pathogenesis
1.4.1 Correlates of Disease Progression
The assessment of an infected person's disease status and the prediction of 
when and by how much it will alter is of considerable importance in patient 
management and therapy. This is becoming even more important with the 
development and availability of more potent antiviral drugs (Coffin, 1996). One 
of the main characteristics of AIDS is the severe depletion of the CD4 cells in the 
blood and measurements of total CD4 cells and CD4:CD8 cell ratios are widely 
used to monitor patients' health or disease status. CD4+ cell counts were found 
to give a reliable prognosis of disease in a very comprehensive international 
study (Multicohort Analysis Project Workshop, 1994). However, it has been 
shown that plasma viral load is the single best predictor of time of progression 
to AIDS (Hammer, 1996; Mellors et al, 1996; Saag et al, 1996). Mellors et al 
measured viral RNA concentrations in plasma in a study of 180 patients over 10 
years. The concentrations of subjects' plasma viral RNA were measured on 
entry into the study; these baseline values varied from <500 to 294000
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molecules/ml. The predictive value was significantly better than CD4+ counts, 
for which only the lowest quartile (<320 cells/ pi) gave a significant correlation 
with disease progression.
The measurements of T cell subsets and viral load are relatively expensive and 
require specialist facilities and expertise normally available only in developed 
countries. However, data is now being obtained from other countries including 
some in Africa. For example, T cell subset analysis is routinely done in Entebbe 
on blood samples taken from members of the Natural History cohort in rural 
SW Uganda and, in a 3 month period in 1996, all the HIV-positive samples taken 
from this cohort were assayed for viral load by Professor F Gotch and her 
colleagues at the Chelsea & Westminster Hospital, London (Kengeya-Kayondo 
et al., 1997). These data should eventually allow a detailed comparison of the 
rates of disease progression in infected Africans and persons in developed 
countries.
1.4.2 Disease Progression
In most cases, infection with HIV causes a mild, often subclinical, primary 
illness followed by an asymptomatic phase, which may last for many years, 
leading eventually to severe immunosuppression, the onset of AIDS and death. 
This sequence is illustrated diagrammatically in Figure 1 (Pantaleo, 1993).
The acute phase is characterized by a high viral load (illustrated in Figure 1 by 
the RNA copies per ml of plasma) in the blood which triggers humoral and ceU 
mediated immune responses to antigenic epitopes in viral proteins. These 
responses then lead to a large reduction in the plasma viral load, which may be 
maintained at a low level throughout an asymptomatic phase which can last for 
many years. However, the development of severe immunodépression, 
associated with the destruction of many of the plasma lymphocytes (illustrated 
in Figure 1 by the CD4+ T lymphocyte count), leads to a large increase in viral 
load, opportunistic infections and death.
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Figure 1. Schematic representation of the time course of disease 
progression from HIV infection to AIDS and death. It illustrates the 
changes in plasma viral load and the CD4+ lymphocyte level/m l of 
blood at various stages (Figure adapted from Pantaleo, 1993).
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It used to be thought that the low levels of plasma virus following the clearance 
of virus by the primary immune response reflected a very low viral turnover 
during the asymptomatic stage, which could almost be regarded as a latent 
phase. However, studies have shown that the rate of turnover of virus and virus 
infected cells is much greater than previously believed: quantitative data 
obtained in the mid-1990s led to a marked change in our understanding of viral 
pathogenesis (Ho et ah, 1995; Wei et al., 1995). These two groups studied the 
changes in plasma viral load and CD4+ T cell turnover in peripheral blood of a 
total of 42 asymptomatic persons with CD4+ T cell counts ranging from 18 to 
480 per mm^ and plasma viraemia ranging from 15 to 554 virions / ml X1Œ. The 
mean half-life for plasma virus turnover was deterrrdned at 2 days, and the 
mean doubling time for infected CD4+ T cells in peripheral blood was found to 
be 15 days. The average rate of CD4+ T cell turnover in peripheral blood was 
calculated at 4 X 10  ^cells per day, and the average total HIV-1 production was
6.8 X 10  ^virions per day (Ho et al., 1995; Wei et al., 1995). They concluded from 
these data that there is a continuous turnover of virus infected cells during the 
asymptomatic phase of infection and that during this phase the rate at which 
infected PBMC are destroyed is balanced by the rate of cell replacement, so for a 
time the plasma viral load and the number of CD4+ T cells are in dynamic 
equilibrium.
Wolthers et al. (1996) assessed the rate of CD4+ and CD8+ T cell turnover in 
samples from 14 HIV-1 infected persons from the early asymptomatic stages 
and up to the diagnosis of AIDS using the indirect method of telomere 
measurement. They observed no decrease in CD4+ T cell telomere length and 
concluded that CD4+ T cell turnover in HIV infected persons was no higher 
than that of uninfected persons. This study also noted an increased CD8+ T cell 
turnover, suggesting that this cell type was infected, but was replenished during 
HIV infection at an elevated rate (Wolthers et al, 1996). In contrast to the "Sink 
analogy" made by Ho et al, Wolthers et al suggested that the CD4+ T cell 
depletion was due to the effect of HIV-1 infection on CD4+ T cell precursors.
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which in some way hindered the replacement of CD4+ T cells (Wolthers et ah, 
1996).
Further studies by Mohri et al (2001) and Ribeiro et al. (2002) supported the 
model for T cell dynamics proposed by Ho et al. (1995) and Wei et al. (1996). 
Using a deuterium labelling system they investigated the in vivo T cell turnover 
dynamics of 7 asymptomatic HIV infected persons with CD4 + T cell counts 
ranging from 48 to 804 cells per mm^ and plasma viral loads from 7.6 XICP to 5.0 
X 105 RiqA copies per ml. They compared their T cell dynamics with those of 4 
aged matched healthy controls (Mohri et ah, 2001; Ribeiro et ah, 2002). They 
showed that in the HIV-1 infected persons the CD4+ T cell activation rate was 
increased, whereas the CD8+ T cell activation rate was not. The CD4+ T cell 
death rate was increased, but the CD8+ T cell death rate was not. The fraction of 
activated T cells was significantly increased in the CD8+ T cell population, 
because the activated CD8+ T cells remained active and proliferated for a longer 
time before recycling to a resting state (Mohri et ah, 2001; Ribeiro et ah, 2002). 
Other researchers have found an increased turnover of CD4+ and CD8+ T cells 
in HIV-1 infected persons. Sachsenberg et al. (1998) found the mean daily 
turnover of CD4+ and CD8+ T cells was 2-times and 6-times higher respectively, 
and that the CD8+ CD45RO+ T cell subset was selectively expanded 
(Sachsenberg et ah, 1998). Lempicki et ah (2000) also found increased CD4+ and 
CD8+ T cell turnover: comparing 57 HIV-1 infected persons with 67 healthy 
controls. They found that the HIV infected persons had increased fraction of 
proliferating CD4+ and CD8+ T cells (Lempicki et ah, 2000).
Hellerstein et ah (2003) used a short-term and a long-term deuterium labelling 
system to establish that the human T cell memory /  effector cell sub-population 
is made up of short-lived and long-lived cells. They found that in response to 
advanced HIV-1 infection the number of proliferating CD4+ and CD8+ T cells 
increased, and the ratio of short-lived (effector) cells to long-lived (memory) 
cells increased. In uninfected controls the short-lived cells made up 4 to 6% of 
the CD4+ T cell pool and in persons with advanced HIV-1 infection this had 
increased to 20 to 25%. They concluded that HIV-1 infection alters the
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development of T cells towards an increased fraction of short-lived cells 
(Hellerstein et ah, 2003).
Viral titres do not vary significantly within a patient during the asymptomatic 
phase (Mellors et al, 1996) indicating that a dynamic equilibrium is established 
after seroconversion so that the viral load remains relatively low and stable 
during the asymptomatic phase. Eventually, however, the equilibrium becomes 
unbalanced. The virus load in the peripheral blood, which is indicative of the 
total replicating virus in the various lymphoid tissues, becomes high enough to 
outstrip the rate at which the infected CD4+ T cells destroyed by virus or by the 
immune system can be replaced. At this stage the immune system breaks down 
and the opportunistic infections characteristic of AIDS develop (Bednarik & 
Folks, 1992; Coffin, 1996; Saag et al, 1996).
It has become apparent from studies in several developed countries that the rate 
of disease progression varies between HIV-infected persons, who have been 
divided into three groups; rapid progressors, typical progressors and 
nonprogressors. Rapid progressors may develop AIDS 2 to 3 years after HIV 
infection (Phair et al., 1992). Their antibody response to viral proteins is lower 
than the responses seen in the other two groups, as is the ability of their 
antibodies to neutralize autologous virus (Pantaleo et al, 1995; Haynes et al, 
1996). The viral load following initial HIV infection remains high, suggesting an 
inefficient immune response (Mellors et al, 1995). Typical progressors remain 
asymptomatic for 8 years after HIV infection (Hendriks et ah, 1993; Hendriks et 
al, 1998). Their viral load drops following the primary immune response to HIV 
infection (Mellors et al, 1995) which includes neutralizing antibodies and 
cytotoxic T cells to immunodominant HIV epitopes (Arendrup et al, 1992; Koup 
et al, 1994). Nonprogressors may be HIV positive for 15 years or longer without 
developing AIDS (Sheppard et al, 1993; Pantaleo et al, 1995). Nonprogressors 
have a high level of neutralizing antibodies and a persistent high level of CTL in
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their peripheral blood, especially CD8+ CD38- CTL (Haynes et ah, 1996; 
Rosenburg et al., 1997).
Compared with the rate in HIV-infected Americans and Europeans as outlined 
above (Phair et ah, 1992; Hendriks et al., 1993; Sheppard et al., 1993; Hendriks et 
al., 1998), the rate of disease progression appears to be faster in many infected 
persons in African. In one study 163 HIV-l-infected female Kenyan sex workers 
were followed from seroconversion to the time of HIV-related disease, AIDS 
and death. The mean time from seroconversion to the first onset of clinical 
symptoms was 3.5 years, and the time from seroconversion to progression to 
AIDS was 4.4 years (Anzala et ah, 1995). In a study of HIV-infected Africans 
attending the clinics in the Natural History cohort in rural SW Uganda the time 
from seroconversion to progression to AIDS was 4.4 years, and the time from 
seroconversion to death was less than 6 years (Morgan et al., 1997).
It has been postulated that more rapid disease progression in some infected 
persons in African is due to higher rate of exposure to pathogens which leads to 
frequent or chronic activation of virus-susceptible cells (Bentwich et ah, 2000). 
Helminthic infections are common in many parts of Africa and may be involved 
in immune activation of T helper 2 cells which is thought to facilitate the 
progression to AIDS in HIV-1 infected persons (Bentwich et ah, 1995). In many 
parts of sub-Saharan Africa the incidence of Mycobacterium tuberculosis more 
than 25% (Bundy et ah, 2000). Mycobacterium tuberculosis infection can result in 
the increased expression of the HIV co-receptor CCR5 (Fraziano et ah, 1999) and 
is associated with a higher rate of HIV-1 replication (Goletti et ah, 1996; Garrait 
et ah, 1997).
Clearly, the factors involved in different rates of progression are not fully 
understood and it seems probable that the rate depends on host as well as viral 
factors. For example, it has been proposed that some rapid progressors do not 
mount an effective CTL response (Wolinsky et ah, 1996). Others have proposed 
that differences in progression rate correlate with HLA halotype (Steel et ah, 
1988). Furthermore, African HLA halotypes are different to those in Caucasians
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and genetic factors may also affect the rate of progression in Africans. The 
homozygous deletion in CCR5 gene, which results in the production of a non­
functional receptor for HIV appears to be confined to Caucasians and would not 
confer protection to Africans (Dean et ah, 1996; Samson et ah, 1996).
1.4.3 Virus/  Host Interactions during Disease Progression 
It is now apparent that different types of cells and tissues may be important sites 
of HIV-1 replication at different phases of disease progression and viral variants 
isolated at different phases may show different cellular tropisms.
At the time of sero-conversion the main sites of virus replication are GDI- 
positive cells in the blood (macrophages, T4 cells and dendrocytes) but at later 
on other tissues and organs may be infected, including the brain (Bottiger et ah, 
1991; Epstein et ni, 1991), thymus (Beaulieu et ah, 1996), lungs (Agostini et ah, 
1995) and gut (Donaldson et ah, 1994).
Livingstone et ah measured the proviral loads in cell fractions from HIV-infected 
patients and showed that CD8 cells, together with dendrocytes, may form a 
major site for HIV replication in many patients (Livingstone et ah, 1996). 
However, fewer patients had significant amounts of HIV provirus in their 
monocytes. There was a significant reduction in the number of circulating CD8 
lymphocytes in patients with low CD4 counts. The mechanism of infection of 
CD8 lymphocytes, which as mature cells do not express CD4, is uncertain but 
the authors proposed that it could be via infection of immature lymphocytes in 
the thymus or by a GDI-independent mechanism involving chemokine receptor 
molecules (see Section 1.5.4).
Two groups of primary isolates have been defined, depending on their ability to 
infect macrophages or infect and induce the formation of syncytia in 
immortalized GD4+ cell lines (Âsjô et ah, 1986; Fenyo et ah, 1988; Gheng-Mayer et 
ah, 1989; Tersmette et ah, 1989). The majority of primary HIV-1 isolates replicate 
to low levels in peripheral blood mononuclear cells (PBMG) and do not replicate
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in immortalized T cell lines (Âsjô et ah, 1986; Schuitemaker et al., 1991; De-Jong et 
al., 1992; Connor et al., 1993; Connor & Ho, 1994). These isolates are classified as 
macrophage-tropic (M-tropic) viruses. Some M-tropic viruses are also able to 
replicate in primary T cells; some of these induce syncytia in primary T cells (SI 
viruses), but others (NSI viruses) do not. At late stages in infection viruses may 
appear which can infect and induce the formation of syncytia in immortalized 
CD4+ cell lines (Âsjô et al., 1986; Schuitemaker et al., 1991; De-Jong et al., 1992). 
These viruses are classified as T cell line-tropic (T-tropic) primary viruses, some 
of which have yielded laboratory adapted viruses which have lost the ability to 
replicate in primary macrophages (Schuitemaker et al., 1991; Westervelt et al., 
1992; Keys et al., 1993). Almost all viruses isolated shortly after sero-conversion 
are M-tropic and NSI (De-Jong et al., 1992; Zhang et al., 1993; Zhu et al., 1993; 
Fiore et al., 1994) and appear to be responsible for sexual transmission (Zhu et al., 
1993). T-tropic SI variants emerge later and are often associated with the 
development of AIDS (Tersmette et al., 1989; Connor et al., 1993).
The differences between M- and T-tropic viruses may have been over­
emphasized as Valentin et al. found that all the primary isolates they tested, 
including rapid/high SI and slow/low NSI viruses, were able to infect 
macrophages (Valentin et al., 1994). Also, Simmons et al. found that many 
primary isolates, both NSI and SI, some which had been biologically cloned, and 
some T cell line adapted viruses were able to replicate in macrophages to give 
virus titres similar to those obtained from PBMC cultures (Simmons et ah, 1996). 
The role of macrophage infection during AIDS has been highlighted by the 
observation (Orenstein et ah, 1997) that large amounts of FIIV-l are produced by 
these cells when the CD4+ cell count is low. Previously, the source of the 
increased viraemia at this stage of disease had been unexplained.
The presence of a persistent latent reservoir of HIV-1 infection in resting CD4+ T 
cells has been demonstrated in vivo (Chun et al., 1997; Kinter et al., 2003; 
Siliciano et al, 2003). Viral DNA has been detected in two forms in resting 
CD4+ T cells; extrachromosomal and integrated into the cell genome (Zack et al, 
1990; Spina et al, 1995; Finzi et al, 1997; Hermankova et al, 2003).
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Zack et al. (1990) demonstrated in vitro that HIV-1 is able to enter these inactive 
cells and although viral RNA is partially reverse transcribed, integration of the 
DNA rarely occurs. It is possible to produce progeny virus from resting CD4+ T 
cells if mitogenic stimulation occurs within 2 days of infection, after this time 
unintegrated viral DNA is broken down. Such breakdown of viral DNA may 
account for the large number of apparently uninfected CD4+ T cells in 
circulation (Zack et ah, 1990). Spina et al. showed that resting CD4+ T cells could 
be infected by HTV-1 in vitro. After 3 to 5 days they detected stable, full length 
extrachromasomal viral DNA. They showed low levels of early mRNA 
transcription and demonstrated that the addition of IL-2 and PHA would 
induce the production of infectious virus (Spina et al, 1995).
In contrast Finzi et al. found that resting CD4+ T cells from asymptomatic HIV-1 
infected subjects harboured integrated viral DNA. This study isolated 
replication-competent virus from 0.2 to 16.2 per 10  ^purified resting CD4+ T cells 
of asymptomatic patients undergoing antiviral therapy (Finzi et al, 1997). 
Hermankova et al. (2003) demonstrated that HIV-1 DNA in the resting CD4+ T 
cells of patients receiving HAART was predominantly integrated. This group 
found 100 HIV-1 DNA molecules /  10  ^resting CD4+ T cells. They found that 
only 1% of these infected resting cells could be induced to produce mRNA at 
high levels and that a subset of these could also produce infectious virus 
(Hermankova et al, 2003).
Chun et al. (1998) examined the resting CD4+ T cells of 10 HIV-1+ subjects 10 
days to 4 months after primary infection for a duration of 0.2 to 17 months after 
the initiation of HAART. The resting CD4+ T cells contained integrated viral 
DNA, which yielded infectious virus after cell activation in all 10 cases. They 
speculated that the reservoir of latently infected CD4+ T cells could have 
become established in early acute HIV-1 infection when plasma viral load is 
high and the level of CD4+ T cell activation is elevated (Chun et al, 1998).
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1.5 Virology
1.5.1 Classification
HIV is a member of the lentivirus group of the Retroviridae family of viruses 
which have been found in a wide variety of mammals (Coffin, 1991). Other 
members of the lentivirus group include Visna /  Maedi virus and Caprine 
arthritis-encephalitis virus found in sheep and goats (Murphy et al., 1995), 
equine infectious anaemia virus found in horses (Cheevers and McCuire, 1985), 
bovine immunodeficiency virus of cattle (Snider et al., 2003) and the feline 
lentiviruses found in lions, cheetahs, pumas and bobcats and which are closely 
related to the feline immunodeficiency virus found world wide in domestic cats 
(Brown et al., 1994; Olmsted et al., 1992). Another member of the group is 
simian immunodeficiency virus (SIV) which infects as many as 33 non-human 
primates is sub-Saharan Africa and captive Asian macaques (Peeters et ah, 2002). 
The primate lentiviruses HIV and SIV may be grouped by phylogénie analysis 
into 7 major lineages (Courgnaud et ah, 2003). HIV-1 and SIVcpz which infects 
chimpanzees are grouped together in one of these 7 lineages; and within this 
lineage the 3 HIV-1 subgroups M, O and N are represented (Cao et ah, 1999). 
HIV-2 is grouped together with SIVsm and SIVmac from sooty mangabeys and 
captive macaques respectively (Sharp et ah, 1995). The discovery that macaque 
monkeys develop AIDS when infected with SIV and the similarities between 
HIV and SIV has led to the use of macaques as an animal model for HIV 
infection of man (This concept is discussed in section 1.8.2). The five other 
primate lentivirus lineages are represented by: SIVagm isolated from various 
species of African green monkey, SIVsyk isolated from Sykes' monkeys, 
SIVlhoest isolated from THoest monkeys (which is grouped together with 
SIVmndi from mandrills and SIVsun from sun-tailed monkeys), SIVcol isolated 
from guereza colobus and SIVqsn isolated from greater spot-nosed monkeys 
(Courgnaud et ah, 2003).
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1.5.2 Viral Structure
The HIV-1 vrrion is a spherical structure approximately lOOnm m diameter 
surrounded by a lipid bilayer. Figure 2 shows the virion with the component 
parts of the virus labelled (Nye & Parkin, 1994). The virion core is contained by 
the p24 capsid protein, which encases the two strands of viral RNA, the p9 
nucleocapsid protein and the enzymes protease, reverse transcriptase (RT) and 
integrase. The virus envelope consists of an outer lipid bilayer through which 
the gp41 transmembrane glycoproteins extend and attach to the gpl20 envelope 
glycoproteins and within, it contains an inner layer of p l7  matrix protein (Nye 
& Parkin, 1994).
The Envelope Glycoprotein
Approximately 70 - 80 envelope glycoprotein molecules are located on the virus 
surface. Each glycoprotein is synthesised as a gpl60 precursor molecule which 
is enzymically cleaved to form the gpl20 and the non-covalently attached gp41 
transmembrane molecules. The gpl20 molecule consists of a 60kd polypeptide 
backbone within which there are 24 asparagine-linked glycosylation sites; the 
positions of 13 of the glycosylation sites are conserved, but 11 of them are 
located in hypervariable regions and their positions may vary in different 
isolates. There may be as much as 30% variation in the amino acid sequence of 
the gpl20, this variation is greatest in the hypervariable regions of the 
glycoprotein, shown in figure 3 as VI, V2, V3, V4 and V5. Figure 3 (Leonard et 
al., 1990) represents the structure of a gpl20 molecule of the HIV-Iihb isolate. 
There are 5 disulphide bonded loop structures in the gpl20 molecule: the fourth 
loop is a simple, single disulphide loop which contains the third hypervariable 
(V3) region. The binding site for the CD4 cell receptor for HIV has been mapped 
to the second, third and fourth conserved domains of the gpl20, shown in figure 
3 as C2, C3 and C4. The CD4 binding site is thought to have linear epitopes in 
the closely associated C3 and C4 hydrophilic domains located near to the third 
and fifth hypervariable regions of the gpl20 and these may be conformationally 
affected by amino acid residues in the C2 and C4 hydrophobic domains
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Figure 2. Structure of an HIV virion with the component parts of the 
virus labelled. The conical nucleocapsid is encased in a lipid bilayer 
envelope in which are embedded the surface and transmembrane 
glycoprotein molecules. The whole structure is a sphere of 
approximately lOOnm in diameter (Nye & Parkin, 1994).
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Figure 3. Schematic representation of the surface glycoprotein 
molecule (gpl20) of HTV-Ihtb. The amino acids in the peptide backbone 
are numbered and the carbohydrate branches and disulphide bonds 
are identified. The positions of the conserved regions (C1-C5) and the 
hypervariable regions (V1-V5) are indicated (Leonard et al, 1990).
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(Olshevsky, 1990). As suggested by the location of the CD4 binding site in a 
conserved part of the gpl20 structure, this epitope is conserved across many 
subtypes of HIV-1 and maybe of importance in the development of a vaccine or 
for an antiviral treatment post-infection (Pinter et ah, 1993; Barren et al., 1995).
The V3 loop has a relatively conserved structure consisting of a loop of 30 to 35 
amino acids with an overall positive charge. This loop held together at its base 
by a disulphide bond and with a type II .. .-turn at the apex (LaRosa et ah, 1991; 
Kwong et ah, 2000). There is much experimental evidence that the V3 loop 
region is important in the interactions between the virus and host cells and the 
immune system. For example, sequence analysis has revealed that amino acid 
variations in the areas flanking the apex of the loop correlate with the 
differences in viral phenotype and cell tropisms. Syncytium-inducing isolates 
have positively charged amino acids in positions 11 and 28 of the V3 loop, and 
non-syncytium-inducing isolates have neutral or negatively charged residues in 
these positions (Chesebro et ah, 1992; Touchier et ah, 1992; Cao et ah, 1993).
Amino acids in the VI, V2, C2, V3 and CD4-binding regions of the gpl20 
molecule have been shown to be involved with the tropism of an isolate. The 
apex of the V3 loop region appears to be especially important in deterrnining 
whether a virus is M- or T-tropic (Hwang et ah, 1991; Gann et ah, 1992; De-Jong et 
ah, 1992). Further, viral tropism can be changed by point mutations in the env 
gene that cause a single amino acid substitution in the VI loop apex (Boyd et ah, 
1993). The growth of HIV-1 chimeras in microglial cells cultured in vitro was 
found to depend on the V3 loop sequence and could be blocked by V3-specific 
antisera, indicating that this region also determines viral tropism for brain cells 
(Sharpless et ah, 1992).
The V3 loop appears to be of major importance in the attachment of the virus to 
receptor molecules at the surface of susceptible cells. Several groups have 
shown that the amino acid sequence of the V3 loop is important in second or co­
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receptor usage (see below), determining the specificity of co-receptor binding 
(Choe et ah, 1996; Cocchi et ah, 1996; Kozak et ah, 1997). Hence, it seems probable 
that the V3 loop may form part of the region of gpl20 which binds to the 
secondary receptor.
The V3 loop is also a major immunological determinant, inducing both humoral 
and cell mediated immunity to the virus. The presence of a B-cell epitope, which 
has been described as the principal neutralizing determinant (PND), is evidence 
of the immunological importance of this region (Goudsmit et ah, 1988; 
Matsushita et ah, 1988; Palker et ah, 1988; Rusche et ah, 1988; Javaherian et ah, 
1989; Kenealy et ah, 1989). The peptide sequence around the loop apex acts as an 
epitope which induces specific antibodies in most infected and vaccinated 
persons and these can be analyzed in peptide-based enzyme immuno assays, 
which were reviewed by Moore (1993). Small peptides encoded by the V3 loop 
have been shown to induce neutralizing antibodies in experimental animals 
(Palker et ah, 1988; Javaherian et ah, 1989,1990; Durda et ah, 1990; Neurath et ah, 
1990; Jiang et ah, 1992) and although some early studies indicated that 
neutralizing antibodies were isolate-specific, later data indicates that peptides 
which include the conserved GPGR loop apex induce neutralizing polyclonal or 
monoclonal antibodies with a broader specificity (Javaherian et ah, 1990; Gorny 
et ah, 1992). In addition, the loop apex is a target for cytotoxic T cells in mice 
immunized with recombinant HIV gpl60 or a consensus V3 peptide (Takahashi 
et ah, 1986; Jiang et ah, 1992).
1.5.3 Virus Replication
Early work was focused on the infection and growth of HIV in cell lines derived 
from the T helper sub-set of lymphocytes which express the CD4 glycoprotein 
on the surface. Most of our detailed knowledge of the replicative cycle has been 
acquired from studies with infected CD4+ lymphocytes, and is described below 
and illustrated in figure 4 (Turner and Summers, 1999).
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Figure 4. Schematic representation of the virus replication cycle in an 
infected CD4+ lymphocyte. The replication cycle commences with the 
virus binding to receptor molecules at the cell surface followed by 
fusion of the viral and host cell membranes and ends with the release 
of progeny virus which bud through the host cell membrane and 
mature (Turner and Summers, 1999).
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Binding to the CD4 receptor molecule on the cell surface induces conformational 
changes in the gpl20 which is followed by fusion of the virus envelope with the 
cell membrane; this is a poorly understood stage in the replication cycle which 
involves a fusogenic domain in the gp41 transmembrane glycoprotein and cell 
surface receptors CXCR4 and CCR5 (as discussed in section 1.5.4) (Dalgleish et 
ah, 1984; Klatzmann et ah, 1984; Choe et ah, 1996; Feng et ah, 1996; Clapham et ah,
1991). Once inside the cell the viral enzyme reverse transcriptase (RT) 
transcribes the viral RNA into double stranded DNA (Whitcomb and Hughes,
1992). The dsDNA migrates towards the cell nucleus as a preintegration 
complex, where the Vpr accessory protein connects it to the cellular nuclear 
import system (Miller et ah, 1997; Nie et ah, 1998). Vpr also stops the host cell 
cycle in the G2 phase (Jowett et ah, 1995). Inside the nucleus viral integrase 
integrates the DNA into the cellular chromosomal DNA (Vink and Plasterk,
1993). Following viral genomic integration, viral gene expression is controlled 
by both cellular and viral factors. Cellular activation leads to the early 
expression of regulatory and accessory viral genes; tat, rev and nef, and to the 
late expression of accessory genes vif, vpr and vpu and the structural genes gag, 
pol and env (Kim et ah, 1989; Felber et ah, 1990). HIV mRNA is produced and 
migrates from the nucleus to the host cell ribosomes, where translation occurs. 
Early gene expression produces Tat mRNAs that are fully spliced. Tat is a 
transcriptional trans-activator of HIV genes, which binds to the transactivation 
response element (TAR) at the 5' end of HIV RNAs and stimulates 
transcriptional elongation leading to the production of full-length viral mRNA 
molecules in the cell nucleus (Feinberg et ah, 1991). The rev protein regulates the 
splicing of mRNA transcripts in the nucleus and their export to the cytoplasm 
prior to translation (Emerman and Malim, 1998). Nef is a phosphoprotein that 
down regulates the surface expression of CD4 (Garcia and Miller, 1992), and 
has also been seen to enhance HIV infection of primary lymphocytes and 
macrophages (Balliet et ah, 1994; Miller et ah, 1994). The v if gene product is a 
23kd protein which enhances virus infectivity of cells by species-specific 
interaction with a cellulcir factor (Simon ct ah, 1998). The vpu protein is involved
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in the dissociation of gpl60 from CD4 receptors in the endoplasmic reticulum in 
the production of the gpl20 and gp41 in viral protein assembly (Schnittman & 
Fauci, 1994) and enhances virion release from the cell (Klimkait et al., 1990). 
Assembly of the virions occurs at the cell membrane where the RNA, RT and 
core proteins associate with viral envelope glycoproteins and the immature 
viruses bud from the cell membrane (Schnittman & Fauci, 1994). Maturation of 
the virus particles takes place after budding. HIV proteases cleave the 
polyproteins into functional proteins and the structural components form the 
mature virion; gag is cleaved to form the p l7  matrix, the p24 capsid, the p9 
nucleocapsid and the p6 proteins and organisation of the viral core is completed 
(Gottlinger et al, 1989).
1.5.4 Primary and Secondary Receptors
As described above, viral attachment to a susceptible cell is initiated by the 
binding, with high affinity, of the HIV envelope glycoprotein gpl20 to the CD4 
molecule (Dalgleish et al., 1984; Klatzmann et al, 1984) which is expressed on the 
surface of many cell types including T lymphocytes, dendrocytes and monocyte 
/  macrophages. The CD4 molecule is a glycopolypeptide with four 
immunoglobulin-like domains, the outer VI immunoglobulin-like domain of 
which binds the gpl20 molecule (Capon and Ward, 1991).
Some CD4-expressing human and animal cells are resistant to infection by HIV- 
1 and syncytial formation (Maddon et al, 1986; Ashorn et al, 1990; Chesebro et 
al, 1990). Their research has shown that the CD4 molecule was essential for 
entry of HIV-1 into lymphocytes and that other cells which expressed CD4, 
either naturally or after transfection with the CD4 gene, bound the virus but did 
not become infected. These studies, and further experiments with animal cells 
transfected with the CD4 gene and fused with human cell heterokaryons, re­
enforced the idea that the non-human CD4+ cells lacked human-specific 
cofactor(s) required for fusion with HIV-1 expressing cells (Maddon et al, 1986; 
Ashorn et al, 1990; Chesebro ct ah, 1990; Dragic et ah, 1992; Broder et ah, 1993).
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Feng et al. reported that laboratory adapted viruses were able to infect a variety 
of non-human cells which co-expressed CD4 and a G protein-coupled seven- 
transmembrane receptor, named HUMSTSR or LESTR, of unknown function 
(Feng et ah, 1996). They also showed that CD4 cells which expressed this protein, 
which they termed "fusin", could be fused with HeLa cells expressing the 
envelope of HIV-1. Feng et ah drew attention to the sequence similarity between 
fusin and the receptor for interleukin 8, an a-chemokine (CXC). Antibodies to 
fusin (CXCR4) inhibited infection and cell fusion by T-tropic viruses but not by 
macrophage-tropic viruses (Feng et ah, 1996; Hori et ah, 1998). In contrast, 
infection by macrophage-tropic primary viruses but not T-tropic viruses can be 
inhibited by p-chemokines RANTES, M IP-la and MIP-ip (Cocchi et ah, 1996). 
Paxton et ah (1996) then suggested that some persons who remained sero­
negative even after multiple exposures to HIV could be due to the expression of 
high levels of these chemokines by their T cells. They showed that the p- 
chemokines inhibited the in vitro infection of T cells by primary viruses but not 
laboratory adapted viruses. The findings of Paxton et ah (1996) indicate that, in 
addition to the CD4 glycoprotein receptor, macrophage-tropic viruses utilize a 
second cell surface molecule which is distinct from CXCR4. Alkhatib et ah (1996) 
and Dragic et ah (1996) also showed that infection of CD4 cells by macrophage- 
tropic, but not T-tropic viruses, was inhibited by p-chemokines, high levels of 
which are secreted by CD4 and CD8 T cells. They and several other groups 
reported that transfection of p-chemokine receptor genes into CD4-expressing 
cell lines made them susceptible to infection by macrophage-tropic variants. 
Choe et ah (1996) compared the efficiency of infection of recombinant HIV-1 
viruses in HeLa-CD4 cells transfected with p-chemokine receptors 1 to 5 (CCRl - 
CCR5). CCR5 was more effective than CCR3, supporting infection by a wider 
range of variants, including those in clades A, B, E and F: the other receptors 
were inactive. As noted above they showed that the structure of the V3 loop was 
an important determinant in the interaction between the virus and the 
chemokine receptors. Similar results were obtained by Doranz et ah (1996) who 
showed that CD4 target cells transfected with CCR5, but not CXCR4, were fused
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by cells expressing glycoproteins from macrophage-tropic viruses. The 
laboratory adapted H IV -Itub glycoprotein only responded to CXCR4 and a dual­
tropic primary strain which replicates in both macrophages and T cell lines 
utilized both CXCR4 and CCR5: the V3 loop sequence of this strain was 
intermediate between those of M- and T-tropic viruses (Doranz et ah, 1996).
Samson et al. (1996) and Dean et al. (1996) reported that two persons who 
remained seronegative after repeated exposure to HIV were homozygous for a 
deletion in their CCR5 gene, which resulted in the production of a non­
functional receptor. Their evidence indicated that persons who were 
heterozygous for this deletion also had some protection against infection. This 
deletion appears to be confined to Caucasians and would not confer protection 
to Africans, including the repeatedly exposed but seronegative members of the 
MRCPA cohorts in Uganda.
The hypothesis that primary, macrophage-tropic, NSI viruses utilize CCR5 and 
related p-chemokine receptors and that SI variants and cell line adapted viruses 
utilize a-chemokine receptors now appears to be an over-simplification as the 
observed receptor usage of some NSI variants does not correlate qualitatively 
with their cell tropisms in vitro (Cheng-Mayer et al., 1997). For example, some 
virus isolates can use both CCR5 and CXCR4 but are unable to infect 
macrophages. Simmons et al. (1996) found that several dual-tropic SI primary 
isolates, which grew equally well in T cells and macrophages, could utilize 
either CXCR4 or CCR5 to infect CD4 cells. Further, 3 macrophage-tropic SI 
strains utilized CXCR4 but not CCR5. They and others have suggested that 
other co-factors or receptors may be used by some strains of HIV-1. 
Schmidtmayerova et al. (1996) reported that although p-chemokines inhibit the 
infection of T cells by primary viruses, they stimulated their growth in 
macrophages: conflicting data, which depended on culture conditions, was 
obtained for the inhibition of HIV replication in dendrocytes with p-chemokines 
(Rubbert et al., 1997).
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There is growing evidence, summarized by Endres et al. (1996) that some HIV 
isolates can infect a variety of cells in the absence of CD4: generally, HIV- 
infection of CD4- cells proceeds slowly and there are no cytopathic effects. 
However, Endres et al. (1996) showed that some strains of HlV-2 can use CXCR4 
to infect CD4- human and animal cells productively and that the CD4- 
independent infection was inhibited by a monoclonal antibody specific for 
CXCR4. In an interesting parallel with the effect of HIV-1 infection on the 
expression of CD4, the expression of CXCR4 at the cell surface was down- 
regulated by infection with HlV-2. However, there is some evidence that the 
ability of HlV-2 to replicate in CD4- cells depends on the presence of mutations 
in envelope and transmembrane glycoproteins (Reeves and Schulz, 1997). 
Clearly, research on the roles of different receptor molecules and other co­
factors in HIV infection is still at an early stage. Dittmar et al. (1997) have shown 
that immune escape from neutralizing antibodies may result in changes in 
receptor usage. The fairly simple model of disease progression involving 
mutations within the viral glycoproteins, especially the V3 region, leading to 
different receptor/co-factor usages associated with changes in cell tropisms and 
widening of the range of cells and tissues susceptible to infection needs to be 
proven, especially with viruses which have not been selected by culture in vitro.
1.6 Molecular Biology
1.6.1 The Genome
Like other retroviruses, the lentivirus genome consists of two copies of RNA. 
These RNA encode the structural proteins which form the viral core and the 
surface envelope glycoprotein plus several enzymes, and regulatory or 
accessory proteins as described above.
The molecular organization of the genome of HlV-1 is shown in figure 5 (Myers 
et al., 1993). The HlV-1 genome contains approximately 9.2 kilobases of RNA (or 
of DNA m the integrated provirus); the size varies between isolates, depending 
on the presence of insertions or deletions. A block of approximately 680 bases at
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Figure 5. The molecular organization of the genome of HlV-1. The 
locations of the viral structural and accessory genes and the long 
terminal repeats (U3RU5) are indicated (Myers et ai, 1993).
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the 5' end are directly repeated at the 3' end of the genome to form the Long 
Terminal Repeat (LTR).
The gag and env genes encode the core and envelope proteins, respectively and 
the pol vifi vpu, vpr, tat, rev, and nef genes encode reverse transcriptase, integrase 
and other non-structural or accessory proteins. The LTR functions as a powerful 
viral transcriptional promoter, the activity of which is greatly enhanced by 
factors produced during cell activation.
There are numerous splice donor and acceptor sites which may be used to give a 
series of RNA transcripts, as shown in figure 6 (Myers et al, 1993). The gag and 
pol genes are not spliced and each is transcribed to produce polycistronic 
mRNAs which encode the core and polymerase proteins, respectively. Both 
proteins are cleaved by the virion protease, encoded by the pol gene, to produce 
several proteins: the gag gene product is cleaved into the pl7, p24, p7 and p6 
structural proteins and the pol gene product is cleaved to give the viral reverse 
transcriptase (RT) protease and integrase enzymes. The env, vif, vpr, tat, vpu, rev, 
and nef gene products are produced from spliced transcripts encoded by the 3' 
part of the genome. The env gene encodes the precursor glycoprotein gpl60 
which is cleaved by host cell enzymes into glycoproteins gpl20 and gp41 (see 
above).
1.6.2 Genetic Diversity
The process of DNA synthesis by reverse transcription is highly prone to error, 
and in the absence of a proof-reading mechanism for correcting the mistakes, 
the mutation rate of HlV-1 is very high (approximately 1 mutation per 
replication cycle) (Ewald, 1994).
Mutations can be point mutation, insertions, deletions or due to recombination 
events. Point mutations, where one nucleotide is substituted for another, may 
result in the alteration of the amino acid sequence of the protein. Substitutions 
may cause the insertion of stop or nonsense codons in the genetic sequence.
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Figure 6. Functional organization of the HIV-1 genome. The figure 
shows the splice donor and acceptor sites used to give a series of RNA 
transcripts which are translated into viral proteins (Myers et ah, 1993).
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which can block protein synthesis. Insertions and deletions of one or more 
nucleotide may also occur, these can cause reading-frame shifts and may also 
block protein synthesis. Recombinations can take place between strands of viral 
DNA and during reverse transcription. In persons where multiple infection has 
taken place template switches may result in the sudden exchange of large 
amounts of the genetic material between two isolates, which may be from 
distinct HIV-1 subtypes (Birx et ah, 1996). High virus turnover (Ho et ah, 1995) 
leads to an accumulation of errors in the viral genome and rapidly results in the 
formation of a "swarm" of variants, some of which may escape immune 
detection (Coffin, 1992; Bruce et ah, 1993). The rate of variation is not equal 
through out the genome; the structural genes gag, -pol and env have differing 
rates of substitution with env being the most variable. Within the env gene there 
are five hypervariable regions (VI - V5) and five constant regions (Cl - C5). It 
has been shown that amino acid sequence variations caused by mutations in the 
V3 loop coding region of the env gene can lead to alterations in the antigenicity, 
tropism and phenotype of the isolate. It seems likely that the same genetic 
variation which allows a variant to escape immune detection may also alter its 
cell tropism and lead to wider distribution of the virus in the body (Bonhoeffer 
et ah, 1995).
Based on gag and env coding sequences, 3 groups and a number of clades or 
subtypes of HlV-1 have been identified. The major group of HIV-1 isolates, or 
group M, contains 9 clades that have been labelled A, B, C, D, F, G, H, J, and K 
(McCutchan et ah, 1996; Triques et ah, 2000). Isolates originally grouped into 
clades E and I have been reassigned as circulating recombinant forms (CRTs) 
with mosaic genomes of more than one subtype. The clade E isolates have all 
been renamed as CRF01_AE (Robertson et ah, 1999) and the clade I isolates are 
now known as CRF04_cpx viruses (Nasioulas et ah, 1999). Each clade contains 
a number of viral isolates that are genetically related to each other and the 
clades are distinguishable from each other by nucleotide distances (Myers et ah, 
1993; Birx et ah, 1996). In 1990 two HIV-1 isolates from the Cameroon were 
found to be genetically different from oüier HIV-1 isolates (De Leys at ah, 1991).
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Further divergent isolates have been discovered which grouped with these 
viruses from the Cameroon, because of their overall genomic sequence 
differences from group M isolates they were labelled as outliers in the 
phylogenetic grouping of HIV-1 and became HIV-1 group O (Chameau et al., 
1994; Gurtler et al., 1994). Phylogenetic analysis of an isolate of HIV-1 (YBF30) 
obtained in the Cameroon in 1995 revealed that it grouped between SIVcpz- 
gab and HIV-1 group M. This isolate and one other grouped together and 
were labelled the new non-M, non-O group of HlV-1: group N (Simon et al.,
1998).
The genetic diversity of HIV-1 is greatest in Africa and groups M, O and N and 
all of the clades of HIV-1 can be found in Africa (Loussert-Ajaka et al., 1995; 
Louwagie et al., 1995; Simon et al., 1998; Vidal et al., 2000). The global 
distribution of HIV-1 groups M, O and N and group M clades are shown in 
Figure 7 (Information for this figure was obtained via the www.hiv.lanl.gov 
website). Uganda is a country which shows a wide genetic diversity of HIV-1, 
where variants of clades A, B, C, D and G have been found, although the vast 
majority of variants are in clades A and D (Albert et ah, 1992; Bruce et ah, 1994; 
Kaleebu et ah, 1995). Analysis of the env genetic sequence of central and east 
African isolates has revealed many variations not seen in American and 
European clade B viruses.
1.7 Immunology
Many of the studies on the immunological responses to HIV infection have been 
influenced by the need to produce an effective vaccine or improve viral 
diagnosis. Exposure to HIV results in a three tier immune response; initially 
involving the non-specific activation of dendritic cells, macrophages, the release 
of cytokines and complement and the action of natural killer cells, followed by 
cytotoxic T cells and then neutralizing and other antibodies (Roitt, 1991; 
Oldstone, 1997; Palucka and Banchereau, 1999). In response to infection with 
HIV-1 the immune system produces antibodies to specific epitopes of the virus 
which direct the antibody-dependent cytotoxic cells to the
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Figure 7. Global distribution of HIV-1 groups O, N and M and group 
M clades.
(Information for this figure was obtained via the www.hiv.lanl.gov 
website.)
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virus infected cells (Broliden et al., 1996). Cell mediated immune (CMl) 
responses are generally thought to be responsible for the control of intracellular 
infections and the clearance of infected cells. The cellular response to an acute 
viral infection may clear the target organ of virus before the neutralizing 
antibody titres are raised (Nye and Parkin, 1994). Infection with HIV-1 results in 
specific CTL responses and virus-induced antibody production. Although little 
is known about the mechanisms of protection against viral infection or diseases 
it is possible that protection may depend on the combined activities of cell 
mediated and humoral immune responses. The presence of neutralizing 
antibodies is generally regarded to be an important component in the immune 
system and it has been assumed that a vaccine able to induce a broadly 
neutralizing repertoire of antibodies would give some protection against HIV-1 
infection. Therefore it is important to measure the neutralizing activities of 
antibodies induced both by vaccination and by natural infection with HIV and, 
where possible, to relate these activities with those of other immune systems, 
e.g. cell mediated immunity and the extent of protection or rate of disease 
progression.
The need to produce sensitive, specific and reliable serological methods for the 
diagnosis of HIV has lead to intense research and development activity, much 
within commercial and public health sectors, which fall outside this review. 
However, much work has been done to develop serological methods which 
could be used as research tools, for example in clinical epidemiology of HIV in 
developing countries where a simple assay to determine virus subtype would 
be invaluable. This was one of the major objectives of the work described in this 
thesis.
1.7.1 Serology and Sero-surveillance
Sera from HIV-infected persons react with most or all of the virus-induced 
glycoproteins and proteins, including non-structural proteins. Some of the 
glycoprotein epitopes, for example those in the V3 loop region of the gpl20 and 
in the transmembrane glycoprotein, gp41, induce a Yory strong serological
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response in almost all infected people and are especially useful in diagnostic 
studies.
Solid phase enzyme-linked immunosorbent assay (EIA) methods using 
synthetic peptides, chiefly from the V3 loop region, have been developed to 
identify the epitopes recognized by antisera. This system has been used to 
survey antisera from different geographical locations to see if the serological 
responses reflected the sequence or subtype differences and to determine 
whether simple serological assays could be developed into a sero- 
epidemiological tool (Blomberg et al., 1993). As described in this thesis, work 
carried out using a simple EIA with V3 loop peptides led to a confusing array of 
cross-reactivity as the African antisera reacted with more than one synthetic 
peptide, often from subtypes other than that of the infecting isolate. However, 
antisera from asymptomatic persons infected with HIV-1 gave less cross­
reactivity, indicating that this system could be usefully developed (Smith et al.,
1994). A study carried out with antisera from Uganda, Rwanda, Thailand and 
Brazil identified cross-reactivities between genotypes A and C and between 
genotypes B and D; Ugandan genotype D caused the most cross-reactivity 
(Cheingsong-Popov et al., 1994). Antisera from the genotypes A and B in 
Thailand were serotyped using 14mer peptides representing the amino acids 
spanning the V3 loop apex. In this study highly concordant results were 
obtained between serotype by the V3 loop EIA and genotype by PCR (Pau et ah, 
1993). In work carried out with Ugandan sera has suggested that the V3 loop of 
the gpl20 is the major antigen of isolates from clades A, C and D (Pestano et ah,
1995). In a study by Kaleebu plasma from Ugandans infected with clade A, C 
and D isolates were serotyped by V3 EIA using 14 to 16 amino acid peptides 
spanning the loop apex: Although clades A and D could be distinguished from 
each other, clades A and C were indistinguishable by this method (Kaleebu, 
1995). Introduction of a peptide blocking stage in which the sera are pre­
incubated with excess peptide in solution has been shown to give a more 
specific EIA which may be used at different disease stages (Barin at ah, 1996).
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The nature of the antibody response to the V3 loop over the time course of HIV 
infection was examined by a group from the Netherlands (Zwart et al, 1992). 
Antibodies produced at the time of seroconversion were found to react in an 
EIA specifically with the V3 loop peptide with an amino acid sequence 
corresponding to that of the infecting virus isolate. The investigation of follow- 
up samples revealed that the levels of peptide reactivity increased and more 
cross-reactivity was seen during the 5 years after seroconversion. However, 
despite this broadening of the antibody response the peptide specificity (i.e. the 
peptide with which the antiserum reacted most strongly at seroconversion) 
remained unchanged. Only very rarely was there a change in antiserum 
specificity. At the later stages of infection antiserum reactivities with V3 loop 
peptides did not reflect the V3 loop sequences of the virus isolates circulating at 
that time. At the later stages of infection antiserum reactivities were strongest 
with the V3 loop peptides representative of the isolate present at seroconversion 
(Zwart et al, 1992).
1.7.2 Neutralizing Antibodies
The immune system produces neutralizing antibodies which bind to cell-free 
virus preventing entry of virus into target cells and fusion of virus infected ceUs 
with uninfected cells. The principal neutralizing determinant has been identified 
as the V3 loop of the envelope glycoprotein m subtype B isolates of HIV-1 
(Palker et al, 1988; Rusche et al, 1988). Peptides which mimicked the amino acid 
sequence of the V3 loop of a virus isolate were able to absorb the neutralizing 
antibodies from the antisera (Javaherian et al, 1989). The addition of 
homologous V3 loop peptide to a neutralization system reduced the antiserum 
neutralizing effect on isolates H IV -Imn and H IV -Iihb (Carrow et al, 1991): These 
experiments confirmed the identification of the PND in subtype B isolates. 
Inoculation of laboratory animals with V3 loop peptides has been shown to 
produce antibodies capable of neutralizing HTV-1 isolates in vitro (Kenealy et al, 
1989; Laman et al, 1992).
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It has been shown (Oram et ah, 1991; Albert et al, 1992; Bruce et al, 1993, 1994; 
Myers et al, 1993) that many African isolates of HIV-1 encode V3 loop 
sequences, which are dissimilar from those of North American and European 
viruses. Although it has not been shown that the V3 loop epitopes of African 
variants of HIV-1 induce neutralizing antibodies or cell mediated immunity, it is 
probable that this V3 loop region encodes important immunogenic epitopes in 
all variants of HIV-1.
Early virus neutralization experiments were done using laboratory adapted 
viruses grown on various T cell lines and sera from infected persons. Later, 
peptides encoded by env gene sequences of subtype B laboratory adapted 
viruses were used to produce antibodies in laboratory animals. Antibodies 
raised by injecting goats with V3 loop peptides encoded by H IV -Iiiib  and HIV- 
I r f  had isolate-specific neutralizing and SI inhibiting activities (Palker et al, 
1988). Neutralization of two subtype B virus isolates (H IV -Imn and H IV -Iihb) by 
a six amino acid peptide (GPGRAF) which formed the apex of the V3 loop was 
seen in another study, but the apex regions of both isolates were the same 
(javaherian et al, 1990). Many other groups also recorded type-specific 
neutralization using cell line adapted viruses (Goudsmit et al, 1988; Haigwood 
et al, 1990; Arendrup et al, 1993; White-Scharf et al, 1993).
To deterrnine whether a V3 subunit vaccine could induce group specific 
neutralizing antibodies, Wagner et al synthesised a 36mer V3 consensus peptide 
based on the sequences of HIV-1 isolates from America, Europe and Africa 
(Wagner et al, 1992). This peptide was used to demonstrate good cross­
reactivity with a range of antisera of different subtypes and also to neutralize 
H IV -Iiiib  on the GEM cell line. It was also shown to induce specific cytotoxic T 
lymphocytes in mice.
Low passaged primary isolates are thought to resemble most closely the viruses 
present in infected humans. Neutralization epitopes are less accessible on the 
envelope glycoprotein of primary isolates of HIV-1 than on the cell line adapted 
strains (Moore and Ho, 1995). Many studies have shown correlation between 
antibody affinity for the mature processed oligomer of gpl60 and neutralization
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of virus (Fouts et al., 1997; Roben et al., 1994). The cell line adapted viruses and 
low passage primary isolates grown on PBMC showed marked differences in 
their susceptibility to neutralization. Only about 30% of primary isolates could 
be adapted to grow on T cell lines, and primary isolates have been shown to be 
less sensitive to neutralization with soluble CD4 (Daar et ah, 1990; Ashkenazi et 
al., 1991; Moore et al., 1992). In light of these discoveries it was thought that 
antibody neutralizations should also be carried out using primary isolates to 
reduce the possibility of misleading results (Matthews, 1994; Sawyer et al., 1994). 
In an attempt to address the issue of possible differences between the cell line 
adapted and primary virus isolates Mascola et al. (1994) carried out a series of 
experiments using Thai and North American primary isolates from subtypes A 
and B grown on PBMC. These isolates were also adapted for growth on cell lines 
to allow definitive comparisons of the two systems. Overall type-specific 
neutralization was seen, and the primary isolates were less susceptible to 
neutralization. Work done with two Ugandan primary isolates on PBMC also 
resulted in type-specific neutralization (Atkin et al, 1993).
Cross-clade neutralization of primary isolates on PBMC has been reported by a 
few groups (Trkola et ah, 1995; Mascola et ah, 1996a; Moore et al., 1996). There 
has been an extensive neutralization study involving primary isolates from all of 
the 9 subtypes of the major group of HIV-1 using PBMC where an attempt was 
made to establish a correlation between genotype and "neutralization serotype" 
(i.e. the susceptibility of an isolate to serum neutralization). Five neutralization 
serotypes were identified, and these did not correlate with the genotypes of the 
isolates with the exception of the subtype E isolates from Thailand in which a 
correlation was found (Kostrikis et al., 1996). The cross-clade neutralization and 
identification of neutralization serotypes may be an important step in the 
approach to developing a vaccine able to neutralize a large percentage of HIV-1 
isolates world wide.
Much of the antibody response to the envelope glycoprotein may be raised not 
to mature oligomer, but to envelope glycoprotein that has become detached 
from the virion and which have increased exposure of antigenic epitopes
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(Parren et al., 1997). Immune response to these exposed epitopes on the 
monomeric or unprocessed glycoprotein may result in a population of memory 
B cells which is restimulated by exposure to less antigenic cross-reactive 
epitopes on mature glycoprotein, and the response to the less antigenic epitopes 
may be suppressed. This is known as original antigenic sin (Fazekas de St. 
Groth, 1966). In order to overcome this phenomenon and produce neutralizing 
antibodies a vaccine must present epitopes exposed on mature virions.
Near the C-terminal part of the extracellular gp41 there is a neutralization 
epitope, incorporating the linear sequence ELDKWA, that is conserved in many 
isolates of HIV-1. The human antibody 2F5 which maps to this linear sequence 
is broadly neutralizing in vitro (Muster et ah, 1994).
The mature oligomeric gpl20 of cell line adapted isolates has two major exposed 
neutralization epitopes: the V3 loop and the CD4 binding site. Antibodies to 
these two epitopes neutralize cell line adapted isolates efficiently, though 
antibodies to V3 loop epitopes may be strain specific (Sattentau and Moore,
1995). The V3 loop of primary isolates is less accessible and therefore antibodies 
to this epitope are much less effective at neutralizing primary isolates (Bou- 
Habib et ah, 1994; D'Souza et ah, 1997). The CD4 binding site is also less 
accessible on the mature glycoprotein of primary isolates and antibody affinity 
to this epitope is much reduced in comparison to that on cell line adapted 
isolates (Sattentau and Moore, 1995). However two epitopes located near to 
these two sites with reduced accessibility in primary isolates have been 
identified by antibodies with strong neutralizing potential. One epitope involves 
residues at the base of the V3 loop in the C2 and C3 regions and the V4 region. 
The monoclonal 2G12, which has been mapped to this epitope, broadly 
neutralizes primary isolates (D'Souza et ah, 1997). The second epitope is located 
in part of the CD4 binding domain and is influenced by the V2 loop: monoclonal 
antibody bl2  maps to this epitope and has been shown to broadly neutralize 
primary isolates cross-clade and from a range of geographical locations (Kessler 
et ah, 1997). However these two epitopes are not thought to be very
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immunogenic, and antibodies b l2  and 2G12 were obtained initially from a 
single infected donor.
Despite the low immunogenicity of HIV-1 envelope and limited accessibility of 
neutralizing epitopes, antibodies to the V3 loop and CD4 binding site have been 
used in passive immunization of chimpanzees and severe combined 
immunodeficiency mice with human peripheral blood lymphocytes; complete 
protection from cell line adapted isolates was achieved (Parren et al., 1995). Such 
evidence suggests that antibodies are important in protection from HIV-1 
infection.
Several groups have reported that some antibodies have an enhancing effect on 
the infectivity of HIV-1 and that these may play a role in the pathogenesis of 
HIV in vivo. In most cases enhancement by antibody involves complement 
(Robinson et al., 1988a) whereas in animals infected with HIV-1 or SIV 
enhancement involves cells bearing Fc receptors (Takeda et al., 1988; Homsy et 
al., 1989). It was shown (Robinson et al., 1988b) that antibodies in human sera 
could be separated into neutralizing and enhancing fractions by affinity 
chromatography, suggesting that the antibodies were induced by different 
antigenic domains. Two separate complement-dependent enhancing domains 
have been identified in the transmembrane gp41 (Robinson et al., 1990) and 
antisera produced by vaccinating rabbits with peptides from many regions of 
the gpl60, including the V3 loop, possessed enhancing activity for cell line 
adapted viruses (jiang et al., 1991). The role of enhancing antibodies in 
pathogenesis or immunity is unclear but they should obviously be taken into 
account in vaccine development studies.
1.7.3 Cell Mediated Immunity
There is evidence to suggest that major histocompatibility complex (MHC)- 
restricted HIV-specific CTL may have an important role in the immunological 
mechanisms of protection from infection by HIV and disease progression. 
Rowland-Jones et al. illustrated the presence of virus-specific CTL in an 
uninfected baby bom to an infected mother (Rowland-j ones ct al, 1993).
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A group of 10 nonprogressing HIV-1+ persons with stable CD4+ T cell counts of 
more than 500 cells/ pi for 11 to 15 years were studied by Harrer et al. (1996). 
Eight of the ten nonprogressors had strong HlV-1 specific HLA class I-restricted 
CTL, recognising epitopes in gag, RT, nef and env proteins. A subset of these 
nonprogressors were found to have strong HIV-specific CTL activity, weak 
neutralizing antibody responses and a low viral load. Thus indicating that a 
cross-reactive neutralizing antibody repertoire is not necessary for long term 
nonprogression. However, it could be possible that some as yet undefined 
immune function has limited the viral load in these nonprogressors, and this 
reduced viral burden has maintained the CTL responses to HIV.
It has been shown that some individuals do not produce antibodies following 
exposure to HIV, but do have a CMI response. A group of exposed, but HIV- 
uninfected women were studied in the Gambia three out of six of these women 
were found to elicit HIV-specific CTL in response to peptide presentation by the 
most common Gambian human leukocyte antigen (HLA) class I molecule, HLA- 
B35 (Rowland-Jones et al., 1995).
Epitopes that are recognised by HLA class I-restricted HIV-specific CTL have 
been mapped to the V3 loop (amino acids 308-322) and to a region in the C- 
terminal part of gpl20 (aa 381-392). Five gag-specific epitopes have been 
mapped; three to p24 and two to pl4. Five RT-specific epitopes have been 
mapped to areas which were translated from conserved regions of pol (Walker 
and Plata, 1990).
Vaccination of macaques has been shown to stimulate nef-specific CTL, which 
caused suppression of SIV replication (Gallimore et al., 1995). DNA vaccination 
of BALB/ c, AKR or C57BL mice with recombinant vaccinia virus expressing 
HIV-2rod env resulted in cross-reactive CTL to HIV-2rqd and SIVmac 
(Agadjanyan et al., 1997). CTL specific to gag and nef proteins were detected in 
macaques mucosally vaccinated with a nef depleted SIVmac and protected from 
challenge with SIVmac (Cranage et al, 1997).
The MRC funded a project to evaluate CTL responses in infected Ugandans 
exposed to HIV-1 clade A, B, C or D viiuses; Me Adam et al. (1998) found cross­
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reactive CTL to gag p55, but no cross-reactivity with HIV-2. The cross-clade 
reactivity may be important in recombinant vaccine design, as it suggests that a 
vaccine may also induce cross-reactive CTL (Me Adam et al, 1998).
It was suggested that CTL might have had a role in the pathogenesis of AIDS. 
CD8+ CTL were thought to contribute to the depletion of CD4+ T cells by lysis 
of HIV infected cells and cells with gpl20 bound to their surface (Walker & 
Plata, 1990). The role of CD8+ CTL in infected CD4+ T cell lysis was confirmed 
when Yang et al. (1996) studied the recognition and lysis of CD4+ T cells 
infected with H IV -Iiiib by CD8+ HLA class I restricted, HIV-1 specific CTL 
clones. They showed that HLA A2- and B14- restricted CTL clones recognised 
the HIV-1 infected CD4+ T cells as the production of intracellular p24 
increased and prior to the peak virus production from the infected cells. They 
demonstrated lysis of the infected CD4+ T cells by Gag, envelope and RT 
specific CTL clones, despite HLA class I down-regulation on the surface of the 
infected cells (Yang et al., 1996).
Klenerman et al. (1996) proposed a model to investigate the effect of CTL lysis 
on CD4+ T cell depletion during HIV-1 infection. They found that the CD8+ 
CTL lysis of infected cells did not significantly increase the rate of CD4+ T cell 
depletion, but did reduce the amount of virus released from infected cells. 
Therefore they deduced that CTL-mediated lysis reduced viral load by 
limiting virus production from infected CD4+ T cells (Klenerman et al., 1996). 
Shankar et al. (1999) determined that the mechanism engaged by CD8+ CTLs 
for the lysis of HIV-infected CD4+ T cells was the granule exocytosis 
pathway. This involves the release of perforin and serine proteases into the 
intercellular space and results in target cell lysis (Kagi et al., 1994). The effects 
of CD8+ CTL lysis on uninfected bystander CD4+ T cells were examined and 
they concluded that minimal damage occurred to these cells (Shankar et al,
1999). However Shankar et al. (1999) did find that HIV-infected CD4+ T cells 
did cause lysis of uninfected CD4+ bystander cells via the fas-mediated lytic 
pathway, which may contribute significantly to CD4+ T cell depletion in vivo.
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The relative importance of humoral and cellular immune responses in host 
protection during initial infection with HIV and disease progression have yet to 
be determined.
1.8 Prevention and Cure
1.8.1 Chemotherapy
Antiviral chemotherapy is now widely used in developed countries, and as our 
improved understanding of HIV pathogenesis emerges it has become apparent 
that antiviral therapy should be administered as soon as the CD4 cell count 
reaches 350 cells per mm^ in order to reduce the viral load and the distribution 
of HIV in the body (Volberding, 2003). It has been observed that a number of 
antiviral drugs lead to the rapid selection of resistant variants and also to 
intolerance by the patient. In response to these problems combination drug 
therapies are on trial and new antiviral agents are being developed (Eron, 1996; 
Hammer, 1996; Pennisi & Cohen, 1996; Trono, 1996; Kirk, 1998; Volberding, 
2003).
Five classes of antiretroviral drugs are currently available for the treatment of 
HIV infection: Nucleoside reverse transcriptase inhibitors, nucleotide reverse 
transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, 
protease inhibitors and fusion inhibitors (De Clercq, 2004a).
Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs and NtRTIs) 
are aimed at the reverse transcription stage of the virus replication cycle. These 
drugs are substrate analogues which are incorporated into the DNA by reverse 
transcriptase and terminate DNA elongation (De Clercq, 1992). Many of these 
analogues are in use or in clinical trials (e.g. zidovudine, didanosine, 
lamivudine, stavudine, lamivudine, abacavir, emtricitabine and NtRTI tenofovir 
disoproxil fumarate).
Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to reverse 
transcriptase close to the nucleoside binding site and slow down polymerization
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(De Clercq, 1992). Three NNRTIs are available for therapy - nevirapine, 
delavirdine and efavirenz.
Protease inhibitors (Pis) inhibit the unique retroviral protease which is required 
for virus maturation. Pis currently in use are indinavir, ritonavir, saquinavir, 
nelfinavir, amprenavir, lopinavir (with ritonavir) and atazanavir (De Clercq, 
2004a).
The fifth type of antiretroviral drugs are fusion inhibitors (FIs) such as the 
licensed T-20 (Enfuvirtide) which prevents HIV binding to the host cell by 
binding to gp41 during fusion. The use of T-20 is limited to patients with viruses 
that are resistant to the drugs or combinations of the drugs mentioned above 
(Moyle, 2003).
Treatment with three of these drugs in a combination therapy, such as 
nevirapine /  zidovudine /  didanosine has been shown to reduce the plasma 
viral load to undetectable levels for prolonged periods in 75% of antiretroviral- 
naive individuals with CD4 counts of 200-600 cells/ pi. This is an example of the 
type of triple combination therapy used to overcome the problems of drug 
resistance by viral variants (Hammer, 1996). Typical treatment in Western 
Europe is a combination of two nucleoside analogues and one protease 
inhibitor (Volberding, 2003). Highly active anti-retroviral therapy (HAART) has 
become the normal approach to anti-HIV chemotherapy as more effective 
combinations of drugs have been licensed for use. Further improvements of the 
drug regimens are being developed, such as single tablets combining more than 
one drug and once-daily dosage which inevitably increase patient compliance. 
Future antiviral chemotherapies are under investigation, one of which is based 
on the suppression of CD4+ T cell activation by the cytokine interleukin-16 
(Baier & Kurth, 1997). Integrase catalyses the integration of viral DNA into host 
cell DNA, a unique and essential step in viral replication. The oligomeric 
enzyme acts in the cell cytoplasm to process the viral DNA and then in the cell 
nucleus where integration takes place. MAP30 and GAP31 proteins and 
curcumine and doxorubicin form complexes with viral integrase and prevent 
integration in infected cells (Thomas and Brady, 1997). Integrase inhibitor S-
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1360, a diketo acid derivative, is now in clinical trials (De Clercq, 2004b). 
Transcription inhibitors aimed specifically at the transactivation of the viral LTR 
by the Tat protein are another group of drugs under investigation. N- 
anriinoirnidazole derivatives (S-1153 and AG1549) and pyridine oxide 
derivatives (JPL-32, JPL-88 and JPL-133) may attribute part of their anti-HIV 
activities to the inhibition of Tat (De Clercq, 2004b). The use of chemokine 
receptors as secondary receptors for HIV cell entry (as discussed in section 1.5.4) 
has led to the development of therapies using modified chemokines and small 
molecule antagonists to prevent HIV binding with these receptors on the cell 
surface. Many companies are now researching chemokine-receptor blocking 
therapeutics (Cohen, 1997).
The global prevalence of HIV is illustrated in appendix I (UNAIDS and WHO,
2003), which identifies many developing nations with high numbers of infected 
persons. Many developing countries have poor medical health systems due to 
weak economies and unstable political situations. In practice this may mean that 
reliable distribution of drugs throughout some countries may not be possible, 
incorrect prescription of drugs may occur due to inadequate facilities for 
diagnosis and improper use of drugs by poorly educated patients is common 
(Heymann et al., 1993; Stevens et al, 2004). It is important to realise that in a 
weak economic environment expensive antiviral treatments are not available to 
the infected public as a whole and priorities centre on improving the medical 
infrastructure and increasing education about the transmission of HIV 
(Kengeya-Kayondo et al, 1997). Most of the developing countries rely on 
international organizations to donate drugs or to provide them at reduced cost 
for the treatment of many HIV-related secondary infections. However, few 
drugs are available for the treatment of HIV infection and this has prompted the 
World Health Organisation to initiate an international effort to increase the 
availability of antiretroviral drugs to 3 million infected persons in developing 
countries by 2005 (Elliott, 2002). Some treatment programs or trials are 
underway in Africa to prevent mother to child perinatal transmission of HIV 
(Perez ct al, 2004; Taha et al, 2004). Evaluation studies have been carried out in
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some African countries and assessments are planned in others to enable wider 
access to therapy for HIV (Katzenstein et al., 2003; Nguyen et al., 2003; Kober 
and Van Damme, 2004; Zulu et al, 2004).
1.8.2 Vaccines
The effectiveness of newer combinations of anti-HIV drugs may improve the 
outlook for the control of HIV infections by chemotherapy, however lengthy 
treatment periods are required and the drugs are relatively expensive, i.e. about 
$10,000 per person each year. The cost would be much too high for persons in 
developing countries which have the highest incidence of HIV. Therefore, the 
development of an effective vaccine is still very important for the global control 
of HIV. The preparations for AIDS vaccine trials in developing countries must 
respect the ethics of the host nation and consider the public reaction to AIDS 
vaccination (Katongole-Mbidde, 1994). Communication with the people of 
vaccine host nations and their education into the vaccination programme should 
be an important preparation stage for vaccine trials.
In order to assess the efficacy of an AIDS vaccine the use of an animal model has 
been essential. HIV-1 has been shown to infect chimpanzees, gibbon ape, and 
rabbit, but development of disease does not parallel that of humans. The 
chimpanzee species is endangered, thus massively limiting their experimental 
usage (Gardner and Luciw, 1989). The use of a rodent as an animal model for 
AIDS has been precluded due to the inefficient replication of HIV in rodent cells 
caused by post-transcriptional blocks (Bieniasz and Cullen, 2000; van Maanen 
and Sutton, 2003). FIV in cats can provide a model for HIV disease and 
development of this system to study the efficacy and immune correlates of 
vaccines is underway (Burkhard and Dean, 2003). SIVmac (closely related to 
HIV-2) infection of rhesus macaque monkeys leads to disease and this has been 
the basis of the development of the animal model for AIDS (Geretti, 1999).
52
Experiments carried out by Joag et al. (1997) in pig-tailed macaques have 
established that they may be used as a model for intravaginal transmission of 
HIV. A single intravaginal inoculation of a chimeric virus SHIVku-i resulted in 
infection that led to AIDS in the animals. Chimeric viruses or SHIVs consisting 
of SIVmac genome with HIV gene insertions (including tat, rev, vpu and env) 
have been shown to infect macaques and produce neutralizing antibody and 
CTL responses (Joag et al., 1997; Ui et ah, 1999). The use of SHIV chimeras allows 
testing of potential human vaccines in the macaque model (Barouch et al., 2000).
Early vaccine development was centred on the use of the HIV envelope protein 
to produce protective neutralizing antibodies, more recently there has been a 
shift in focus towards the production of a cell mediated immune response 
(specifically CTLs) from vaccination. However it is now widely accepted that a 
successful vaccine for AIDS will have to stimulate the whole immune system; 
innate, humoral and cellular responses (Letvin, 1998; McMichael et al., 2002). 
The major types of vaccines developed for HIV include chemically inactivated 
whole virus, antigen subunits, live attenuated virus, plasmid DNA with viral 
gene inserts and live recombinant vectors expressing viral DNA.
Vaccines based on chemically inactivated whole virus have been used 
successfully to prevent viral infection such as influenza. Early studies showed 
that formalin-inactivated whole SIV vaccine protected macaques from 
challenge with the same strain of SIV (Murphey-Corb et al., 1989, Desrosiers et 
ah, 1989). A number of research groups followed different protocols. The 
strains of SIV varied, examples used included SIVmac251 and SIVsmE660. A 
variety of vaccination regimens were carried out and the macaques were 
challenged w ith various doses of live virus via intravenous and mucosal 
routes. Cranage et al. (1992) showed protection of 4 /4  macaques from 
intrarectal (mucosal) challenge with SIV after a series of intramuscular 
vaccinations. Putkonen et al. (1992) went on to demonstrate the use of whole
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inactivated  SIVmac to p ro tec t 4 /4  m acaques from  hetero logous challenge w ith  
SIVsm.
The success of these whole inactivated virus vaccine studies was short lived 
as research revealed that protection was due to anti-cell immune responses. 
The vaccine strains of SIV and the challenge stocks were all grown on hum an 
cell lines. Therefore the virus membrane presented antigenic human cell 
proteins at its surface against which the macaques' immunities were raised, 
and hence protection was afforded. Experiments to confirm this suspicion 
showed that macaques vaccinated with whole inactivated SIV grown on 
human cells were not protected from SIV challenge with virus grown on 
macaque cells (Stott, 1991; Cranage et al., 1993; Putkonen et al., 1993; Goldstein 
et al., 1994).
Antigen subunit vaccines for AIDS have also been investigated. They consist of 
an immunogenic carrier in combination with a viral protein (mainly envelope 
glycoproteins). Studies in macaques with SIV subunit vaccines have been 
carried out following some early promising work by Berman et al. (1990) in 
which 2 chimpanzees were protected from homologous HIV-1 infection by 
vaccination with recombinant gpl20. A glycoprotein enriched subunit vaccine 
protected 2 of 4 macaques from homologous SIV infection in research by 
Murphey-Corb et al. (1991). Giavedoni found that vaccination with SIVmac 
gpl30 alone did not protect macaques from viral challenge. However, when 
SIVmac gpl30 was used as a boost in conjunction with recombinant vaccinia 
virus expressing SIVmac gpl30, then the viral load of the macaques after virus 
challenge was reduced (Giavedoni et al., 1993). Similarly, reduced viral load and 
partial protection from infection was achieved after vaccination with gag and 
env proteins and with env proteins alone by Israel et al. (1994). In a more recent 
study 8 macaques were protected from homologous challenge with SHIV- 
W6.1D after vaccination with recombinant HTV-1 gpl20 in SBAS2 adjuvant. All 
the protected animals had anti-gpl20 antibodies and virus neutralizing 
antibodies after vaccination, but pre-challenge only 3 of the 8 had intermittent
54
CTL responses (Mooij et ah, 1998). Further development of the research into 
subunit vaccines is required to increase the vaccine antigenicity and to establish 
correlates of immunity. Towards this end the production of oligomeric envelope 
glycoproteins is being optimised. It is hoped that oligomeric conformations will 
give rise to antibodies capable of neutralizing primary virus isolates. If so, then 
they may play an important role in conjunction with DNA vectors in bimodal 
vaccines for HIV.
Live attenuated virus vaccines rely on in vitro laboratory propagation of 
replication competent virus with reduced pathogenicity and they have been 
used successfully to prevent virus infections such as measles, polio and chicken 
pox. Initially studies with SIV attenuated by deletions in the nef gene showed 
that macaque monkeys could be protected from subsequent wild-type virus 
infection (Daniel et ah, 1992). Use of the macaque model has led to the discovery 
that vaccination with live nef attenuated SIVmac will protect macaques from 
intravenous challenge with pathogenic SIVmac, by rectal mucosal challenge and 
from cross-strain challenge (Cranage, 1993; Cranage et ah, 1997). In a SIV vaccine 
study with a 12 base pair deletion in nef repair of the deletion occurred by a 
sequence duplication event and subsequent sequence mutation. The gene repair 
coincided with a reversion to virulence and resulted in an increased viral load 
and consequent disease progression (Whatmore et ah, 1995). Studies in this line 
of vaccine development showed that the attenuated SIV vaccine strain caused 
AIDS and death in neonatal and adult macaques (Baba et ah, 1995; Hofmann- 
Lehmann et ah, 2003). In contrast, work carried out by Desrosiers (1998) with 
SIV attenuated by ne/deletion and by nef and vpr deletions has not led to disease 
in macaques after 9 years of follow up. However there are still some safety 
concerns regarding the possible pathogenicity of such attenuated viral strains, 
and many unanswered questions about the long-term efficacy of vaccinating 
people with live attenuated strains of HIV. There is an ongoing study of just 
such a scenario in Australia of 7 people infected with a naturally occurring HIV- 
1 with deletions in ?jcf and in the LTR part of the viral genome. These infected
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persons had maintained low levels of plasma viraemia for between 13 and 17 
years and had no disease progression (Dyer et al., 1999). More recently the CD4+ 
lymphocyte counts of 3 of them have declined significantly perhaps signalling 
the start of immunodeficiency and disease progression (Learmont et al, 1999). 
The safety concerns seen in the attenuated SIV vaccines would appear to be 
extended to the attenuated hum an HIV infections. However these attenuated 
virus studies have revealed a wealth of information about the 
immunopathogenicity of the AIDS virus and are of value in the elucidation of 
the correlates of protection (Whitney and Ruprecht, 2004).
Limitations with the vaccination approaches described above have led to 
research into new DNA vaccine constructs including the development of 
plasmids and live recombinant vectors to deliver viral immunogens more 
capable of raising humoral and cellular responses. The development of the 
"prime-boost" concept of vaccine delivery has increased the efficacy of these 
recombinant vaccines. Priming with a recombinant vector (such as a DNA 
plasmid with the viral gene) initially stimulates the CTL response to the 
expressed protein. These cellular responses are then expanded when the boost 
vaccination of a different recombinant vector construct (such as a replication- 
defective pox virus vector expressing the viral protein) occurs a few weeks later 
(Woodland, 2004).
DNA plasmids expressing HIV or SIV genes have been developed for use as 
AIDS vaccines or as a component thereof. The plasmids vary enormously, use 
different delivery systems and express different HIV or SIV genes. Early work 
by Wang et al (1993) demonstrated the potential of DNA vaccination for AIDS. 
Wang et al showed that 8 of 10 BALB/c mice inoculated with plasmid DNA 
expressing H IV -1 hxb2 gpl60 elicited cellular and humoral immune responses. 
Antisera from 8 of the mice neutralized HIV-1 nm in MT-2 cells and inhibited 
CD4-binding. Lymphocyte proliferation to recombinant gpl20 (rgpl20) was also 
observed. Lu et al (1996) vaccinated 7 macaques with a plasmid expressing a
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combination of 5 SIVmac genes by intramuscular, intravenous and gene gun 
routes. One plasmid encoded an 8.2kb S1Vmac239 insert and expressed non­
replicating virus particles. The other 4 plasmid constructs expressed SIV 
envelope glycoproteins. Throughout the vaccination regimen the immune 
responses of the macaques were monitored; transient neutralizing antibodies 
were elicited in all 7 macaques and persistent CTL responses to env were raised. 
However viral challenge with SIVmac251 led to infection in all monkeys and to 
CD4+ cell loss subsequently. In the vaccinated macaques as compared to the 
control group the acute viral stage was foreshortened, but chronic infection was 
not prevented and viral loads in this latter stage were not reduced. Egan et al. 
(2000) showed that 3 of 4 macaques had much reduced viral loads following 
virus challenge after SIV gag DNA plasmid vaccination. This study correlated 
gag-specific CTL response with protection from disease progression. Barouch et 
al. (2000) initially showed protection from disease after SHIV-89.6P challenge in 
all 8 macaques vaccinated with an S1Vmac239 gag and HIV-1 89.6P env 
expressing DNA plasmid coupled with an IL-2-immunoglobulin cytokine 
fusion protein or with an IL-2-immunoglobulin plasmid. Seven of the 8 
macaques have remained disease free for 2 years post-chaUenge. One macaque 
died after 52 weeks of AIDS after viral mutation in gag allowed escape from CTL 
recognition (Barouch et al. 2002). The death of this monkey exposes a worrying 
limitation of the protection offered by this type of vaccine. Perhaps more 
promising was the small pilot study carried out by Letvin et al. (1997) with only 
2 rhesus macaque monkeys. The main aim of the study was to examine the 
humoral antibody titres elicited in response to plasmid DNA vaccines 
expressing HIV-1hxbc2 derived env (as gpl20 and membrane bound gpl60) and a 
boost of HIV-Iiiib gpl60. The gpl20 binding antibody titres rose considerably 
after the protein booster. Pre-boost antisera did not neutralize SHIVhxbc2 in MT- 
2 cells whereas post-boost antisera did. Env-specific CTL responses were also 
observed in both monkeys. Protection from disease following SHIV challenge 
was achieved over a 21 week follow up period. More importantly this small
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study illustrated the potential of bimodal vaccination to extend the immune 
responses and to encompass both the cellular and the humoral elements.
A wide variety of live recombinant vectors expressing genes from AIDS viruses 
have been developed including alphaviruses, herpesviruses, recombinant yeast. 
Salmonella, Listeria, adenoviruses and poxviruses. After disseminated vaccinia 
infection in an HIV infected person (Redfield et al., 1987) safety concerns about 
vaccinating immunocompromised persons with vaccinia virus has led to 
research into the efficacy of using attenuated poxviruses NYVAC, ALVAC 
and modified vaccinia Ankara (MVA) to deliver the immunogens. NYVAC 
originated from the vaccinia virus Copenhagen strain and has specific 
virulence and host range genes deleted from its genome rendering it safe to 
use in hum an vaccines (Paoletti, 1996). ALVAC is derived from canarypox 
virus and is unable to produce infectious virus progeny in mammalian cells 
(Baxby and Paoletti, 1992). MVA is attenuated vaccinia virus Ankara strain 
obtained after passage 500 times on primary chick embryo fibroblasts. MVA 
has multiple deletions in its genome and has very limited replication on 
human cells, enabling its use safely even in the immunocompromised host 
(Mayr et ah, 1978; Meyer et al., 1991; Blanchard et al., 1998). MVA was used at 
the end of the Smallpox eradication campaign to successfully and safely 
vaccinate more than 120000 people (Mayr et ah, 1978). In one study the use of 
MVA as a vector for SIV vaccine constructs led to persistent anti-vector 
antibody responses from all the macaques throughout the immunization 
regimen. These anti-MVA vector antibodies were associated w ith a reduction 
in the CTL response to the expressed SIV recombinant protein (Sharpe et al., 
2001). Adenovirus vectors such as those using adenovirus serotype 5 (Ad5) 
have also been studied for use as delivery systems for AIDS virus genes. 
However pre-existing immunity due to CD8+ T lymphocytes and neutralizing 
antibodies to the Ad5 capsid in human populations limits the recombinant 
protein expression of the vector (Gahéry-Ségard et al., 1998; Sumida et al..
58
2004). Further development of novel adenovirus vectors with different capsid 
proteins may overcome this limitation (Gall et at, 1998).
Much of the early vaccine research into the use of live recombinant vectors as 
vaccines for AIDS was carried out using small numbers of macaques and 
expression of SIV or SHIV genes. Israel et at (1994) used 2 recombinant 
vaccinia vectors expressing SIVmacBK28 gag or env genes to prime 6 macaques 
and then boosted them with gag an d / or env proteins. The 3 macaques which 
received the recombinant vector expressing SIV env and env protein had 
partial protection from disease following viral challenge; w ith reduced viral 
load in two and apparent clearance of virus from blood and lym ph nodes in 
one. Of the 3 macaques which received the recombinant vector expressing SIV 
gag and env and the gag and env protein boosts only 1 macaque had a 
reduced viral load following viral challenge compared to the controls. All 6 
macaques had neutralizing antibodies to env and those vaccinated w ith gag 
had neutralizing antibodies to gag. Lymphocyte proliferative responses were 
seen in 4 of the 6 macaques, but these did not correlate with protection from 
SIV challenge. Benson et at (1998) inserted SIVK6W gag, pol and env into the 
NYVAC vector and administered this vaccine (NYVAC-SIV) to 24 macaques. 
Eight received NYVAC-SIV alone, 8 received NYVAC-SIV and NYVAC 
expressing interIeukin-12 (NYVAC-IL-12) and 8 received NYVAC-SIV, 
NYVAC-IL-12 and NYVAC expressing interleukin-2 (NYVAC-IL-2). After 3 
vaccinations the antibody titres of the macaques which had received NYVAC- 
SIV alone were 3 times higher than those of the macaques which had received 
the cytokine expressing vectors. The macaques which also received NYVAC- 
IL-12 had CTL responses after 3 vaccinations. Half of each group were 
challenged intravenously and half intrarectally (mucosally) w ith SIVmac251. 
All of the macaques that were challenged intravenously became infected. Five 
of 11 macaques challenged intrarectally were able to clear the virus and 6 of 
11 became chronically infected, but their disease progression was slower than 
that of controls. In this study CD8^ T-helper cell induction by vaccination
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correlated with post-challenge viral load and slower progression to disease. 
Ourmanov et al. (2000) carried out a study involving 24 macaques with a 
lengthy follow up period. Three groups of 6 macaques were vaccinated with 
recombinant MVA expressing gag, pol an d /o r env genes from SIVsmH-4 and 6 
control macaques received non-recombinant MVA. Four weeks later they 
were challenged intravenously with the closely related SIVsmE660. Following 
viral challenge all of the macaques became infected; the 18 which had 
received MVA-SIV recombinant vaccines had reduced plasma viral loads 
compared to the controls, and 4 of these became virus culture negative after 6 
to 16 weeks. After 19 months post-challenge 10 of the vaccinated monkeys 
and 1 control monkey were still alive. Four of the surviving vaccinated 
monkeys had no apparent disease progression. Barouch et al. (2001) studied 
the immune responses and subsequent viraemia post-SHIV-challenge of 4 
macaques immunized with recombinant MVA expressing SIVmac239 gag-pol 
and HlV-1 89.6 env. The vaccinated macaques elicited strong CTL responses and 
high titre neutralizing antibodies following the highly pathogenic SFIIV-89.6 
challenge and showed no signs of disease progression. In this study pre­
challenge CTL responses correlated with reduced post-challenge viral loads. 
Amara et al. compared the immunogenicity and the protective efficacy of a 
combined DNA plasmid and a recombinant MVA vector vaccine w ith the 
recombinant MVA vaccine alone (Amara et al, 2001, Amara et al., 2002). One 
group of macaques was immunized twice with a DNA plasmid expressing 
SHIV-89.6 gag, pol, vif, vpx and vpr of SIV origin and env, tat and rev of HIV-1 
origin. These were followed by a third immunization of the recombinant 
MVA booster expressing SHIV-89.6 gag, pol and env. A  second group of 
macaques were immunized with of 3 vaccinations of rMVA. Seven months 
after the booster the macaques were challenged intrarectally w ith the 
pathogenic SHIV-89.6P. Comparison of the immune responses to the 
vaccinations by the 2 groups revealed that the rMVA only vaccine raised 
much lower levels of CD8+ T lymphocytes and much higher titres of envelope 
binding antibodies than the DNA plasmid /  rMVA vaccine combination.
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After viral challenge all of the macaques became infected; the levels of 
infected CD4 cells was higher in the rMVA only vaccinated macaques and the 
cell free viral load was higher in the DNA plasmid /  rMVA vaccinated 
macaques. Despite these differing patterns and kinetics of the immune 
responses to the two vaccine systems all of the vaccinated macaques 
controlled their infections to the limit of detection and maintained their CD4 
cell counts.
Further understanding of the immune correlates of protection raised by 
experimental HIV vaccines is essential to the development of an effective 
prophylactic vaccine. In order to determine how far the safety, immunogenicity 
and protection seen in vaccine animal models is extended to the prevention of 
HIV infection in humans (or the slowing of disease progression) the next stage 
in vaccine development has been the commencement of human HIV vaccine 
trials. To this end the limitations of the animal models available are 
acknowledged and a number of candidate vaccines have been tested in human 
trials to establish their safety and immunogenicity.
A large number of candidate vaccines have been evaluated within the AIDS 
Vaccine Evaluation Group (AVEG) which was set up in 1990 to monitor Phase I 
clinical trials of 14 vaccines in HIV-uninfected recipients. The first 14 candidate 
vaccines contained the envelope glycoproteins, gpl20 or gpl60 singly or 
together, from cell line adapted viruses. The vaccines induced virus-neutralizing 
antibodies with strong neutralizing activities against homologous and, in some 
cases, heterologous cell line adapted viruses. However, none of the antibodies 
was able to neutralize primary HIV-1 isolates (Matthews, 1994; Wrin & 
Nunberg, 1994; Mascola et ah, 1996b). Whereas sera from naturally infected 
persons binds preferentially to native forms of gpl20/160, sera from vaccinees 
preferentially bound to denatured forms of gpl20, suggesting the lack of 
antibodies against conformational epitopes (VanCott et al, 1995a). It seems 
probable that the vaccines had sub-optimal protein conformations that did not
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mimic the oligomeric structure of gpl20/gp41 in the envelope glycoprotein. 
Vaccination of rabbits with a highly purified oligomeric form of gpl60 induced 
high titre antibodies, some of which neutralized some primary HlV-1 isolates 
(VanCott et ah, 1997). The inability of sera raised in vaccinees to neutralize 
primary isolates may be due to differences in the exposure of specific epitopes in 
these viruses, compared with the vaccine strain. This is evidenced by the 
inability of V3 loop-specific antibodies to recognise macrophage-tropic viruses 
(Bou-Habib et ah, 1994) and the lower neutralizing activity of V3 loop specific 
antibodies towards primary compared with the cell line adapted virus HIV-1 mn 
(VanCott et ah, 1995b). This parallels the differential susceptibilities of primary 
and cell line adapted viruses to neutralization by soluble CD4 (Daar et ah, 1990; 
Ashkenazi et ah, 1991; Moore et ah, 1992). As mentioned above, the possibility of 
misleading results should be minimised by using primary isolates instead of cell 
line adapted viruses in antibody neutralization assays, especially in vaccine 
studies (Matthews, 1994; Sawyer et ah, 1994).
Vaccine-induced CTL were found most frequently (15-40%) in recipients of the 
live vector vaccines, such as the recombinant pox vectors with HIV-1 env gene 
(McEhath et ah, 1997). The next stage of trials evaluated vaccines with DNA 
plasmid or live recombinant vectors expressing HIV env and other HIV genes. 
Recombinant Canarypox vaccine expressing gpl60 or gpl20 with gag /  pol of 
H IV -Imn were tested in humans; 90% developed antibodies and 40% CTLs 
(Oxford and Jeffs, 1996). The DNA plasmid vaccine trial carried out recently by 
MacGregor et ah (2002) had some unexpected results. Eighteen volunteers were 
vaccinated with a DNA plasmid expressing H IV -Imn env and rev at 3 doses 
(lOOpg, 300pg and lOOOpg). No antibodies were detected by ELISA to rgpl20 of 
H IV -Imn or rgpl60 of H IV -Iiiib  following vaccination. CD4+ CTL responses to 
env were detected in the peripheral blood of 66% of the 12 vaccinees who 
received 300pg or lOOOpg of the vaccine, and CD4+ CTL responses to rev were 
detected in the blood of 50% of these higher dosed groups. The complete lack of 
CD8+ CTL response in humans to tliis DNA plasmid was not anticipated.
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However some encouraging results were obtained from a vaccine trial recently 
completed in Uganda, where an ALVAC vector expressing H IV -Imn env (clade 
B), gag and pol (protease) was assessed for cross-clade immunogenicity to 2 of 
the predominant HIV-1 clades in the population (clades A and D). At present 
the recombinant genes are from clade B viruses and it is important that the 
vaccine-induced CTL should be able to recognise and lyse primary isolates of 
HIV-1 from various HIV-1 clades. Five of the 20 vaccinees in this trial had 
detectable CD8+ CTL responses following vaccination to clade B gag or env: All 
5 had cross-clade reactivity with clades A and / or D. Three of the vaccinees had 
antibodies capable of neutralizing cell line adapted H IV -Imn and the antibodies 
of 2 of these vaccinees were capable of neutralizing primary virus albeit at low 
titres. None of these antibodies were able to neutralize viruses from clades A or 
D (Cao et al 2003). As demonstrated in this study, a single clade vaccine is able 
to raise cross-clade CD8+ CTL responses in a population where multiple viral 
clades are present.
In a recent vaccine study carried out in the United Kingdom a regimen of 
plasmid or MVA vector or a DNA-prime MVA-boost both expressing HIV-1 
clade A Gag p24/p l7  and a number of clade A CTL epitopes has been assessed. 
Twenty nine of the 35 volunteers elicited HIV-specific CTL responses to the 
vaccine (Mwau et al, 2004).
In  an  earlier trial to  investigate CTL responses 4 volunteers w ere vaccinated 
w ith  ALVAC-HIV expressing gpl60MN and  boosted tw ice w ith  rg p l2 0  of HIV- 
lsF2 an d  4 volunteers w ere vaccinated w ith  ALVAC-HIV expressing gpl20MN 
and  gp41, gag and  protease from  HTV-Ilai n o t com bined w ith  a  booster of 
envelope glycoprotein. CD8+ CTL responses to  envelope w ere detected in  100% 
of the vaccinees and  in  the group w hich  received the m ultip le  gene expressing 
vector 3 of 4 had  CD8+ CTL responses to  gag. The CD8+ CTL responses to  NSI 
prim ary  isolates from  clades A to  F w ere then  assessed for 2 vaccinees from  each 
group: one of sam ples from  the ALVAC plus booster g roup show ed  b road  
cross-clade reactivity to all 6 p rim ary  isolates, the o ther d id  no t recognise any. 
The sam ples tested from  the ALVAC w ithou t booster g roup  show ed restricted
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reactivity -  one with isolates from clades A, B, C, D and E and the other with 
isolates from clades A, B, C and F (Farrari et at, 1997). Clement-Mann et al. 
(1998) vaccinated 101 volunteers in 3 groups with either recombinant ALVAC 
expressing H IV -Imn gpl60 alone, ALVAC expressing H IV -Imn gpl60 with a 
booster of H3V-1sf2 rgpl20 or HIV-1sf2 rgpl20 alone. Neutralizing antibodies to 
H IV -Imn and HIV-1sf2 were found in the sera from aU of the ALVAC- 
gpl60/rgpl20 vaccinees, in less than 65% of ALVAC-gpl60 alone vaccinees and 
in 89% of rgpl20 only vaccinees. CD8+ CTL responses were detected in the 
peripheral blood of 37% of ALVAC-gpl60/rgpl20 vaccinees, 22% of ALVAC- 
gpl60 alone vaccinees and in 10% of rgpl20 only vaccinees. In another trial 
investigating this bimodal type of vaccine Evans et al. (1999) used ALVAC 
expressing gpl20, gp41, gag and protease genes and CTL epitopes from nef and 
pol simultaneously vaccinated with or boosted with HIV-1sf2 rgpl20 to vaccinate 
119 volunteers. CD8+ CTL responses were elicited to a broad range of epitopes 
(env 22%, gag 32%, nef 16%, and pol 19%) and were detected for up to 10 
months after the last vaccination. These trials indicate that immunogenicity may 
be significantly improved by optimisation of recombinant immunogens to 
include gag and other HTV genes with env and by their administration in 
combination with glycoprotein boosters in a bimodal vaccine regimen.
Two VaxGen vaccines have recently completed phase III trials: AIDSVAX B/B 
and AIDSVAX B/E (Berman et ah, 1999; VaxGen website: 
http://w ww.vaxgen.com ). AIDSVAX B/B is a subunit vaccine made up of 
rgpl20 from H IV -Imn and HIV-1gne8 (both subtype B). The AIDSVAX B/B trial 
took place in North America and Europe and involved 5400 volunteers at risk 
for HIV infection. The primary endpoint of the trial was to prevent sexual 
transmission of HIV-1. The vaccine did not achieve this endpoint, however there 
were significant reductions in HIV-1 infection among black and Asian vaccinees. 
The protection from infection coincided with higher levels of neutralizing 
antibodies observed in these two ethnic groups. AIDSVAX B/E is a similar 
vaccine made up of rgpl20 derived from HIV-1 isolate sequences of clade B and
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of clade E, which is common in Thailand where this trial took place. The 
primary endpoint of the trial was to prevent blood-borne HIV-1 transmission in 
2546 injecting drug users. The secondary endpoint was to slow disease 
progression in vaccinees who became infected with HIV-1. Neither of these 
endpoints was achieved.
However disappointing the protective outcome of these first two phase III trials 
may be, they provide an enormous amount of useful information regarding 
immunogenicity, safety and logistics of vaccination and follow up. These 
vaccine trials have demonstrated a function model for phase III trials of other 
AIDS vaccines.
If an AIDS vaccine is to be effective it should expose conformational epitopes in 
the gpl20 for the induction of high titre virus neutralizing antibodies to primary 
isolates and it should present multiple epitopes in the envelope, gag and other 
virus proteins to stimulate specific CTL responses with cross-clade reactivity 
(Ada & McEhath, 1997). A further complexity to be overcome in the vaccine 
design involves the presence of CTL epitopes that can be presented by the 
diverse MHC class I alleles found within the population to be vaccinated 
(McEhath et ah, 1997). Systems of vaccine delivery that stimulate mucosal 
immunisation is another area of research to be developed, as the majority of 
HIV infections are transmitted via this route (Lehner and Anton, 2002).
1.9 AIDS Research in Uganda
1.9.1 Preliminary Studies
At about the time when the fhst cases of "slim disease" were being recorded and 
shown to be associated with the presence of antibodies to HIV-1 (Serwadda et 
ah, 1985) the extent of HIV infection in several hospitals was examined in a 
number of serosurveys. These were organized mainly by local clinicians and 
nurses who dispatched many blood samples for analysis at the Centre for 
Applied Microbiology (CAMR) at Porton Down, Wiltshhe, UK, thereby
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initiating a prolonged collaboration between Uganda and CAMR in AIDS 
research. These serosurveys demonstrated the severity of the HIV epidemic in 
urban Uganda and along the main highways (Carswell, 1987; Hudson et ni, 
1988; Carswell et ah, 1989; Berkley et ah, 1990) and led to the first isolations of 
Ugandan variants of HIV and the characterization of some of these in MRC- 
funded projects based at CAMR (Downing and Roff, unpublished data; Oram et 
ah, 1990,1991). The preliminary serosurveys were followed by more systematic 
surveys organized by the WHO and based in the Uganda Virus Research 
Laboratory at Entebbe.
1.9.2 The WHO and the Uganda Virus Research Institute (UVRI)
The UVRI (Director: Dr S. Sempala) has a long history of bio-medical research 
and through its Department of General Virology (Head: Dr Benon 
Biryahawaho) the Institute collaborated with the WHO and several European 
and American laboratories to undertake virological and molecular studies on 
Ugandan variants of HIV-1. This collaboration led to the development of the 
capacity for large scale serosurveiUance studies and in 1987 the Institute 
undertook a national survey to determine the extent of HIV infection in various 
parts of the country. This survey revealed a peak in HIV-1 infection in 20-24 
year old women at 25% and a peak for men aged 25-29 years at 24%; overall 
women were 1.31 times more likely to be infected with HIV than men (Berkley 
et ah, 1990). However only 60% of these positives were confirmed by Western 
blot and the overall prevalence may have been lower. In addition to its 
continuing role as a primary HIV diagnostic centre, the Department has 
developed the facilities and expertise for the virological, serological and 
molecular biology techniques required for the isolation and characterization of 
HIV, including tissue culture, the analysis of HIV antibodies and the genotyping 
of viruses by heteroduplex mobility assays (HMA) of polymerase chain reaction 
(PCR) products from DNA extracted from leucocytes from infected persons. 
Through its AIDS clinic (Head: Dr B. Tugume), UVRI provides a diagnostic 
service for the local population and the clinic has been a valuable source of HIV-
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infected materials. The Department of General Virology has initiated 
collaborative projects with other laboratories, including CAMR, to provide virus 
isolates, virus infected cells and matched sera for collaborative studies in the UK 
and elsewhere. Many of the viruses and sera used in this study were produced 
from blood samples obtained by the Department from the UVRI clinic.
The scientific capacity of the Department is recognized world wide and in 1995 
the MRC made a joint award of a project grant to UVRI and the MRC 
programme on AIDS in Uganda (MRCPA) with the objectives of further 
strengthening the virological capacity at UVRI in order to characterize Ugandan 
variants of HIV. A summary of the work done in this project is given at the end 
of the next section.
1.9.3 The Medical Research Council Programme on AIDS in Uganda 
(MRCPA)
In 1988 the British MRC was approached by the Ugandan government for 
assistance in the emerging HIV-1 epidemic. This request led to the development 
of the MRC Programme of Research on AIDS in Uganda based at the UVRI in 
Entebbe. The aims of the programme were to investigate the epidemiology and 
the natural history of HIV-1 infection and associated disease progression in 
rural Uganda. To date HIV-2 infection has not been detected in Uganda, 
although it is present to the south in the bordering area of north western 
Tanzania (Schmutzhard et ah, 1989).
In 1989 a general population cohort was established in a sub-county in the rural 
Masaka district one hundred miles south west of Entebbe (See map in Appendix 
II). Almost half of all adult deaths in this rural sub-county are HIV-related and 
80% of young (13 - 25 years) adults' deaths are due to AIDS. This cohort was set 
up including about 10,000 people, half of them adults over 13 years of age. The 
general population cohort is surveyed annually and yields information on the 
prevalence and incidence of HIV-1 in the area and the effects of education and 
intervention studies. Recruitment of individuals to the cohort averaged 70% in 
the 15 neighbouring villages, but was lower in the trading centres, and follow
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up averaged 62%. HIV-1 seroincidence in this area had been estimated at 1% per 
year in a study of nearly 8000 subjects (Mulder et al., 1994). This study has now 
completed the tenth annual round of the survey. Age-sex standardized HIV-1 
seroprevalence in this cohort over the last 4 years has declined from 7.7% to 
6.4% (Whitworth et al, 2002).
In 1990 the Natural History cohort in rural SW Uganda was established within 
the general population cohort. To date, 390 participants have been enrolled, 93 
seroprevalent subjects, 86 seroincident subjects and 168 sero-negative control 
persons of whom 43 are of discordant relationships. The aims of this cohort are 
to determine the rate of progression to disease and the risk factors for 
progression. In the Natural History cohort there is continual recruitment of sero­
negative spouses of discordant relationships, new cases of HIV-1 infection and 
their matched HIV-1 negative controls from the general population cohort. The 
Natural History cohort sees participants quarterly at the clinic where a detailed 
health questionnaire is filled out. A full medical examination is carried out and 
treatment is administered by the clinicians. Blood, faeces and urine samples are 
collected for laboratory investigations including tests for STDs, T cell counts and 
isolation of HIV-1. The HIV-1 prevalence rates in young men (aged 13 to 24) had 
fallen from 3.5% in 1990 to 1% in 1995 and in young women (aged 13 to 24) from 
9.7% to 7% in the same time course. The overall prevalence rate of the rural 
study population in the Natural History cohort had stabilised at 8% (Kengeya- 
Kayondo et al., 1995,1996; Mulder, 1995).
The MRC ADR project grant, which terminated in September 1996, was focused 
on the isolation and characterization of primary isolates from cohorts in the 
MRCPA. One of the main objectives of the project was that the UVRI/MRC- 
ADP facility would act as a primary laboratory which would supply samples 
from infected persons for analysis in collaborating secondary laboratories in the 
UK and Europe. This objective was successfully achieved by collaborations with 
the Regional Public Health Laboratory at Cambridge, which housed one of the 
two MRC Repositories for HIV in the UK, the University of Edinburgh, which 
accommodated the other MRC Repository, the WHO International Laboratory
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for Biological Standards based at the National Institute for Biological Standards 
& Control (NIBSC) at South Mimms, Hertfordshire and CAMR at Porton Down 
which also had large culture and sample collections. Of special interest in this 
study was the virus isolation and characterization work carried out in Dr Ulrich 
Desselberger's laboratory at Cambridge and by Dr Harvey Holmes at NIBSC. As 
shown in the Materials and Methods Section, primary isolates and sera from the 
Natural History cohort in rural SW Uganda were obtained from the MRC's 
Cambridge repository: almost all of these had been genotyped by DNA analysis 
of sequences from the gag and env genes. In addition, primary virus and serum 
samples from persons in the Entebbe/  Kampala area were obtained from the 
WHO.
The MRC-ADP project at Entebbe had genotyped about 100 proviruses from the 
Natural History cohort in rural SW Uganda by DNA sequence analysis of the 
gag (p24) gene and by heteroduplex mobility assays (HMA) of the V3-V5 
regions of the env gene. Sequence data was obtained for 73 proviruses, 41 of 
which were assigned to clade D, 27 to clade A and 1 to clade C: although clade B 
proviruses have been reported from Uganda, none were detected in this cohort. 
Phylogenetic analysis of the gag sequences revealed that there is considerable 
diversity within the p24 region in both clades, with a maximum divergency of 
about 10%. This level of divergence is probably a reflection of the long 
established presence of HIV in this community. More closely related sequences 
were obtained from sexual partners in the 4 known couples included in the 
study. HMA analysis of the env gene gave broadly similar results: out of 84 
which gave unambiguous data, 32 proviruses were assigned to clade A and 52 
to clade D. However, comparison of the two sets of data indicates that some of 
the proviruses were recombinants. Thus, for the 60 proviruses for which both 
DNA sequence and HMA data is available, 10 (16.7%) had gag and env gene 
sequences from different clades. A similar frequency of recombinant genomes 
has been reported for several other African countries where multiple clades of 
HIV are present (Comelissen et al, 1996; Kampinga et al, 1997). These 
recombinants must have been produced during mixed infections and lead to
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rapid major changes in virus genotype. The implications of a large proportion of 
genetic recombinants in disease progression or vaccine strategies are unknown. 
The Natural History cohort in rural SW Uganda offers a unique opportunity to 
study the interaction between a relatively well characterized group of viruses 
and their infected hosts.
1.10 Study Objectives
There were two main objectives in the work presented in this study:
Firstly, to develop an assay to determine the subtype or clade of the viruses 
which were circulating in Uganda. A simple and inexpensive assay would be 
invaluable in epidemiological studies including, for example, the distribution of 
different viral clades in different parts of a country or wider region and to show 
if the pattern was changing with time. At present, HIV variants are typed by 
molecular techniques involving the amplification of viral or proviral nucleic 
acid sequences by the polymerase chain reaction (PCR) followed by DNA 
sequencing or heteroduplex mobility assay (HMA). As these methods are very 
time-consuming, require sophisticated laboratory facilities and experienced 
staff, they are very expensive. Therefore, the objective was to develop an 
enzyme-linked immunosorbent assay (ELISA) which could be used with plasma 
or sera to distinguish between the subtypes or clades of HIV-1 thought to be 
circulating in Uganda at the time: in 1991 these were thought to be clades A, B, 
C and D.
Secondly, to study some of the virological and immunological factors that might 
be important in the development of a vaccine against HIV and AIDS in East 
Africa. As the work has progressed it has become increasingly apparent that 
although vaccination appears to protect monkeys from simian AIDS (Daniel et 
al., 1992; Cranage et al., 1997; Joag et al., 1997), the correlates of infection are not 
known. Similarly, the factors (genetic, viral, immunological, environmental) 
responsible for the marked differences progression to disease in infected
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humans are also unknown. It seems probable an effective vaccine against HIV 
and AIDS will have to stimulate similar protective responses in the vaccinees 
and it is therefore important that these factors and their interactions should be 
investigated both in infected persons and in vitro. I have studied the interaction 
between virus neutralizing antibodies and Ugandan viruses from the two main 
clades (A and D) present in Uganda with the object of correlating this data with 
other viral properties - chiefly viral phenotype - and with clinical data obtained 
from patients in the Natural History cohort in rural SW Uganda (Section 3.8). I 
have also produced HIV-neutralizing antibodies in laboratory animals and 
compared their properties with those of antibodies in human HIV-1+ antisera. 
This work was started at a time when the influence of virus clade on 
neutralizing activities was not known. The early data was conflicting with one 
report that neutralization of variants from Thailand appeared to be clade 
specific; antibodies from persons infected with clade E viruses did not neutralize 
clade B viruses, and vice versa (Mascola et al, 1994). Further data have indicated 
that many human sera had good cross-clade neutralizing activities (Trkola et al, 
1995; Kostrikis et al, 1996; Mascola et al, 1996a; Moore et al, 1996). However, 
when this work was started this question had not been analyzed in depth and it 
was not known, for example, how many viruses were able to evade 
neutralization, whether disease progression was related to the emergence of 
neutralization-escape mutants.
In collaboration with the MRCPA and UVRI in Entebbe I have had access to 
isolates of HIV-1 and HIV-1 positive antisera and plasma from the UVRI clinic 
and from the Natural History cohort in rural SW Uganda. I also made two 
working visits to the MRC laboratories and UVRI in order to obtain follow-up 
samples from members of the Natural History cohort. I have used materials 
from both of these sources in the work described in this thesis.
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The work has been organized into four main areas:
1 / Analysis/characterization of Ugandan sera using a panel of synthetic 
peptides corresponding to North American and African V3 loop linear epitopes.
2 / Raising of antibodies against peptides corresponding to a major 
neutralization epitope in the V3 region of the surface glycoprotein and the 
characterization of these antibodies.
3 / Isolation and phenotypic characterization of variants of HIV-1 from two 
regions of Uganda.
4 / Characterization of neutralizing antibodies using cell line adapted and 
primary isolates of HIV-1.
Finally, I have tried to relate the virological and immunological properties of 
some of the isolates with the clinical data obtained from the Natural History 
cohort in rural SW Uganda.
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2. MATERIALS AND METHODS
All the materials used in the study are detailed in Appendix IV.
2.1 Viruses and matching plasm ^sera
Some primary isolates and many plasma, designated with "U" numbers, were 
obtained from the CAMR repository of African isolates and plasma samples. 
These samples were prepared from blood samples received at CAMR in 1985/ 6 
from Dr Wilson Carswell (Mulago Hospital) who obtained them from AIDS 
patients attending various clinics and hospitals, mostly in the Kampala area of 
Uganda.
Samples of sera/plasma were also obtained by Dr Hanny Friesen and her 
colleagues in Save The Children from sero-positive asymptomatic mothers 
attending ante-natal clinics in Kampala in 1985/7. These were also dispatched 
directly to CAMR.
Additional plasma/ serum samples from 42 AIDS patients and 93 asymptomatic 
persons, taken mostly in the UVRI clinic between 1990 and 1992, were obtained 
directly from the Department of General Virology at UVRI (Department Head: 
Dr Benon Biryahawaho). Matching samples of leucocytes, frozen in liquid 
nitrogen, were also obtained for many of these samples and I made primary 
isolates from some of these, as described in Section 2.8.2., to give a group of 
twelve paired samples of antiserum and virus from HIV-1+ asymptomatic 
individuals. A further 2 matched primary virus/plasm a samples were made 
and identical samples of these were dispatched to the World Health 
Organization and may obtained through Dr Harvey Holmes at the National 
Institute for Biological Standards and Control. These isolates and their genotypic 
and phenotypic properties are described in the Results Sections 3.3 and 3.4.
For most of these samples, the dates of sero-conversion were unknown, there 
was very limited clinical data and it was not possible to obtain follow-up 
samples at later dates. However, from the beginning of 1994, well characterized
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samples became available from actively managed cohorts within the MRC 
Programme on AIDS in Uganda.
Paired virus and plasma samples from the sero-positive participants in the 
MRCPA Natural History cohort were obtained from the MRC AIDS Reagent 
Programme (Director: Dr Harvey C. Holmes). The viruses had been isolated in 
one of the Programme's collaborating laboratories - the Public Health 
Laboratory at Cambridge (Director: Dr Ulrich Desselberger) - within the MRC- 
funded Repository for HIV. The corresponding proviruses had been subtyped 
by DNA sequencing of their gag and env genes by Catriona Baker, working in 
the same laboratory.
Natural History cohort Incident Virus/Plasma Samples:
Sample Age Sex Sero­ Isolation
number conversion date
3004 27 M 21.04.92 18.11.93 (19)
3011 35 M 09.09.93 18.01.94 (16)
3012 32 M 24.03.91 18.01.94 (34)
3013 29 M 08.09.92 18.01.94 (16)
3018 18 F 13.06.91 18.01.94 (31)
3021 44 F 02.07.91 22.02.94 (31)
3025 39 M 09.01.92 22.02.94 (25)
3028 36 F 09.04.91 22.02.94 (34)
3029 53 F 09.12.91 22.02.94 (26)
3032 27 F 23.04.91 13.04.94 (36)
3046 21 F 19.11.91 26.05.94 (30)
3048 51 M 27.01.93 26.05.94 (16)
3049 32 M 01.06.92 26.05.94 (23)
3052 40 M 06.02.93 13.07.94 (17)
3053 55 M 17.10.93 13.07.94 (9)
Numbers in brackets = months since seroconversion. Seroconversion dates
were estimated from the time of the first positive and the time of last negative 
results.
74
I made additional isolates, as described in Section S.5.2.2, from blood samples 
obtained directly from the Natural History cohort in rural SW Uganda by Dr 
Dilys Morgan of the MRCPA, who also supplied sequential serum samples from 
some of the persons listed above.
Before use all sera were heat inactivated at 56°C for 1 hour; this destroyed any 
virus present thus allowing their use outside of containment facilities and also 
destroyed any complement components.
2.2 Peptides
The following peptides for use in antibody binding assays, competitive 
inhibition assays and adsorption assays were based on published V3 loop 
sequences (Gurgo et al, 1988; Oram et al, 1991; Albert et al, 1992; Myers et al, 
1993; Bruce et al, 1994; Robertson et al, 1995). These peptides were supplied by 
the AIDS Reagent Project of the Medical Research Council or purchased from 
Cambridge Research Biochemicals, Northwich, UK. The countries of origin of 
the proviruses are shown in parentheses and their genetic subtypes in square 
brackets:
MN (USA) RKRIHIGPGRAFYTTKN [B]
MAL (ZAIRE) RRGIHFGPGQALYTTG [A/D]
Z6 (ZAIRE) RQSTPIGLGQALYTTRGRT [D]
Z3 (ZAIRE) RQSIRIGPGKVFYAKGG [U]
U1685 (UGANDA) IQRTSIGSGQALYTTR [D]
U2999 (UGANDA) IQRTHIGTGQALHTTR [D]
U31 (UGANDA) RQRTPIGLGQALYTTK [D]
The following consensus peptides spanning the V3 loop apex were based on 
consensus sequence data for subtype A and D Ugandan proviruses (Albert et al, 
1992; Bruce et al, 1994):
UG A apex RKSVHIGPGQAFYATG 
UG D apex RQSTHIGPGQALYTTN
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These and the following peptides, which were based on the same published 
data (Gurgo et ah, 1988; Albert et al., 1992; Bruce et al., 1994), were synthesized by 
Dr Cliff Shone, CAMR, Porton Down.
MN V3 loop apex HIGPGRAF
UG D V3 loop apex HIGPGQAL
UGD NFÏ3 terminus of V3 loop CTRPYNNTRQSTHI
UG D COOH terminus of V3 loop GQALYTTNIIGDIRQAHC
For the immunization of rabbits, the following full length V3 loop peptides were
obtained from the AIDS Reagent Project of the MRC (Dr Harvey Holmes). This
part of the project was funded by the European Vaccine for AIDS (Project EVA)
and the peptides were synthesised by Dr M.S.Munns (Washington Singer
Laboratories, University of Exeter): The amino acid sequences were confirmed
by nuclear magnetic resonance by Dr Robin Wait (CAMR, Porton Down).
UG A:
AC-CAACTRPNNNTRKSVHIGPGQTFYATGEIIGDIRQAHC-NH2 
UG D:
AC-KAACTRPYNNTRQSTHIGPGQALYTTNIIGDIRQAHC-NH2
U31:
AC-EAACTRPYYNIRQRTPIGLGQALYTTKGRGTTKVIGQAHC-NH2
MN:
AC-EAACTRPNYNKRKRIHIGPGRAFYTTKNIIGTIRQAHC-NH2
Additional residues were added to the N-terminal cysteine residue of the V3 
loop, shown in bold in order to couple the peptides to a protein carrier (see 
below).
2.3 Antibody Binding Assays
Peptides were dissolved in water at 2pg/m l and 50|il (lOOng) dried overnight in 
the wells of 96 well plates (Nunc). The plates were washed 5 times with wash 
solution - phosphate buffered saline (PBS; 8.0g/l NaCl, 1.21g/l K2HPO4, 0.34g/l
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KH2PO4, pH 7.3) containing 0.1% Tween 20 - and blocked with wash solution 
containing 10% calf serum for Ihr. at 37°C. Sera were diluted in blocking 
solution and lOOpl added to coated and uncoated (control) wells and incubated 
for 2 hr. at room temperature. The plates were washed and reacted with lOOpl of 
conjugate for Ihr. 45min at room temperature to detect binding of the antibodies 
to the peptides; anti-human IgG-horse radish peroxidase (Sigma) was used for 
human sera and anti-rabbit IgG-horse radish peroxidase (Jackson 
ImmunoResearch Laboratories, Inc.) was used for rabbit sera. The conjugated 
antibodies were diluted in wash solution containing 10% calf serum at the 
manufacturers' recommended dilutions, which varied from batch to batch. The 
plates were washed 5 times with wash solution and the bound antibody 
determined by reaction with lOOpl of 3,3',5,5'-tetramethylbenzidine 
dihydrochloride (TMB) solution - one TMB tablet (Sigma) dissolved in 10ml of 
buffer (O.IM citric acid, 0.2M dibasic sodium phosphate, pH 5.0) plus 2|l i 1 of 30% 
H2O2. After 30 min. the reaction was stopped by the addition of 50pl of 2M 
H2SO4. The absorbance was read at ?^=450nm (Devash et ah, 1990).
Most sera were analyzed at a single dilution, usually 1:200, and those giving 
absorbency readings at X=450nm greater than twice that obtained in the absence 
of peptide were scored positive. Some sera were assayed at serial two-fold 
dilutions and the readings used to calculate a titre arbitrarily defined as the 
dilution that corresponded to an absorbance value of 0.5 after subtraction of the 
negative control. To control the effect of day-by-day assay variations, a reference 
serum (U 3529), which reacted with all the peptides used in the study, was 
included in each set of assays. Figure 8 shows the titration by two-fold serial 
dilution of antiserum U3529 as an example of a graph from which the serum 
titre at absorbance value 0.5 was measured.
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Figure 8. Shows the titration by antibody binding assay of two-fold 
serial dilutions of antiserum U3529 as an example of a graph from 
which the serum titre at absorbance value 0.5 was measured. The 
graph shows the linear relationship between the absorbance (l=450nm) 
and the antiserum dilution in the assay.
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Appendix VI shows a comparison of serum titres at the absorbance value of 0.5 
and the absorbancy readings at 1:200 serum dilution. A number of duplicate 
readings are also shown to demonstrate the consistency of the assays. To justify 
the use of both types of measurements to establish positive or negative reactivity 
of a serum with a peptide it was necessary to compare some data. 1 considered 
that a high reading at 1:200 should reflect a high titre at 0.5 absorbance if these 
two types of reading were to be used in this thesis. In view of the good semi- 
quantitative correlation between the two methods, shown graphically in 
Appendix VI, 1 felt justified in using the much more rapid single serum dilution 
method for analysis of a large number of samples. The absorbance readings at 
1:200 serum dilutions enabled the reactivity of many sera to be assessed by 
avoiding repeated experiments with serial dilutions of each serum. All assays 
were carried out using duplicate samples and all were repeated to confirm the 
results. No direct quantitative comparisons were made between these two types 
of measurements of serum reactivity with peptides.
Larger amounts of peptides gave no significant increase in the specific signals, 
indicating that the well surfaces were saturated by lOOng of peptide.
The mean and standard deviations were calculated for titrations of the reference 
serum with each peptide and results with a probability of greater than 0.05 of 
variation outside the mean value were discarded.
The data obtained from these antibody binding assays were grouped and 
presented in Table 4 in section 3.2.3. The tabulated data was subjected to Chi 
squared analysis. The null hypothesis was rejected if the probability of an 
error was less than 5%.
2.4 Competitive Inhibition Assays
These were performed by pre-incubating lOOpl of a dilution of antiserum with 
lOOpl of serial two-fold dilutions of peptides in blocking solution for 2 hr. at 
room temperature; the mixtures were then added to antigen coated or un-coated 
wells in antibody-binding assays, as above (Wolfs et ah, 1991).
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2.5 Adsorption of Antibodies to Sepharose-Peptide Columns
Activated CH-Sepharose 4B (Pharmacia) is formed by estérification of the 
carboxyl groups in the agarose polymer with N-hydroxysuccinimide; this active 
ester is able to form covalent bonds with primary amino groups.
Peptides were coupled to activated CH-Sepharose 4B by adding Im g of peptide 
dissolved in O.IM sodium bicarbonate buffer, pHS.O to 1ml of activated 
Sepharose for 1 hr. at room temperature. The peptide-Sepharose mixture was 
then transferred to a small column, washed with blocking solution and 0.5ml of 
a 1 in 20 dilution of antiserum in blocking solution was applied to the column. 
After 1 hr. at room temperature, non-adsorbed antibodies were eluted with 2ml 
of blocking solution and assayed as described above.
2.6 Coupling of Peptides to Carrier Protein
Coupling of the V3 loop peptides to keyhole limpet haemocyanin (KLH) was 
achieved through the side-chain of terminal amino acid residues added to the 
N-terminal amino acid of the V3 loop peptide. To facilitate specific rather than 
random couplings, the peptides were synthesized with additional amino acid 
residues, as noted above. As the peptides had different amino acid sequences it 
was necessary to use three methods to achieve specific coupling of the carrier 
protein to N terminal residues of the peptides. The methods were;
2.6.1 Glutaraldehyde Coupling, which couples via the free amino group in the 
N-terminal lysine residues, was used for the UG D peptide which did not 
contain any lysine residues in the V3 loop.
l-2mg of peptide was dissolved in a solution of 4m g/m l KLH in O.OIM sodium 
phosphate (pH 7.4) and lOpl 25% (v/v) glutaraldehyde was added in 2.5pl 
aliquots. The mixture was stirred at 4°C for 60 min and then for a further 60 min 
after the addition of 0.5mg of sodium borohydride (Briand et ah, 1985). The 
conjugate was purified by dialysis.
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2.6.2 Carbodiimide Coupling, which couples via the free carboxyl group of 
glutamic or aspartic acids (Goodfriend et at, 1964) was used with the MN and 
U31 peptides, both of which contained lysine but not acidic amino acid residues 
within their V3 loops.
0.5ml of an aqueous solution (4mg/ml) of l-ethyl-3(3-dimethylaminopropyl) 
carbodiimide (EDC) was added to 0.5ml of water containing 2mg of peptide. 
The pH was adjusted to 4.5 - 5.1 and the solution was stirred for 5 mins. 5mg of 
KLH dissolved in 0.5ml of water, pH 4.5 to 5.1, was added to the peptide-EDC 
mixture and stirred overnight at room temperature. The conjugate was purified 
by gel filtration through a 30 by 1.6 cm column of Sephadex G-50 (fine: 
Pharmacia) equilibrated with 150mM NaCl at 4°C and fractions containing the 
conjugate were detected spectrophotometrically at X,=280.
2.6.3 Coupling w ith maleimidobenzoyl-N-hydroxysuccinimide (MBS): this 
method couples via disulphide bridges between cysteine residues and was used 
for the UG A peptide, which contained both lysine and glutamic acid residues 
within the V3 loop.
Maleimidobenzoyl-KLH (KLH-MB) was produced by adding lOpl aliquots of 
MBS (Img in 50pl dimethyl formamide) to 250pl KLH (4mg/ml in O.OIM 
sodium phosphate, pH 7.4). Unreacted MBS was removed after 30 min. by 
filtering through a PD 10 column (a Sephadex G-25 Medium column, 
Pharmacia) equilibrated with 0.05M sodium phosphate (pH 6.0): fractions 
containing the conjugate were detected spectrophotometrically at 1=280. The 
MB-KLH fraction was then titrated to pH 7.5 with 2M NaOH and mixed for 2-3 
hours with 40-100 fold excess of peptide (Green et at, 1982). Peptide 
concentration was estimated from the amount of free thiol using 5, 5'-dithiobis 
(2-nitrobenzoic acid) (DTNB) assay (Riddles et at, 1979). After incubation the 
solution was typically turbid.
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2.7 Immunization of Rabbits
Sixteen New Zealand White rabbits were used in the peptide inoculation 
programme. All of the rabbits were pre-bled and their sera were assayed by the 
antibody binding assay and found to have no V3 loop specific IgG reactivity. 
Four rabbits were inoculated with each of the peptides: two with conjugated 
peptide-KLH and two with uncoupled peptide as shown in Table 12.a in the 
results Section 3.7.1. The vaccination programme consisted of subcutaneous 
inoculations spaced four weeks apart; two inoculations of lOOng of the specified 
conjugated or unconjugated peptide mixed 1:1 with Freund's incomplete 
adjuvant, followed by four inoculations of lOOpg of the peptide or peptide 
conjugate containing the same amount of peptide mixed 1:1 with Freund's 
incomplete adjuvant^. Two weeks after each of the lOOpg inoculations a blood 
sample was taken from the marginal vein of each rabbit's ear. These blood 
samples were allowed to clot for 30 min at 37°C. The clots were reduced 
overnight at 4pC the sera were then removed from the clot with a pastette. The 
sera were assayed for V3 loop specific IgG activity by the antibody binding 
assay described above (data are shown in the Results Section).
2.8 Preparation of Peripheral Blood Mononuclear Cells
2.8.1 Preparation of Feeder Cells for Co-cultivation Experiments 
Concentrated buffy coat cells obtained from the Blood Transfusion Service 
typically containing about 8 x 10  ^ cells, mostly white cells in about 100ml of 
plasma were diluted 1:1 in Dutch modified RPMl 1640 cell medium (ICN Flow) 
containing 10% foetal calf serum (RPMI/FCS): The suspension was centrifuged 
at 200g for 10 min. at 25°C and the diluted plasma was discarded. The 
sedimented cells were resuspended in the same medium and 35ml gently 
layered onto 15ml of Ficoll-Paque (Pharmacia) in 50ml centrifuge tubes, which 
were centrifuged at 250g for 30 min. at 25°C. Using a wide bore pastette, the
 ^ Personal correspondence from  D r H an  H uism an , C entral L aboratory of lire N etlrerlands R ed  C ross 
Blood T ransfusion Service, PO  Box 9190,1006 AD A m sterdam .
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lymphocytes were taken off from the layer above the red blood cells, 
resuspended in RPMI/FCS and washed twice by centrifugation at 250g for 10 
min (B(|)yum, 1968). For immediate use in virus cultivation experiments, the 
PBMC were resuspended to 5 x ICP cells/ml in RPMI/FCS containing lOOIU/ml 
Kanamycin (Sigma). After 6 hrs, the culture was stimulated with 
phytohaemagglutinin (PHA) at Ipg /m l and incubated at 37°C for 4 days. The 
cells were centrifuged at 200g for 15 min and then resuspended in fresh medium 
containing 10 lU /m l interleukin-2 (IL-2) obtained from the MRC-ARP.
For long-term storage, the freshly prepared PBMC were resuspended in 90% 
PCS plus 10% dimethyl sulfoxide (DMSO: Sigma) to give approximately 5 x 10  ^
cells/ml and 1ml aliquots frozen (-2°C/min) before transfer to the gas phase of 
liquid nitrogen^. These stocks were then resuscitated for use in virus cultivation 
and neutralization experiments.
2.8.2 Preparation of PBMC from Infected Persons
Five millilitre blood samples were collected from infected persons in 7 ml 
vacuum tubes containing EDTA (Becton Dickinson Vacutaner Systems). The 
blood samples were handled in the Category II containment laboratory at UVRI 
in Entebbe. They were transferred into 15ml plastic tubes and were centrifuged 
in sealed buckets at 250g for 5 min at 25°C and the plasma were carefully 
collected from the surface and stored at -80°C for experimental use. The cells 
were diluted in RPMI/FCS to a volume of 10ml and the whole suspension 
gently layered on 4ml of Ficoll-Paque in 15 ml centrifuge tubes. These were 
centrifuged at 400g for 30 m in at 25°C. Using a wide bore pastette, the 
lymphocytes were taken off from the layer above the red blood cells, 
resuspended in 10ml of RPMI/FCS and washed twice by centrifugation at 250g 
for 15 min. The lymphocytes were resuspended in FCS plus DMSO and stored
^ Stocks of PBM C w ere  P H A  stim ula ted  after sto rage p rio r to  u se  in  the v iru s coculture a n d  neu tra liza tion  
experim ents described below , tlris enabled  tlie use of tlie sam e uns lunu la  ted PBM C stocks in  oilier 
experim ents.
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in liquid nitrogen, as above, before transfer, with the matching plasma samples, 
to CAMR in a "dry shipper" containing liquid nitrogen.
For virus isolation, the infected PBMC were cocultivated with feeder cells in a 
category III containment facility at CAMR, as described in the following section.
2.9 Virus Isolation
For virus isolation, the infected PBMC were co-cultivated with feeder ceUs in a 
category III containment facility at CAMR. This was done by co-cultivating 1-2 x 
10  ^ patient PBMC with 1.5-2 x 10  ^ PHA-stimulated PBMC/ml in lOmls of 
RPMI/FCS containing 10 lU /m l recombinant IL-2 (RPMI/FCS/IL-2) in 25cm^ 
flasks. The cultures were re-fed every 3 or 4 days with RPMI/FCS/IL-2; once a 
week, 0.5-1 x 10  ^ PHA-stimulated PBMC were added. The cultures were 
examined daily by light microscopy for the development of a cytopafhic effect. 
The development of syncytia indicated virus growth in the culture. The 
supernatant was removed once a week to monitor HIV p24 antigen (p24 Ag) 
production for evidence of virus growth.
Before testing for p24 Ag, the virus supernatants were treated with 1/10^ 
volume of 1% Empigen and heat inactivated at 56°C for 30 min. The vials were 
then sprayed with 70% alcohol and removed from the category III laboratory to 
the serology laboratory. The Coulter p24 antigen assay kit was used for these 
experiments as recommended by the manufacturer (Popovic et al., 1984; Burke et 
ah, 1990). To calculate the p24 concentration in virus cultures, a calibration curve 
for absorbance at 450nm against p24 Ag concentration was plotted for each 
assay using the antigen provided in the kit manufacturer's kit. An example of a 
p24 calibration curve is shown in Figure 9. Several attempts were made to 
prepare "in house" p24 assay kits, using the components and methods 
recommended by the MRC-ADP. However, I found that the sensitivity of the "in
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Figure 9. Calibration curve obtained for the absorbance (Â=450nm) 
versus concentration of p24 antigen standard, measured using the 
Coulter p24 antigen assay kit.
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house" assay was much lower than that of the Coulter kit and was not suitable 
for measuring the low levels of p24 produced in microtitre plate cultures of 
many primary isolates.
I found that primary cultures containing less than lOOpg/ml of p24 antigen 
were unsuitable for use in virus neutralization experiments; after inhibition by 
antiserum they produced amounts of p24 antigen which were below the 
sensitivity of the Coulter p24 antigen assay kit.
Isolation attempts were terminated on the 28th day. In positive cultures suitable 
for virus neutralization experiments, Im l aliquots of the supernatants and of 
cells resuspended in 90% FCS plus 10% DMSO were transferred to 1.8ml 
cryotubes (Nunc) and stored in the gas phase of liquid nitrogen.
2.10 Virus Expansion
Virus expansion was carried out by incubating 2 x 10  ^infected cells with 1.5-2 x 
10  ^ PHA (Ipg/m l) -stimulated PBMC/ml in 25 cm^ tissue culture flasks 
(Corning) and the volume made up to 10 ml with RPMI/FCS with 10 lU /m l IL- 
2: 2 flasks were set up for each isolate and a culture containing 1.5-2 x 10  ^
uninfected PBMC in lOmI of RPMI/FCS with IL-2 was kept as a control. The 
medium was changed twice weekly and 2-3 x 10  ^PHA-stimulated cells were 
added once a week (Folks et ah, 1986).
Isolates were adapted to grow in several T cell lines (MT-2, C8166, JM and H9) 
and the monocyte line U937 (Schwenk and Schneider, 1975; Sundstrom and 
Nilsson, 1976; Miyoshi et ah, 1981; Salahuddin et ah, 1983; Popovic et ah, 1984). 
Virus supernatants from infected PBMC cultures were incubated with the cell 
line (5 x ICP cells/ml) in lOmI of RPMI plus 10% FCS and 100 lU /m l kanamycin 
(Popovic et ah, 1984) in 25cm3 flasks. These cultures were incubated at 37°C and 
5ml of the supernatant was replaced with fresh medium every 4 days. The 
cultures were examined daily by light microscopy for the development of a 
cytopathic effect. The supernatant was removed once a week to monitor HIV
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p24 antigen (p24 Ag) production for evidence of virus growth. Virus expansions 
were terminated when the p24 level reached lOOpg/ml or on the 28th day.
Virus stocks were aliquoted into 1.8ml cryotubes and stored in the gas phase of 
liquid nitrogen as described above.
2.11 V irus T itr ation
In order to obtain known titres of the isolated virus stock for use in the 
neutralization studies, virus titrations were carried out and the results expressed 
as end-point titres (EPTs), i.e. the limiting dilution at which virus growth 
produced lOOpg/ml of p24.
The isolated virus stock supernatant was diluted in RPMI/FCS to give six ten­
fold dilutions from 1:10 to 1:10 .^ A PHA-stimulated culture of PBMC was 
diluted in RPMI/FCS to give 1 x 10  ^cells/ml and lOOpl dispensed into the wells 
of a 96-well round bottomed plate (Corning), followed by the addition of lOOpl 
of the virus dilutions (3 replicates per dilution) to each well. The plates were 
incubated at 37°C in pods gassed with 5% CO2 in air. The culture medium was 
changed on days 1 and 3, and a 200pl Empigen-lysed sample from each well 
was analyzed for p24 antigen using the Coulter p24 assay kit on day 7.
From the results of these titrations the EPT that produced lOOpg/ml of p24 was 
determined for each virus stock grown in a particular batch of PBMC. Virus 
titrations that grew but produced less p24 than lOOpg/ml were considered 
"negative" in this assessment of EPTs. I used this threshold value, because virus 
titrations that produced much lower p24 concentrations did not produce 
enough virus growth for detection by Coulter p24 antigen assay kit in the 
neutralization experiments after inhibition by antisera. I used the same 
threshold value for all of the isolates to ensure that there was a sufficiently high 
level of virus growth in all the neutralization experiments. The virus titrations 
also allowed me to use a standard level of virus infectivity in the neutralization 
experiments (Whalley et al., 1991). The same batch of PBMC was used for both 
virus titration and neutralization of a particular virus stock as it has been 
obscrv'cd that different PBMC may affect the virus growth (Folks et ah, 1986).
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Titration of viruses was also carried out on cell lines in order to determine the 
EPT that produced lOOpg/ ml of p24 for each virus stock for each cell line in 
which it was grown. Virus stock supernatant from the expanded cell line culture 
was diluted in RPMI/FCS and lOOpl of each dilution (3 replicates per dilution) 
was added to lOOpl of the same cell line (5 x 1(F cells/ml) in a 96-well round 
bottomed plate (Corning). The plates were incubated at 37°C in pods gassed 
with 5% CO2 in air. The culture medium was changed on days 1 and 3, and on 
day 7 a 200|il Empigen-lysed sample from each well was analyzed for p24 
antigen using the Coulter p24 assay kit. A titration was considered positive if 
the amount of p24 antigen in the supernatant was lOOpg/ ml or more and from 
these results the EPT that produced lOOpg/ml of p24 was determined for each 
virus stock for each cell line in which it was grown.
2.12 Back-Adaption of H IV -Imn to PBMC and adaption to cell lines
The cell line adapted isolate H IV -Imn (Gallo et ah, 1984) was obtained as 
chronically infected H9 cells from MRC-ADP. The culture was expanded by co­
cultivation with uninfected H9 cells at a ratio of 1:4, in 25cm^ flasks. The 
supernatant from the culture was frozen in 1ml cryotubes and stored in gas 
phase liquid nitrogen. The cell line adapted MN isolate was back-adapted to 
PBMC by infecting 10ml of 1 x 10  ^PBMC/ml with the supernatant from the 
H IV -Imn infected H9 cell culture in 15ml of RPMI/FCS in 25 cm^ flasks. The 
culture was stimulated with IL-2 every 4 days and fresh PHA-stimulated PBMC 
were added to the culture weekly. The culture was maintained for 28 days and 
assayed for p24 antigen production every week. Multiple passages were 
required to obtain an end-point titre of 10  ^EPT/  ml for the back-adapted HIV- 
I mn.
H IV -Imn was also adapted to grow in the C8166 and MT-2 T cell lines. To 
achieve this, a 10ml culture (5 x 10  ^ cells/ml) was infected with 5ml of 
supernatant from the H IV -Imn infected H9 culture in 25cm^ flasks and
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incubated at 37^C. Every 4 days, 5ml of the culture supernatant was replaced 
with 5ml of fresh RPMI plus 10% FCS (Popovic et ah, 1984) and 5 x 10  ^cells were 
added weekly. The culture was assayed weekly for p24 antigen production and 
was maintained for 28 days. End-point titres of 10  ^EPT/  ml were obtained for 
H IV -Imn in C8166 and MT-2 cells.
2.13 Virus Phenotyping
Following their isolation from infected blood samples co-cultured with PBMC, 
the phenotypes of the primary isolates were determined from their abilities to 
grow and produce syncytia in cultures of a number of cell lines: MT-2, C8166, 
JM,H9andU937.
The method used to grow these isolates in the different cell lines is described in 
Section 2.10. The cultures were examined by microscopy once a day for the 
development of syncytia and once a week for the production of p24 Ag. Those 
developing syncytia were classed as syncytial inducing (SI) and those which 
produced p24 Ag in the absence of syncytia were classed as non syncytial 
inducing (NSI).
Virus isolates HIV-1ug9200i and  HIV-1ug93070 w ere sh ipped  from  U ganda and  
isolated a t CAMR as described above, b u t identical sam ples w ere sen t to  the 
WHO therefore they w ere labelled using  the WHO system.
2.14 Virus Neutralization Assays
Using low-binding 96 well plates, FIIV-l positive Ugandan plasm a/sera or 
rabbit antisera raised against V3 loop peptides were serially diluted twofold 
from 1:10 to 1:320 or from 1:20 to 1:640 in RPMI/FCS to leave lOOpI of dilution 
in the wells. Virus was diluted in RPMI/FCS to 100 EPTs/ml and lOOpl was 
added to the diluted sera and the reaction mixtures were then incubated for 1 
hr. at 37°C. lOOpl of the virus/ serum (or plasma) mixture were then added to 
lOOuI of a 4-day PHA-stimulated culture of PBMC (diluted to 5 x ICP cells/ml in 
RPMI/FCS/2xIL2) contained in round bottomed 96 well plates (Coming). The 
plates were incubated at 37°C in pods gassed with 5% CO2 in air and after 6-24
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hr. the medium was changed by replacing 150pl with fresh medium 
(RPMI/FCS/IL-2). This step was repeated on day 3 and day 5 (Vujcic et al, 1990; 
Broliden et al, 1991). This wash procedure ensured that there was a massive 
dilution of any unbound antibodies in the assay system after the initial 
antibody/virus reaction. Seven days after virus infection, lOpl of 1% Empigen 
(Calbiochem) was added to each well and the plates were heated at 56°C for 1 
hr.: the inactivated samples were then assayed for p24 by the Coulter p24 
antigen assay kit. Neutralization titres for the antisera against each viral isolate 
were calculated from the reduction in p24 antigen production compared with 
that produced in the HIV-negative human plasma control (Albert et al, 1990) or 
the rabbit pre-bleed serum control.
All dilutions were duplicated for each assay, and each assay was repeated to 
verify the results: All the observations shown in the results section were 
reproducible. Where comparisons were to be drawn directly between sequential 
virus samples these neutralization assays were always part of the same 
experiment, were always carried out in duplicate and the assays were repeated 
together. Controls included wells containing medium but no plasm a/ sera and 
wells containing HIV-negative control plasma. Negative sera used included 
human sera of African origin and British origin; virus growth was not inhibited 
by any of the negative sera used. Control sera used in the assays of the rabbit 
sera raised to V3 loop peptides was of rabbit origin, both pre-bleed sera and 
rabbit sera after inoculation with adjuvant only and adjuvant and uncoupled 
KLH.
An example of a neutralization curve is shown in figure 14, the neutralization 
titre of a plasm a/serum  was defined as the reciprocal of the dilution which 
reduced p24 production by 75% (as discussed in section 3.5). Neutralization 
titres towards some viral isolates were also measured for antiserum GB8 raised 
against a British isolate, and a monoclonal antibody raised against the V3 loop 
apex of H IV-Imn (Gomy et al, 1991).
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Some viruses were also neutralized on MT-2 cells. A 4-day MT-2 cell culture 
was diluted to 5 x KT cells/ml in RPMI with 10% FCS and kanamycin 100 
lU /m l. Virus neutralization on MT-2 cells was carried out using the same 
method and stipulations as described above for virus neutralization on PBMCs.
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3. RESULTS
3.1 Serological Subtyping of Viral Isolates
One of the main objectives of this study was to develop an assay to determine 
the subtype, or clade, of the viruses which were circulating in Uganda so that it 
could be used in epidemiological studies including, for example, the 
distribution of viral subtypes in different parts of Uganda. The approach 
adopted was to develop a serological assay which utilized peptides 
corresponding to the V3 loop regions of viruses from different subtypes: this 
region had been found to show considerable sequence variation between 
different virus isolates (Wahlberg et al., 1991; Cheingsong-Popov et al., 1992) and 
to induce a very strong serological response in many infected persons (Neurath 
& Stride, 1990; Arendrup et al., 1993; Montefiori et al., 1993). However, at the 
start of the study peptide based assays for HIV had not been developed or 
evaluated. Therefore, once the assay had been developed, as described in 
Section 2.3, the next objective was to test the specificity of the assay by 
correlating data obtained from antibody binding assays with V3 loop sequence 
data from autologous proviruses.
Autologous sera corresponding to the 9 virus isolates and 5 proviruses of 
known V3 loop sequence were tested against V3 loop apex peptides encoded by 
one North American (HIV-Imn), 2 Zairian (HIV-lzs, H IV-Imal), 2  Ugandan 
(HIV-1ui685, HIV-1u3i) isolates and 2 apex peptides corresponding to Ugandan 
consensus sequences (UG A and UG D). The sera and proviral DNA sequences 
listed with "U" prefixes were obtained from viruses isolated from AIDS patients 
in 1985/6 (Oram et al., 1991) and those with "AGP" prefixes were obtained from 
AIDS patients sampled in 1990/2 (Bruce et ah, 1994).
The data shown in Table 1 shows that all the 1985/6 sera reacted strongly with 3 
peptides - MN, U1685 and U31 (except for U2999 which did not react w ith the 
U1685 peptide): most of the sera also reacted with the apex UG A and UG D
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consensus peptides. Six of the nine 1985/6 sera reacted with the MAL peptide, 
but only two reacted with the Z3 peptide.
The five 1990/2 sera showed a more varied response to the peptides. Although 
4 out of 5 of these sera reacted strongly, and one weakly, with the MN and Z3 
peptides and 3 reacted with the UG A and UG D apex peptides, only serum 
AGP 37026 reacted with the U31 peptide.
There was no obvious correlation between the V3 loop sequence of a provirus 
and the specificity of the autologous serum. Thus, serum U5055 reacted even 
more strongly with the heterologous MN peptide (RKRIHIGPGRAFYTTKN) 
than with peptides encoded by the Ugandan isolates U31 and U1685 which had 
very similar V3 loop sequences to the U5055 provirus (RQSTPIGLGQALYTTR). 
Moreover, serum U2999 reacted with the MN peptide but not with the U2999 
peptide (IQRTHIGTGQALHTTR) - data not shown.
In a further set of experiments 7 antisera from HIV-1 seropositive asymptomatic 
individuals bled at the UVRI clinic in Entebbe and 1 antiserum from an AIDS 
patient (U1685) and 15 from HIV-1 seropositive individuals attending the clinic 
in rural SW Uganda were assayed using the whole V3 loop peptides of HlV-1 
isolates MN and U31 from the USA and Uganda, respectively, and the two 
consensus peptides UG A and UG D. These results are shown in Table 2 which 
also gives the genetic subtype of these isolates previously determined by gag 
and env gene sequence analysis (unpublished data from CB Bruce and JD Oram 
and C Baker, M Phil thesis. University of Cambridge). One of the subtype D sera 
did not react with any of the 4 peptides and another subtype D serum reacted 
with only the MN (subtype B) peptide. Six of the sera, one subtype A and 5 
subtype D reacted with all 4 of the peptides. An additional five of the subtype D 
sera reacted with the MN peptide and the two Ugandan subtype A and subtype 
D consensus peptides. Six sera (including 3013 subtype C) reacted with 2 of the 
peptides. Cross-subtype antibody binding was seen in 22 of the 23 samples in 
this group of antisera showing that there was no subtype specific binding.
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TABLE 2. BINDING OF ANTIBODIES TO V3 LOOP SPECIFIC PEPTIDES.
ANTISERUM/
PLASMA
(Subtype)
PEPTIDES USED IN ASSAYS
MN UGA UGD U31
C6080 (A) 0.56 1.29 1.57 0.3
UG92001 (D) 0.76 1.12 1.88 -
W15(D) 1.09 1.03 2.19 -
C972 (D) 1.12 0.87 1.94 -
C971(D) 1.42 0.41 0.81 -
U1685 (D) - 1.04 2.29 0.87
UG92031 (D) 0.96 - - -
UG92035 (D) - - - -
3004 (D) 1.12 0.99 1.44 0.68
3011 (A) 1.08 1.5 1.63 -
3012 (A) - 0.57 0.99 -
3013 (C) - 0.47 0.75 -
3018(D) 0.31 - 0.78 -
3025 (D) 0.89 1.3 1.8 0.9
3028 (A/D)' 1.65 1.09 1.39 -
3029 (D) 1.86 - 1.44 -
3032 (D) 0.58 0.93 1.3 0.81
3046 (D) 0.74 0.72 0.58 0.44
3048 (D) 0.46 - 1.33 -
3049 (D) 1.1 0.53 0.58 -
3050 (D) 0.94 0.4 0.69 0.5
3052(A) - 0.36 0.6 -
3053(A) 0.97 0.86 0.73 -
Absorbancy readings (8=450nm) were taken at 1:200 dilutions of plasma. 
* (gag/g/n;).
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Sequential serum samples spanning a 2 year period were obtained from the 
MRC Repository at UVRI. The peptide binding activities of these sera, from 4 
members of the Natural History cohort in rural SW Uganda infected with 
subtype D viruses, were assayed using the whole V3 loop peptides and the 
results are shown in Table 3. The 3004 sera reacted with all 4 of the peptides 
used in the assay; however, the peptide binding activities with all 4 peptides 
decreased in the 2 year period between the first and last sample: the ELISA 
readings with the UG D peptide fell by about 50% over this period, much less 
than readings obtained with the other peptides, which had fallen by between 
74% and 87%. The 3025 sera also reacted with all 4 peptides, though they 
reacted more strongly with the Ugandan consensus peptides than with the MN 
peptide. A decrease in peptide binding activities was also seen in later samples 
of this series of sera, but the reduction of binding to the MN and UG D peptides 
was less than that seen with the UG A and U31 peptides. The reactivity to the 
U31 peptide was lost completely over the 2 year period. The 3029 sera reacted 
with the MN and UG D peptides; over the 2 year sampling period the reactivity 
to the MN peptide decreased by half although that with the UG D peptide 
remained constant. The 3048 sera reacted with the UG D peptide and very 
weakly with the MN peptide. The reactivity with the UG D peptide remained 
constant over the 2 year period, but the MN reactivity was lost after 1 year. 
These results showed that the peptide binding activity of serum samples from 
an individual may vary with time: these variations were gradual decreases in 
peptide binding activity with one or more of the peptides.
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TABLE 3. BINDING OF ANTIBODIES TO V3 LOOP SPECIFIC PEPTIDES.
PLASMA/DATE 
(Subtype)
PEPTIDES USED IN ASSAYS
MN UGA UGD U31
3004/18.11.93
(D)
1.1 0.87 1.27 0.56
3004/03.11.94
(D)
0.33 0.23 0.93 0.3
3004/23.10.95
(D)
0.15 0.12 0.67 0.15
3025/22.05.94
(D)
0.48 1.04 1.26 0.9
3025/05.07.95
(D)
0.11 0.18 0.83 0.11
3025/09.04.96
(D)
0.31 0.25 0.95 -
3029/22.02.94
(D)
1.3 - 0.86 -
3029/05.09.95
(D)
0.4 • - 0.84 -
3029/21.02.96
(D)
0.32 - 0.78 -
3029/06.06.96
(D)
0.61 - 0.77 -
3048/26.05.94
(D)
0.34 - 0.74 -
3048/13.06.95
(D)
- - 0.67 -
3048/04.96
(D)
- - 0.69 -
Absorbancy readings (8=450nm) were taken at 1:200 dilutions of plasma. 
Peptides:
MN:
CTRPNYNKRKRIHIGPGRAFYTTKNIIGTIRQAHC
UGA:
CTRPNNNTRKSVHIGPGQTFYATGEIIGDIRQAHC
UGD:
CTRPYNNTRQSTHIGPGQALYTTNIIGDIRQAHC
U31:
CTRPYYNIRQRTPIGLGQALYTTKGRGTTKVIGQAHC
97
As the majority of antisera were cross reactive with V3 loop peptides based on 
subtype A and D and MN sequences it seems unlikely that the subtype of the 
infecting virus could be distinguished by relatively simple peptide-based assays. 
It was obviously a serious problem that a very high proportion of the sera 
reacted strongly with the MN peptide, and also with peptides encoded by some 
other subtype B viruses (data not shown). To determine whether the peptide 
based assays could be made more specific, the phenomenon of cross-reactive 
antisera was investigated in greater detail.
3.2 Investigation of Antiserum Cross-reactivity
The following experiments were done to determine whether the cross­
reactivities towards the V3 loop peptides were due to the presence of antibody 
molecules with very broad specificities or to a mixture of antibodies with more 
restricted specificities.
3.2.1 Competitive Inhibition Assays
Sera were pre-incubated with peptides before reaction with peptide-coated 
assay plates. The results for serum U5055, which reacted with all the peptides 
used in this study, are shown in figure 10. Its reactivity towards the MN peptide 
(Fig.lOa/) was almost completely inhibited by pre-incubation with MN peptide 
at concentrations as low as 160ng/ml and MN-peptide reactivity was also 
inhibited by the UG D peptide which gave 50% inhibition at a concentration of 
1.25pg/ ml. High concentrations (>10pg/ ml) of the UG A and U31 peptides gave 
little or no inhibition of antibody binding to the MN peptide.
Similarly, the reactivity of serum U5055 towards the UG D peptide (Fig.lOb/) 
was strongly inhibited by pre-incubation with low concentrations (160ng) of the 
autologous peptide, but high concentrations (5-1 Opg/ ml) of the MN and UG A 
peptides were required to give 50% inhibition and the U31 peptide did not 
inhibit.
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Figure 10. Competitive inhibition assays with antiserum U5055 (subtype D) at 
1:500 dilution. Serum reactivities with peptides MN, UG D and U31 after pre­
incubation with peptides MN, UG A, UG D and U31. Each graph shows the 
absorbance (X=450nm) obtained in the standard antibody binding assay plotted 
against the concentration of the competitive peptides.
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Furthermore, reactivity of serum U5055 towards the U31 peptide was inhibited 
by pre-incubation with the autologous peptide 50% inhibition at 160ng, but not 
by the MN peptide (20% inhibition at 5pg/ml) as shown in Fig.lOc/.
Competitive inhibition of antibody binding was also examined for antiserum 
AGP 37026, the results are shown in figure 11.
Antibody binding to the MN peptide (Fig.lla) was completely inhibited by pre­
incubation of the serum with three of the peptides; UG A inhibited at 39ng/ ml, 
MN at 160ng/ml and UG D at lOpg/ml. Pre-incubation with the U31 peptide 
did not inhibit binding to the MN peptide.
Antibody binding to the UG A peptide (Fig.llb) was completely inhibited by 
pre-incubation with 78ng/ml of UG A peptide or with 20pg/ml of UG D: pre­
incubation with the MN peptide inhibited binding of the UG A peptide by 75% 
at 20pg/ ml, but pre-incubation with the U31 peptide did not inhibit binding to 
the UG A peptide.
Antibody binding to the UG D peptide (Fig.llc) was completely inhibited by 
pre-incubation with 78ng/ ml of the UG A peptide, with 160ng/ ml of the UG D 
peptide or with 1.25pg/ ml of the MN peptide; again the U31 peptide did not 
inhibit binding.
Antibody binding to the U31 peptide (Fig.lld) was completely inhibited by all 
four of the assay peptides. 100% inhibition was obtained after pre-incubation 
with the U31, MN and UG A peptides at 39ng/ ml and by the UG D peptide at 
2.5pg/ ml.
These data indicate that the serum U5055 contained antibodies with relatively 
restricted specificities and serum AGP 37026 contained more broadly reactive 
antibodies. Serum U5055 contained two distinct groups of antibodies, those 
which bound the MN and UG D peptides and another group which bound to 
the U31 peptide. The peptide inhibition studies suggested that serum AGP 
37026 also contained two groups of antibodies. One group with a broad 
specificity had a high affinity for the UG A peptide, with a slightly lower affinity
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Figure 11. Competitive inhibition assays with antiserum ACP 37026 
(subtype A) at 1:3000 dilution. Serum reactivities with peptides MN, 
UG A, UG D and U31 after pre-incubation with peptides MN, UG A, 
UG D and U31. Each graph shows the absorbance (l=450nm) obtained 
in the standard antibody binding assay plotted against the 
concentration of the competitive peptides.
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for the MN peptide and a low affinity for the UG D peptide: these antibodies 
were not inhibited by pre-incubation with the U31 peptide. A second, U31- 
reactive group of antibodies in serum AGP 37026 also appeared to be broadly 
reactive, binding strongly to MN and UG A peptides and to a lesser degree to 
the UG D peptide. This suggests that the U31 antibodies in this serum had lower 
specificities than the U31-reactive antibodies in serum U5055.
A further difference between the two sera, shown by these competitive 
inhibition assays, was that the AGP 37026 serum had a higher affinity than the 
U5055 serum for the UG A peptide, even though the two sera gave similar titres 
with this peptide in the standard assay (Table 1). The difference in affinities may 
not be especially surprising as the AGP 37026 serum was obtained from a 
person infected with a subtype A virus and the U5055 serum came from an 
AIDS patient infected with a subtype D virus.
As some of the data obtained in these experiments was difficult to interpret, an 
antibody adsorption method was devised to physically separate antibodies with 
different V3 loop peptide binding specificities. This method was used to obtain 
further evidence for the presence of restricted antibody specificities within an 
antiserum. Unfortunately due to the lack of individual antiserum volumes 
available from Uganda I used different antisera in these experiments. The 
peptides used in these adsorption assays were chosen because the antisera had 
good reactivities to them in the antibody binding assay. With hindsight it might 
have been tidier to have been able to use the same antisera with the same 
peptides for the competitive and adsorption assays.
3.2.2 Adsorption of Antibodies to Insolubilized Peptides 
Antibodies were adsorbed by filtering antisera through columns of Sepharose 
coupled with V3 loop peptides (the 16-19mers spanning the loop apex, as shown 
in Section 2.2) encoded by MN, Z3, U31 or U1685 proviruses: a column 
containing no peptide served as a control. The residual activities in the filtrate 
were then titrated in the standard assay. The results obtained with serum U462 
(subtype D) show that the MN-reactivc antibodies were adsorbed by the MN-
102
peptide column (Fig.l2.i.a) and the Z3-reactive antibodies were adsorbed by the 
MN- and Z3-peptide columns (Fig.l2.i.b).
The U31 peptide column adsorbed the U31-reactive antibodies from serum 
U462 (Fig.l2.i.c) and both the U31- and U1685-peptide columns removed these 
antibodies from serum U1685 (subtype D) (Fig.l2.i.d). Similarly, the U1685- 
reactive antibodies were removed from this serum by adsorption with either the 
U31- or U1685-peptide columns (Fig.l2.ii.a).
However, the U31-reactive antibodies in these two sera were not adsorbed by 
the MN-peptide column (Fig.l2.i.c & d), nor by the Z3-peptide column 
(Fig.l2.i.c). The results obtained with serum P724 (unknown subtype) show that 
MN-reactive antibodies were adsorbed by the MN-peptide column and, in 
contrast to the results obtained with serum U462, also by the Z3-peptide column 
(Fig.l2.ii.b). Similarly, the Z3-reactive antibodies were adsorbed by the MN- and 
Z3-peptide columns (Fig.l2.ii.c).
The results obtained from the competitive inhibition assays and the antibody 
adsorption experiments indicate that some antisera contain antibodies with 
restricted specificities and that the specificities can vary between different 
antisera. For example, the MN-reactive antibodies in serum U462 were not 
adsorbed by the Z3-peptide column which, however, adsorbed these antibodies 
from serum P724. So the MN-reactive antibodies in these two sera had rather 
different specificities.
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Figure 12i and 1211. Reactivities of antisera U462 (subtype D), U1685 
(subtype D) and P724 (unknown subtype) after adsorption to 
insolubilized peptides MN, Z3, U31 and U1685 coupled to Sepharose 
columns: the control columns contained non-derivitized Sepharose and 
are shown on each graph with a black filled square marker. Each graph 
shows the absorbance (X=450nm) against the reciprocal of the 
antiserum dilution for the assay peptide used (MN, Z3, U31 or U1685) 
in the antibody binding assay.
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3.2.3 Determination of the Frequency of V3 loop Binding Antibodies 
The data from the competitive inhibition assays and the antibody adsorption 
experiments showed that many Ugandan sera contained antibodies reactive 
against at least 2 variants of the V3 loop apical epitopes, e.g. the M N/UG D and 
U31 epitopes. To determine the frequency of antibodies reactive with V3 loop 
peptides encoded by MN, U31, and the UG A and UG D consensus sequences 
sera were obtained from 107 Ugandan AIDS patients and 123 sero-positive 
asymptomatic persons (as detailed in the Materials and Methods Section 2.1). 
These sera were assayed and the antibody specificities are summarized in Table
4.
Most (79%) of the sera from the AIDS patients reacted with the MN peptide, 
57% reacted with the UG A apex peptide, 57% with the UG D apex peptide and 
22% with the U31 peptide. Seventeen of the sera did not react with any of the 
peptides, 19 with only one peptide, 23 with 2, 29 with 3 and 19 with all 4 
peptides. All but one of the singly-reactive sera and all except 4 of the doubly- 
reactive sera reacted with the MN peptide. Although equal numbers of sera 
reacted with both of the Ugandan consensus peptides, several sera (14%) 
reacted with only one of them.
A similar pattern was given by sera from the asymptomatic persons, although 
the proportion reacting with the MN or U31 peptides (67% and 14%, 
respectively) was slightly lower than for sera from AIDS patients (79% and 22%, 
respectively): the difference was statistically significant (p<0.05) for the MN but 
not the U31 peptide. Although more sera in this group were singly-reactive - 32 
(25%) compared with 19 (17%) of the sera from the AIDS patients, this difference 
was not statistically significant (p=0.067). However, many of the singly reactive 
asymptomatic sera reacted with either the UG A or UG D consensus peptides 
(4.9% and 10.5%, respectively), compared with 1% and 0%, respectively for sera
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TABLE 4. Comparison of Peptide Reactivities of Ugandan Sera from 1985/6 
and 1990/2 and from AIDS and Asymptomatic Persons.
SERA 
(number in group)
Peptides
MN UGA UGD U31
1985/86 (96) 73 (76%) 67 (70%) 61 (64%) 22 (23%)
1990/92(117) 79(68%) 57 (49%) 64 (55%) 16 (14%)
AIDS Patients (107) 85 (79%) 61 (57%) 61 (57%) 24 (22%)
Asymptomatic Persons (123) 83 (67%) 75 (61%) 75 (61%) 17 (14%)
All HIV-U Sera in Study (230) 168 (71%) 136 (59%) 136 (59%) 41 (19%)
Figures expressed as numbers (and percentage) of sera reacting with V3 loop 
peptides.
N.B. 17 of the AIDS patients / Asymptomatic persons were not included in the 
1985/86 and 1990/92 sample groups.
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from the AIDS patients: these differences were statistically significant (p<0.05) 
and are summarized in figure 13. In a sub-group of 54 asymptomatic mothers 18 
(33.3%) of the sera were singly-reactive: 4 (7.4%) reacted with MN, 12 (22.2%) 
with UG A and 2 (3.7%) with the UG D consensus peptides. This data indicates 
that in many Ugandans the early antibody responses to infection were towards 
either the UG D or MN types of epitope.
A key question concerning the HIV epidemic is whether the ratio of the different 
viral subtypes is fairly constant or whether it is changing due to the more rapid 
spread of one or more subtypes of virus. To address this question, I compared 
the peptide-binding specificities of sera taken in 1985/6 with those taken in 
1990/2: the data is summarized in Table 4. Although the two groups of sera 
showed similar overall reactivities with the MN and UG D consensus peptides, 
70% of the 1985/6 sera but only 49% of the 1990/2 sera reacted with the UG A 
consensus peptide; this difference was significant (p<0.005). As shown in Table 
4, about a quarter of the sera sampled in 1985/6 reacted with the U31 type 
peptide, many with high titres (Table 1): a lower proportion of the 1990/2 sera 
reacted with this peptide but the number of samples was too low for the 
difference to be statistically significant.
Some of the viruses isolated from the 1985/6 patients had V3 loop sequences 
similar to HIV-lusi (Oram et al, 1991) which is not typical of the more recent 
Ugandan proviruses (Albert et al, 1992; Bruce et al., 1994). Surprisingly, 20% of 
the 1990/2 sera, compared with only 7% of the 1985/6 sera, did not react with 
any of the peptides; the difference was statistically significant (p<0.05).
The data obtained using human sera revealed a complex pattern of serological 
responses towards the V3 loop region of the glycoprotein. Comparison of the 
results obtained with sera from AIDS cases with those from asymptomatic 
persons (Fig.l3) indicated that antibody specificities broadened with time, 
making it difficult to develop a subtype specific assay.
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Figure 13. This bar chart illustrates the number of AIDS and 
asymptomatic antisera singly-reactive by the antibody binding assay to 
the V3 loop peptides MN, UG A, UG D or U31.
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The following experiments were performed to determine whether human sera 
recognized different regions of the whole V3 loop peptides.
3.2.4 Assays Using Overlapping Peptides Encoded by Parts of the V3 loop 
To investigate the possibility that there may be more than one antigenic epitope 
within the V3 loop, antibody binding assays were carried out using overlapping 
peptides containing parts of the V3 loop. For these experiments antisera were 
selected which cross-reacted with the V3 loop peptides MN and UG D 
irrespective of the genetic subtype of the autologous virus. These antisera were 
assayed with an eight amino acid peptide corresponding to the MN apex and 
with three overlapping peptides spanning the UG D V3 loop sequence: Partial 
V3 loop peptides were also synthesized for the terminal regions of the MN V3 
loop. However, as nuclear magnetic resonance revealed that the terminal region 
partial V3 loop MN peptides contained a high level of undesirable peptide 
sequences, these MN terminal region V3 loop peptides were unsuitable for use. 
Further attempts to synthesize these peptides at CAMR were unsuccessful. The 
peptides used and the results of these assays are shown in Table 5. Of the 13 
antisera assayed 12 reacted with each of the two whole V3 loop peptides, only 4 
reacted with the MN apex peptide, 2 reacted with the UG D apex peptide, 4 
with the UG D amino terminal peptide and 11 reacted with the UG D carboxy 
terminal peptide. The reactivity of many sera with the carboxy terminal peptide 
indicates that it contains the main antigenic epitope of the V3 loop. The reactions 
with the apex peptides and the amino terminal peptide indicate that other 
epitopes are also present in this region.
Hence, from the data shown in Tables 1, 2 and 5 it appeared that the length of a 
peptide, i.e., the number of residues, also had an important effect on the 
specificity of antibody binding. Thus, whereas many of the sera tested with the 
16-17mer V3 loop apex peptides reacted much less strongly with the UG A 
peptide than with the MN peptide (Table 1) many reacted equally strongly with 
both of the corresponding whole V3 loop peptides (Table 2). One serum, U1685, 
was tested with both the 17/16-mer loop apex (Table 1) and whole loop 
peptides (Table 5), which gave quite different results. The serum reacted very
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TABLE 5. BINDING OF ANTIBODIES TO PARTIAL V3 LOOP PEPTIDES.
PEPTIDES
SERA
(Subtype)
MNV3
LOOP
MN
APEX
UGA
V3
LOOP
UGD
V3
LOOP
UGD
APEX
UGD
NH3
TERM
UGD
COOH
TERM
U3529 1.48 - 1.57 1.82 - - 2.36
C6080(A) 0.56 - 1.29 1.57 - - 0.43
UG92001(D)
0.76 - 1 . 1 2 1 . 8 8 - - -
W15 (D) 1.09 - 1.03 2.19 - - 0.37
C972 (D) 1 . 1 2 0.77 0.87 1.94 0.57 0.57 0.62
C971 (D) 1.42 0.58 0.41 0.81 - - 0.58
U4133 (D) 0.72 - - - - 0.98 1.98
U4132(D) 0.9 - - 1.07 - 1.27 2.13
U455 (A) 0.95 - 0.7 1.5 0.39 - 0.69
U1665 (D) 1 . 1 2 0 . 6 6 1 . 0 2 2.09 - - 1.37
U1685 (D) - - 1.04 2.29 - 0.56 1.42
U393 1.63 0.54 1.24 1.93 - - -
U383 0.94 - 1 . 0 1 1.94 - - 0.53
Absorbancy readings (8=450nm) were taken at 1:200 dilutions o f  sera.
Peptides:
MN:
MN APEX:
UG D:
UG D NHs:
UG D APEX:
UG D COOH: 
UG A:
GTRPNYNKRKRIHIGPGRAFYTTKNIIGTIRQAHC
HIGPGRAF
CTRPYNNTRQSTHIGPGQALYTTNIIGDIRQAHC
CTRPYNNTRQSTHI
HIGPGQAL
GQALYTTNIIGDIRQAHC
CTRPNNNTRKSVHIGPGQTFYATGEIIGDIRQAHC
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strongly with the 17-mer MN loop apex peptide and poorly with the 17-mer UG 
A loop apex peptide peptide (Table 1) but did not react with the whole loop MN 
peptide although it reacted strongly with the whole loop UG A peptide peptide 
(Table 5). Further, although this serum bound strongly to the 17-mer MN loop 
apex peptide (Table 1), it did not bind to the octomeric peptide centred on the 
MN loop apex (Table 5). Presumably, the majority of the UG A-reactive 
antibodies bound to an epitope(s) partly or wholly outside the loop apex, and 
the epitope recognized by the MN-reactive antibodies in the 17-mer loop apex 
peptide was not fully contained within the octomeric peptide and was 
inaccessible or had a different conformation in the whole loop peptide. Similar 
data was obtained with serum U4133 which reacted strongly with the 16-mer 
UG D consensus loop peptide (Table 1) but did not bind to either the 
corresponding whole loop or 8-mer apex loop peptide (Table 5). However, this 
serum reacted with both the anaino-terrninal and carboxy-terminal UG D 
peptides (Table 5), indicating that the antibodies recognized epitopes in both of 
these regions which were possibly not exposed in the whole loop peptide.
The data obtained using human sera and V3 loop peptides of various lengths 
and sequences revealed a complex pattern of serological responses towards the 
V3 loop region of the glycoprotein. For example, comparison of the specificities 
of sera from asymptomatic persons with those from AIDS cases showed that a 
higher proportion of the former were singly-reactive, indicating that specificities 
broadened with time. However, somewhat conflicting data was obtained with 
sequential samples from the Natural History cohort in rural SW Uganda (Table 
3), which showed that some antibody titres declined over a 2 year period^. 
Hence, assay results could well depend on the stage of infection and the effect of 
the time between seroconversion and sampling is unpredictable. These 
problems, together with those involving the choice of peptides, obviously make 
it very difficult to develop a subtype specific assay.
^Sequential sam ples w ere assayed  in  duplicate, in  tire sam e experim ent, w itli tire control an tisera  Ü3029 an d  
assays were repeated.
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3.3 Virus Isolation from Blood Samples
Samples of seropositive blood from persons attending the UVRI clinic in 1990/2 
were used to isolate viruses which, after genotypic and phenotypic 
characterization, could be used in virus neutralization assays using autologous 
and heterologous plasma. At a slightly later stage (1995) characterized primary 
isolates and matching sera became available through the MRC-ADP HIV 
Repository at Cambridge (see above).
3.3.1 Isolation of Viruses from the UVRI clinic
Virus isolation was attempted on 30 samples from the UVRI clinic. The blood 
samples were separated by Ugandan technicians at UVRI into plasma and 
leukocyte fractions, as described in Sections 2.8 and 2.9, and frozen at -80°C or in 
liquid nitrogen, respectively, and then transported to CAMR. Frozen aliquots of 
the infected leukocytes were thawed and added to PHA stimulated cultures of 
PBMC and the cultures examined by microscopy for the development of a cpe 
and by ELISA for the production of p24 antigen. Twelve isolates were obtained: 
most of the cultures which yielded virus were positive, by either cpe or p24 
antigen production, within about 7 days. Two additional primary isolations 
were made, UG92001 and UG93070, giving a total of 14 isolates from the 
Entebbe/  Kampala area and a 44% rate of isolation. The isolates included 2 
subtype A and 7 subtype D viruses and 5 other viruses which were not 
genotyped as shown in table 6.
Although this isolation rate may appear to be quite low, I required viruses 
which grew to a high enough concentration of p24 antigen to allow detection 
after inhibition by antisera in the neutralization experiments (as described in 
Section 2.9). Therefore, I set the threshold for isolation fairly high at a p24 
concentration of 100 p g / ml in the culture supernatant. A few isolates were lost 
to antibiotic-resistant bacterial infections. These presumably originated from the 
blood samples, as they occurred in unrelated circumstances. One sample had a 
viral contamination (confirmed by electron microscopy).
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Attempts to isolate some of the viruses directly on PBMC derived from the same 
infected sample, i.e. without adding feeder PBMC, were not successful, 
although some cultures showed a short-lived "blip" of p24 antigen. Isolation of 
virus on autologous cells was not attempted with samples where CD4 cell 
depletion had been recorded by the clinicians, therefore it was unlikely that lack 
of CD4 lymphocytes would have contributed to these unsuccessful isolations. 
The reasons for the absence of virus growth in autologous cells were not 
investigated but could have been due to the presence of HIV-specific cytolytic T 
cells in the cultures.
3.3.2 Adaption of Primary Isolates to Cell Lines
The viruses isolated in PBMC cultures were adapted to grow in several T cell 
lines (MT-2, C8166, JM and H9) and the monocyte line U937 by infecting 
cultures with supernatants from the primary isolates and monitoring the 
cultures for virus production, as above. Cell line adapted viruses were obtained 
from all of the cell lines for each of the primary isolates where adaption was 
attempted.
The primary isolates, the MT-2 adapted and some of the C8166 adapted viruses 
were expanded by one or two passages in cultures of PBMC or the appropriate 
cell line, and the culture supernatants titred, using cultures of PBMC, MT-2 or 
C8166 cells in microtitre plates, in the virus titration assay described in Section 
2.11. The virus isolates obtained and the titres of the expanded culture 
supernatants are shown in Table 6. This shows that in both PBMC and MT-2 cell 
cultures most of the viruses grew to relatively low titres (ICP to 1(P): the lowest 
titre was 10  ^and the highest ICP.
3.4 Phenotypic Characterization of HIV-1 Isolates
The primary isolates and cell line adapted viruses were phenotyped by 
examining infected PBMC or cell line cultures for the development of syncytia. 
As shown in table 6,10 of the primary isolates induced syncytia in cultures of 
PBMC, i.e., they had the SI phenotype, and 4 were non syncytium inducing
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(NSI). However, when the corresponding MT-2 adapted viruses were cultured 
in MT-2 cells, all but two showed the SI phenotype and similar results were 
obtained with the other cell line adapted viruses. Hence, it appeared that 3 out 
of 4 of the PBMC isolates which had the NSI phenotype in PBMC cultures must 
have contained some SI variants which were selected on adaption to growth in 
the cell lines. Interestingly, one of the viruses which was SI in PBMC cultures 
was obtained with the NSI phenotype when isolated and tested in the cell lines. 
These experiments show that some NSI variants can grow quite well in cell lines 
and in some cases these may even be selected in the presence of SI variants.
The T cell line adapted viruses obtained from the primary isolates had the same 
phenotype in all of the cell lines tested. Thus, 6 of the variants had the SI 
phenotype in all the cell lines tested and 2 other variants (UG92031 and 
UG93070) were both NSI on all the cell lines.
The differences in the phenotypes of PBMC and MT-2 cell grown viruses were 
also reflected by differences in their susceptibilities to neutralizing antibodies 
(see below).
3.5 Virus Neutralization Studies
To assess neutralization of isolates of HIV-1 in various cell systems by antisera I 
decided to measure the reduction in p24 production by the isolates grown with 
dilutions of antisera against a control (HIV-1 negative) serum. I settled for a 
dilution range of sera from 1:10 to 1:640 which was chosen to give a pattern of 
neutralization of the isolates, although in a few of the earlier experiments I used 
a range from 1:10 to 1:320.1 aimed to show with in this range of sera dilutions a 
maximum neutralization at 1:10 dilution and a much lesser degree of 
neutralization at 1:640. All of the neutralization assays were carried out using a 
series of dilutions 1:10 to 1:640 of a HIV-1 negative control serum. When the p24 
levels were measured for the assays if there was a greater than 5% variation 
between the 1:10 and 1:640 dilution readings for the negative control serum and 
the readings for the virus culture with no added antiserum, then the data were 
discarded. On all the neutralization plots shown in this thesis the 1:10 and 1:640
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negative control serum results are shown. All dilutions were duplicated, and 
each assay was repeated to verify the results: All the results shown in this thesis 
were reproducible. Where comparisons were to be drawn directly between 
sequential virus samples these neutralization assays were always part of the 
same experiment and were repeated together.
In order to compare the data from these neutralization assays I decided to 
tabulate the titres at various percentages of neutralization. 50% and 90% 
neutralization tables revealed less information than 75% neutralization tables. 
At 50% neutralization too many antisera titres were >640, and many antisera 
even at 1:10 dilutions did not neutralize the isolates to 90%. Therefore in this 
thesis I had tabulated my data at 75% neutralization of viral p24 production. 
Appendix VII illustrates in more detail how I reached this decision. As 
discussed below the data in Figure 14 and Table 7 illustrate the difficulties in 
interpretation of neutralization data.
Shallow neutralization curves where the virus was neutralized to around 75% 
across a range of antiserum dilutions were difficult to interpret. Examples of this 
cire seen below in Figure 15f/ Isolate C971 on PBMCs with sera C972 and U1685, 
Fig.l6i a /  Isolate 3004 with the autologous serum, Fig.l6i c / Isolate 3052 with 
the serum 3050, Fig.l6iii b /  Isolate 3048 with serum 3025, Fig.l7 Isolate 
UG92035 with serum C6080 and Fig.l9 Isolate UG92001 with sera C972 and 
U1685. In these 8 incidences it was difficult to measure a neutralization titre, but 
in the majority of neutralizations this was not the case. For these 8 
neutralizations all the available data for each antiserum was plotted together on 
one graph (expressed as % p24 produced to allow for inter-test variations) and 
the neutralization titre was assessed from there. Appendix VIII shows 2 
examples of this assessment.
3.5.1 Neutralization of Viruses from the UVRI Clinic
At the time this work was started (late 1992), most laboratories were using cell 
line adapted viruses in neutralization experiments because it was technically 
more difficult and time consuming to do experiments with primary isolates in
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cultures of PBMC (or other primary cells). However, primary isolates were 
being neutralized in a few laboratories and I was helped by Dr Pontiano 
Kaleebu, then at St. Mary's Hospital Medical School in London, to set up the 
assay at CAMR. This enabled me to compare the neutralization data obtained 
with cell adapted viruses with those obtained with primary isolates from the 
same blood samples taken in the UVRI clinic.
3.5.1.1 MT-2 cell Adapted Viruses
Neutralization assays in MT-2 cell cultures were carried out with 5 of the 
Entebbe isolates and H IV -Imn using autologous and heterologous human sera 
and the H IV -Imn monoclonal antibody. The data obtained in one experiment 
involving the neutralization of isolate C971 by 3 Ugandan HIV-positive sera and 
one seronegative control serum is plotted in Figure 14. The neutralization titre 
was arbitrarily defined as the reciprocal of the dilution that caused 75% 
reduction of the p24 antigen formation, relative to an FlIV-1 negative antiserum 
control, after 7 days in culture. Figure 14 shows that neutralization by 2 of the 3 
sera gave a pattern of correlation between growth inhibition and the 
(logarithmic) serum dilution whereas the other serum (C6080) gave a marked 
inhibition of virus growth at much higher dilutions, even though its 75% 
neutralizing titre was about the same (210 versus 270) as one of the other 2 sera. 
This type of neutralizing activity, which was not observed in most experiments, 
is difficult to interpret. This serum gave high neutralizing titres against several 
viruses (see below) so the effect shown in Fig. 14 could indicate that the 
antibodies had either a lower specificity or affinity for the C971 virus. It did not 
appear to be due to a non-specific inhibition of virus growth as it was not 
observed when serum C6080 was used in some other experiments. The results 
of the neutralization experiments with MT-2 cell adapted viruses are
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Figure 14. Neutralization of HIV-1c9ti (Subtype D) in MT-2 cell cultures by 
antisera. The graph shows the concentration of p24 Ag produced in the cultures 
plotted against the reciprocal of the dilution of the neutralizing HIV-1+ 
antiserum (subtype shown in brackets). The arbitrarily defined neutralization 
titre at 75% inhibition of p24 production is indicated by a black dashed line.
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summarized in Table 7.a. These data show that 4 out of 5 of the Ugandan sera 
neutralized the autologous virus, and 5 out of 6 of the Ugandan sera had cross- 
reactive neutralizing activities with titres greater than 20. Four out of six of the 
Ugandan sera neutralized the back-adapted H IV -Imn with titres ranging from 
40 to 200 and the other 2 sera had weakly neutralizing titres (10-20) towards this 
virus. Although 4 of the 5 Ugandan viruses tested were neutralized by several 
Ugandan sera, one (C972) was neutralized by only one (heterologous) serum. 
One of the Ugandan isolates HIV-1ug92035 and H IV -Imn were neutralized by the 
monoclonal antibody to the V3 loop apex of H IV -Imn (MNMab). The V3 loop 
sequences were compared to see if this pattern of neutralization correlated with 
the amino acid sequences of the neutralized isolates. The V3 loop sequences are 
shown in Table 7.b. The monoclonal antibody was mapped to a linear epitope 
on the apex of the V3 loop (HIGPGR) of H IV -Imn (Gorny et al, 1991), shown in 
bold in Table 7.b. There appeared to be no significant differences in amino acid 
sequence in this region of the V3 loop between the 2 isolates which were 
neutralized by the H IV -Imn monoclonal antibody and the 4 isolates which were 
not neutralized.
3.5.1.2 PBMC Isolates
Neutralization assays were performed using cultures of PBMC with 8 of the 
Entebbe primary isolates - six SI isolates, two NSI variants, HIV-1mo47 and HIV- 
l c 97i, and the back-adapted HIV-Imn. The results of these assays are 
summarized in table 8.
Two of the Ugandan viruses (HIV-lc24 and HIV-lwis) and the back-adapted 
H IV -Imn were fairly strongly neutralized by most of the sera used: the most 
notable exception being HIV-lc24 which was not neutralized by its autologous 
serum. The susceptibilities of isolates HIV-1mo47, HIV-1c97i and HIV-lusi to 
neutralization varied considerably between different antisera, which gave titres 
ranging from <10 to >320 for HIV-lc97i and HIV-1mo47 and between <10 and 160 
for isolate HIV-lusi. Isolate HIV-1ug93070 was neutralized by 7 antisera, but all 
with titres #40. Isolate HIV-1ug920oi was neutralized by 7 antisera, but 5 of these
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had titres of 20, or less. By contrast, HIV-lwis was very sensitive to 
neutralization, being strongly neutralized by 7 Ugandan antisera and GB8 and 
MNMab at dilutions of >1:320.
Several Ugandan sera neutralized all or most of the isolates tested, showing 
high neutralizing titres towards some of them. Thus, serum C972 neutralized 7 
out of 8 and sera C971, W15, C6080 and U1685 neutralized all 8 Ugandan 
viruses tested, plus all 5 sera neutralized the back-adapted H IV -Imn. However, 
serum UG92001 neutralized only 4 of the 7 Ugandan isolates tested, plus HIV- 
I mn: like serum C24, it failed to neutralize the autologous virus. As a very small 
volume of the C24 serum was available, it was not possible to test this serum 
against a range of viruses.
The 2 subtype B sera, GB8 and the HIV-Imn monoclonal antibody, were very 
effective against the back-adapted HIV-Imn and the "super-neutralizable" HIV- 
lwi5 isolate, but had little or no neutralizing activity against the other Ugandan 
isolates.
There did not seem to be any genotypic restriction to neutralization between 
subtype A serum C6080 and the subtype D isolates and the subtype B back- 
adapted H IV -Imn.
Also, the NSI isolates, HIV-1mo47 and HIV-1c9ti, were as susceptible to 
neutralization as the SI isolates, showing that there was no significant 
phenotypic restriction to neutralization.
3.5.1.3 Comparison of Neutralization Patterns Shown by MT-2 cell Adapted 
and Primary Isolates
The neutralization patterns obtained with primary isolates and their MT-2 cell 
adapted variants are shown in figure 15a/ to f /  and the data from these and 
additional replication neutralization experiments are summarized in table 9. 
These data show that there were very marked differences in the neutralization 
patterns obtained between some primary viruses and the corresponding cell 
adapted variants. Fig.l5a/ a n d b / show that the HIV-lwis isolate, like some
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Figure 15. Comparison of the neutralization patterns obtained for 
primary isolates with MT-2 cell adapted viruses, grown in PBMC and 
MT-2 cell culture respectively. Fig.l5a/ and b / show HIV-lwis 
(subtype D), 15c/ and d /  show H IV -Imn (subtype B) and 15e/ and f /  
show HIV-1c971 (subtype D). The graphs show the concentration of p24 
Ag produced in the cultures plotted against the reciprocal of the 
dilution of the neutralizing antiserum.
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other primary viruses, appeared to be much more sensitive than the MT-2 cell 
adapted variant to neutralization by a wider range of sera. The H IV-Imn variant 
back-adapted to grow in PBMC was also more susceptible than the MT-2 cell 
adapted variant (Fig.l5c/ and d /). Although the primary and cell adapted 
variants some of the other viruses, like HTV-lc97i (Fig.lSe/ and f/)  and HIV- 
luG92035, showed broadly similar neutralization patterns. There were numerous 
differences in detail: for example, the HIV-1c9ti primary isolate was sensitive to 
neutralization by serum UG92035 which did not neutralize its MT-2 cell adapted 
variant (Table 9). The primary isolate HIV-luG92035 was not neutralized by 
MNMab, which did neutralize its MT-2 cell adapted variant (Table 9).
Figure 15a/ shows a zig-zag pattern in the p24 concentrations produced by 
HIV-lwis at increasing dilutions of sera; one possible explanation for this 
pattern, which was seen in each repeat of this experiment, is that there are a 
mixture of neutralizing and enhancing antibodies in the antisera (UG92031 and 
C971). It may have been caused by the action of a component of the growth 
medium on the specific virus-antibody complexes (Booth, 1977).
All the isolates with high enough titres were used in neutralization assays at a 
virus input level of lOOpI of 100 EFT/ml. I was confident that neutralization 
titres for antisera could be compared between an isolate neutralized on PBMCs 
and MT-2 cells, because the titres for most of the isolates were similar in the two 
cell systems (as shown in Table 6). The greater susceptibility to neutralization 
of MT-2 grown viruses versus PBMC grown viruses was not predicted by 
published work. However, it could not have been due to lower infectivity of 
the isolates on the cell line. Isolates HIV-lwis and H IV -I m n  had the same titre 
in each cell system (see Table 6), so their infectivities would have been the 
same in the two cell systems. Isolate H IV -1 c9ti had a higher titre in MT-2 cells, 
therefore it would apparently grow better there if not added in a standard 
amount of 10 EPTs/ml. Isolate H IV -1 ug9203s was the only isolate that had a 
higher titre in PBMCs, therefore it would apparently grow better there if not 
added in a standard amount of 10 EPTs/ml.
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In view of these data, I decided that data obtained with primary isolates 
cultured in PBMC would be much more relevant to the clinical situation. In the 
later stages of the study neutralization of Ugandan isolates was continued using 
low passage primary isolates cultured in PBMC. This avoided the possibility of 
misleading results obtained by the use of cell line adapted isolates.
3.5.2 Neutralization of Viruses from the Natural History cohort in rural SW 
Uganda
As it proved difficult to obtain follow-up samples and clinical data from persons 
who had attended the UVRI clinic, later work was restricted to primary viruses 
and plasma obtained in 1994/5, through the MRC HIV Repository, from the 
Natural History cohort in rural SW Uganda.
3.5.2.1 Neutralization of Primary Isolates from the Natural History cohort in 
rural SW Uganda
I investigated the neutralization of ten of the isolates from the Natural History 
cohort with autologous and heterologous plasma. Representative neutralization 
V plasma dilution plots are shown in detail in Figures 16i, 16ii, 16iii, 16iv and 
16v and the data from this series of experiments and the repeat assays are 
summarized in Table 10. Plasma that were assayed but did not neutralize the 
viruses have not been plotted on the neutralization charts (Fig.16). Table 10 also 
shows the viral genotype (based on gag and env sequences). Due to problems in 
growing some isolates and the small volume of plasma available for 3029, it was 
not possible to test all of the plasma with all of the corresponding viruses to 
produce a complete "chequer board" analysis. All the neutralization assays 
illustrated in figure 16 were replicated and all the data shown were 
reproducible. The reason for showing the neutralization charts (Fig. 16) as well 
as summarizing the data in table 10 was because of the variation in the shapes of 
the neutralization curves, and the consequent difficulties in their interpretation. 
These difficulties in interpretation include the allocation of 75% neutralization 
titres to shallow curves that vary little with antisera dilution across the range
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Figure 161 to 16v. Neutralization of primary isolates of HIV-1 in PBMC. 
The graphs show the concentration of p24 antigen produced in the 
PBMC cultures plotted against the reciprocal of the dilution of the 
neutralizing plasma.
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tested in these assays. Samples were obtained on more than one occasion for 
3029 and 3049; throughout this thesis the first sample collected is implied, unless 
otherwise indicated by a date in brackets after the sample number.
The salient points to emerge from these data are:
(i) with two exceptions, all the plasma neutralized most of the viruses, in many 
cases with high neutralizing titres.
(ii) neutralization was not subtype (clade) specific.
(iii) some of the viruses were very susceptible to neutralization, others were less 
sensitive.
(iv) all the viruses tested were neutralized by the autologous plasma.
(v) some of the plasma showed virus enhancing activities.
The points listed above are illustrated in detail by the data shown in Fig.s 16i-v 
and Table 10.
(i) Plasma have broadly specific neutralizing activities:
With the exception of plasma 3004 and 3050, which neutralized only 2 out of 10 
or 4 out of 9 viruses, respectively, all the plasma neutralized most of the viruses 
tested. For example, as shown in Table 10 and Fig.s 16i-v, plasma 3048 strongly 
neutralized all the isolates tested. This plasma neutralized the 3 isolates shown 
in Fig.lbi.a/, b /  and c / by more than 95% at a dilution of 1:640 and neutralized 
7 /9  isolates with a neutralization titre of 640 and isolate 3011 with a titre of 480 
but had a lower titre of 160 against the autologous virus (Fig.l6iii.b/). As shown 
in Fig.s 16i-v, plasma 3052 also had very high neutralization titres (200 to >640) 
against the 9 viruses tested and several other plasma, e.g. 3011, 3013, 3028 and 
3032, had high titres against most of the viruses.
The presence of anti-p24 antibodies (Mascola & Burke, 1993) and of non­
antibody factors in antisera including a  interferon, cytokines, chemokines 
(Rantes, Mip-la, Mip-lp, SDF-1) and CD8+ T cell antiviral factor can inhibit 
HIV-1 growtli in a non-specific mamier (Burrer et al., 2001). My results showed
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that many (15 /  23) of the antisera did not neutralize some of the viruses, these 
antisera showed no evidence of the presence of anti-p24 antibodies nor non­
antibody factors which would be expected to inhibit the growth of all the 
viruses with which they were incubated. Many of the non-antibody factors 
mentioned above could be removed by lOKDal to 50KDal dialysis of antiserum 
prior to assessment in neutralization assays. IgG depletion assays would 
determine any contribution to the inhibition of viral growth by other factors.
(ii) Most of the plasma had cross-clade neutralizing activity:
The neutralization experiments with the isolates from the Natural History 
cohort in rural SW Uganda were done using 2 subtype A viruses and 8 env 
subtype D viruses. Both subtype A and D isolates were neutralized by plasma 
obtained from persons infected with env subtype A, C and D viruses. This 
phenomenon is illustrated in several of the figures, including Figure 16i.a/ 
which shows the neutralization of isolate 3004 (subtype D) and Figure 16ii.b/ 
which shows the neutralization of isolate 3011 (subtype A). Two plasma did not 
demonstrate cross-clade neutralizing activity. Plasma 3004 only neutalized 2 
isolates 3004 and 3029 -  both subtype D. Plasma 3029 was only available in a 
very small volume, so this plasma was only assayed against the autologous 
isolate (and sequential autologous isolate).
Similar results were obtained with viruses and sera from the UVRI clinic at 
Entebbe. Thus, figure 17 which shows the neutralization of subtype D isolate 
UG92035 by sera obtained from persons infected with a subtype A virus (C6080) 
or subtype D viruses (e.g., U1685 and W15). The back-adapted HIV-Imn was 
also neutralized by sera from both subtype A and D virus-infected persons 
(Table 8 and Figure 15.d/).
(iii) Viruses differed in their sensitivity to neutralization:
Isolate 3029(22.02.94) was especially sensitive to neutralization: all 13 of the 
plasma used reduced p24 antigen production by more than 95% (Fig.l6iv.a/). 
Other very sensitive viruses included 3004 (Fig.lbi.a/) neutralized at high
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Figure 17. Cross-clade neutralization and antibody enhancement of 
virus growth of primary isolate FïIV-1ug92035 (subtype D) in PBMC by 
antisera from persons infected with subtype A and D viruses. The 
graph shows the concentration of p24 antigen produced in the cultures 
plotted against the reciprocal of the dilution of the neutralizing 
antiserum.
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dilutions by 12 out of 13 plasma, and 3052, neutralized by 12 out of 13 plasma 
(Fig.lbi.c/), nearly all at high dilutions. Isolates 3032 (Fig.l6ii.a/) and 3048 
(Fig.lbiii.b/) were less sensitive, being neutralized by 9/13 and 10/13 plasma 
respectively: many of the plasma had a much lower range of titres against these 
viruses.
(iv) Viruses were neutralized by autologous plasma:
All the isolates were neutralized to varying degrees, with titres ranging from 40 
to greater than 640, by their autologous plasma (see the shaded areas of Table 
10). These results contrasted with some of the data obtained using viruses 
isolated from the UVRI clinic blood samples, two of which (C24 and UG92001) 
were not neutralized by their autologous sera (see the shaded areas of Table 8).
(V) Virus enhancing activities:
Figure 17 and Figure 15f/ show examples of antibody enhancement of the 
growth of the primary isolates UG92035 and C971 (both from Entebbe) by 
antiserum C971 (also from Entebbe). Antibody enhancement was also found in 
four neutralization experiments involving viruses from the Natural History 
cohort in rural SW Uganda: isolate 3029(06.06.96) with plasma 3021 
(Fig.l6iv.b/), isolate 3048 with plasma 3011 and 3049(26.05.94) (Fig.l6iii.b/), 
isolate 3049(26.05.94) with plasma 3011, 3021, 3025 and 3049(26.05.94) 
(Fig.l6v.a/) and isolate 3050 with plasma 3012, 3018,3025 and 3050 (Fig.l6i.b/). 
Five of the eight plasma (C971, 3011, 3021, 3025 and 3049(26.05.94)) were 
involved in the enhancement of the growth of more than one primary isolate. 
Although this enhancement of virus growth was not investigated it may have 
been caused by the action of a component of the growth medium on the specific 
virus-antibody complexes (Booth, 1977), or enhancing antibodies which are 
induced by conformational epitopes in the carboxyl half of the gpl20 molecule 
which may only be able to bind to certain isolates (Takeda et ah, 1992).
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S.5.2.2 Neutralization of "Follow-up" Viruses from the Natural History cohort 
in  rural SW Uganda
I produced sequential isolates of the 3029 and 3049 viruses from blood samples 
which I obtained 2 years after those used to get the original isolates. The two 
isolates of 3029 were made 20 and 48 months, and the two isolates of 3049 were 
made 6 and 30 months, after the first positive tests for HIV. The neutralization 
curves of the earlier and later isolates of 3029 and 3049 are compared in Figs 
16iv and 16v and the data are summarized in Table 11. Several sequential serum 
samples for the two isolates were also included in these experiments. The earlier 
3029 isolate was neutralized at >1:640 dilution by all the antisera tested, 
including the 4 autologous sera, but although the later isolate was still sensitive 
to the autologous sera, it was not neutralized by two heterologous sera (3025 
and 3028) and was much more resistant to two other heterologous sera (3011 
and 3021).
Differences in the neutralization titres of the antisera were also seen between the 
two isolates of 3049. Six antisera had higher titres against the later than against 
the earlier isolate and six antisera, including three of the sequential autologous 
antisera, had lower neutralization titres against the later isolate. The later 
(sequential) 3049 antisera had much high neutralization titres against the earlier 
isolate of 3049 than the antiserum taken at the same time as the first virus 
isolation; this shows a changed or increased immune response to the virus 
during the two years during which the sequential samples were taken.
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TABLE 11. NEUTRALIZATION OF SEQUENTIAL UGANDAN ISOLATES 3029 
AND 3049 IN PBMC CULTURES.
Plasma
(Subtype)
Isolate (Subtype)
3029/94 (D) 
22.02.94
3029/96 (D) 
06.06.96
3011(A ) >640 40
3021 (A) >640 40
3025 (D) >640 -
3028 (A/D) >640 -
3029/22.02.94 (D) >640 640
3029/05.09.95 (D) >640 640
3029/21.02.96 (D) >640 640
3029/06.06.96 (D) >640 640
Plasma
(Subtype)
Isolate (Subtype)
3049/94 (D) 
26.05.94
3049/96 (D) 
28.05.96
3 0 0 4 (D) - -
3011(A ) 30 160
3012(A ) - 30
3018(D ) 80 640
3021 (A) 60 480
3 0 2 5 (D) 70 140
3028 (A/D) 200 60
3032 (D) 640 300
3052 (A) 320 120
3049/26.05.94 (D) 40 120
3049/21.02.95 (D) 540 160
3049/29.01.96 (D) 320 160
3049/28.05.96 (D) 320 120
Figures shown as reciprocal o f  plasma dilution giving 75% HIV-1 inhibition as determined by 
p24 detection.
- = Inhibition less than 75%. Shading indicates autologous virus isolate and plasma.
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3.6 Correlation of Serological and Neutralization Data
Comparison of serological data obtained by reacting human sera with V3 loop 
peptides with the corresponding virus neutralization patterns indicated that 
there was no clear cut relationship between the two types of reactivity. For 
example, considering the isolates from Kampala and UVRI clinic samples: 
several plasma, including C971, C972, W15 and UG92001, did not react with the 
U31 V3 loop peptide (Table 2) but neutralized the U31 primary isolate, with 
neutralization titres ranging from 30 to 120 (Table 8), not significantly higher 
than the titre (160) obtained with plasma U1685, which reacted strongly with the 
U31 peptide. Further, plasma UG92035, which did not react with any of the V3 
loop peptides tested, neutralized 6 out of the 8 viruses tested.
Similar data were obtained with plasma/virus samples obtained from the 
Natural History cohort in rural SW Uganda. For example, plasma from the 
subtype D virus 3004 reacted with whole V3 loop peptides of MN, UG A, UG D 
and U31, but only neutralized the autologous isolate (Table 10), indicating that 
there was no correlation between serotype and neutralization phenotype.
Plasma 3013, from a subtype C virus reacted with peptides of UG A and UG D 
and neutralized isolates of these subtypes equally strongly indicating that the 
genotype (C) did not correlate with the serotype and neutralization phenotype. 
Plasma 3048 reacted with the MN and UG D peptides, but not with the UG A 
peptide, but neutralized both subtype A and D viruses, with equally high titres 
(mostly >640).
Hence, much of my data indicates that, for many of the plasm a/virus 
interactions, at least part of the neutralizing activity was not directed against the 
linear V3 loop epitopes.
3.7 Antibodies Raised against Linear V3 loop Epitopes in  Rabbits
A major problem in attempting to correlate viral genotype or phenotype with 
serological properties, including neutralization specificities and titres, is that the 
sequences of the primary^ immunogens including, for example, neutralization
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epitopes, cannot be established, except possibly for very recently infected 
persons - who are almost impossible to find in an African setting. One way of 
addressing this problem is to study antisera from animals immunized with 
carefully defined epitopes. Therefore, I investigated the ability of linear V3 loop 
epitopes to induce neutralizing antibodies in rabbits and then attempted to 
correlate the immune responses to the known sequences.
The whole V3 loop peptides used as immunogens were obtained as relatively 
highly pure products (>90% purity, as assessed by nuclear magnetic resonance). 
As detailed in Section 2.6, a portion of each peptide was coupled to a carrier 
protein (KLH) and the rabbits were immunized either with coupled or 
uncoupled peptides. The reactivities of the sera were studied in serological 
assays with the V3 loop peptides used as immunogens and their neutralizing 
activities determined using 8 primary isolates from the Kampala/Entebbe area 
and the back-adapted H IV -Im n .
3.7.1 Serological Studies on Antibodies Raised against Whole V3 loop 
Peptides in Rabbits
The reactivities of the rabbit antisera to the MN, UG A, UG D and U31 whole V3 
loop peptides are shown in Table 12.a. Twelve of the 16 rabbits gave an immune 
response, with all 12 reacting with the inoculum peptide. Five of the 12 antisera 
were mono-specific, reacting only with the inoculum peptide (U31 or UG A): 
four reacted with two peptides, two antisera reacted with three peptides and 
one antiserum reacted with all four peptides.
With the exception of antisera 704 and 719, the cross-reactive antisera responded 
most strongly towards the inoculum peptide.
Vaccination with the MN peptide gave the highest titre antisera, which also had 
the most cross-reactivity and vaccination with the U31 peptide gave the most 
specific antisera, which reacted only with the U31 peptide.
Table 12.b is a summary of the data shown in table 12.a, which shows the mean 
titres for the reactive sera. The shaded areas of the table illustrate binding to the
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TABLE 12.a. REACTIVITY OF RABBIT ANTISERA RAISED TO V3 LOOP PEPTIDES.
RABBIT
SERA
INOCULA PEPTIDES USED IN ASSAYS
M N U G A U G D U31
701 M N 5400 1200 - -
705 M N 6000 4200 5400 -
719 M N/KLH 2430 3600 3600 200
723 M N/KLH 3600 1600 1200 -
700 U G A - - - -
708 U G A - 600 200 -
704 U G A /K L H 1800 1200 - -
724 U G A /K L H - - - -
707 U G D - - 200 -
699 Ü G D - 400 500 -
702 U G D /K L H - - 200 -
721 U G D /K L H - - - -
703 U31 - - - 2100
706 U31 - - - -
722 U31/KLH - - - 200
720 U31/KLH - - - 1800
Titres are reeiproeals o f  serum dilutions giving an EIA o f  0.5 OD units. 
- = titre <  100. KLH = Keyhole Limpet Haemagglutinin eonjugate.
TABLE 12.b. SUMMARY OF THE BINDING OF RABBIT ANTISERA RAISED TO V3 LOOP 
SPECIFIC PEPTIDES.
INOCULA PEPTIDES USED IN ASSAYS
MN U G A U G D U31
MN 4400 2700 2600 200
U G A 1800 900 200 -
U G D - 400 300 -
U31 - - " 1400
Titres are reeiproeals o f  serum dilutions divided by the number o f  reactive sera 
(ie. average titre) giving an EIA o f  0.5 units o f  absorbance.
- = titre < 100.
Shading indicates homologous inoculum and peptide.
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inoculum peptide. The table shows that sera from rabbits vaccinated with the 
MN and UG A peptides were cross-reactive, with similar titres towards the MN 
and UG D peptides: however, this cross-reactivity was only partial as 
vaccination with the UG A peptide failed to induce UG A-reactive antibodies. 
Table 12.b. also shows that the UG D peptide was poorly immunogenic.
The specificities of the cross-reactive rabbit antisera were examined by 
competitive inhibition assays. The results for rabbit antiserum 719 at 1:500 
dilution, an example of the sera raised against the MN peptide, are shown in 
Figure 18. As shown in Fig.l8.a/ the MN peptide was the most effective 
competitive inhibitor of the MN-reactive antibodies present in this serum, 
giving 90% inhibition at 2.5pg/ml. The UG A peptide was less effective (80% 
inhibition at 5pg/ml) and the UG D and U31 peptides were not inhibitory. 
Similarly, the UG A peptide was the most effective competitive inhibitor of the 
UG A reactive antibodies, giving 90% inhibition at 0.4pg/ml. The MN peptide 
inhibited UG A reactive antibodies by 90% at 2.5pg/ml. The UG D peptide did 
not inhibit UG A reactive antibodies (Fig.l8.b/). Surprisingly, the UG D peptide 
was a poor inhibitor of the UG D reactive antibodies which, however were 
inhibited strongly by the MN and UG A peptides (Fig.l8.c/).
These data indicated that the MN peptide induced cross-reactive antibodies 
which were specifically recognized by both MN and UG A peptides. The 
inhibition of MN-induced UG D-reactive antibodies by the MN and UG A 
peptides indicates that this reactivity was probably also due to antibodies 
directed against the MN and /o r UG A epitopes. The UG D peptide appeared to 
be less effective as an immunogen, but was a good competitor for the UG D- 
reactive antibodies.
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Figure 18. Competitive inhibition assays of rabbit 719 antiserum (1:500 
dilution) raised to the MN V3 loop peptide. The serum was 
preincubated with MN, UGA, UG D and U31 peptides before 
measuring peptide reactivities. Each graph shows the absorbance 
(l=450nm) obtained in the standard antibody binding assay plotted 
against the concentration of the competitive peptides.
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3.7.2 Determination of Neutralizing Antibodies in Sera from Rabbits 
Immunized w ith V3 loop Peptides
Virus neutralizing activities on PBMCs of 4 of the rabbit antisera were 
determined using 8 primary Ugandan isolates and the back-adapted H IV-Imn; 
the results are summarized in Table 13. One rabbit antiserum for each inoculum 
peptide was selected for use in these experiments; those that reacted most 
strongly with the inoculum peptide in the antibody binding assays were 
selected. The four antisera were 705 (MN), 703 (U31), 704 (UG A) and 699 (UG 
D). Three of the 8 Ugandan isolates (C6080, C971 and UG93070) were not 
neutralized by any of the rabbit antisera, but all of the antisera neutralized at 
least one of the other 5 isolates assayed. All of the rabbit antisera neutralized 
virus isolate UG92001, but at low titres. Most human sera gave a similar pattern 
of low titre neutralization for this isolate and the two sets of data are compared 
in Figure 19. The antiserum raised against the MN peptide neutralized 4 
Ugandan subtype D isolates with titres ranging from 10 to 200 and neutralized 
the back-adapted H IV-Imn with a titre of >320. The antiserum raised to the UG 
A consensus peptide did not neutralize the one subtype A virus tested (C6080), 
but did neutralize two subtype D viruses with titres of 10 and 160 and the back- 
adapted HIV-Imn (subtype B) with a titre of >320. The antiserum raised against 
the UG D consensus peptide neutralized three subtype D viruses, but not the 
subtype A or B viruses. The antiserum raised against the U31 peptide did not 
neutralize the autologous virus and had only low neutralizing activity towards 
one other virus. Isolates C6080, C971 and UG93070 were not neutralized by any 
of the raised antisera, however in previous neutralization assays with human 
antisera both C971 and UG93070 were neutralized - C971 to titres of >320 by 
some antisera (See Table 8).
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Figure 19. Neutralization of primary isolate H1V-1ug920oi by rabbit 
antisera (19.a/) and by human antisera (19.b/). The graphs show the 
concentration of p24 Ag against the reciprocal of the dilution of the 
neutralizing antiserum/ plasma.
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3.7.3 Correlation of Serological Reactivities and Specificities of Virus 
Neutralization by Antisera Raised in Rabbits
There have been several reports that the V3 loop region acts as the PND in 
several (laboratory adapted) viruses and peptides have been used to induce 
specific neutralizing antibodies (Page et al., 1991; Wagner et al., 1992; Keller et al., 
1993; Tolman et al., 1993). However, in this study the data shows that, with the 
exception of the U31 peptide, the serological responses to the peptide vaccines 
were very broadly-specific and a similar lack of specificity was observed in the 
neutralization experiments. This was shown, for example, by the neutralization 
of subtype D viruses as well as the back-adapted HIV-Imn variant by the sera 
induced by the MN peptide and by the neutralization of subtype D viruses and 
HIV-Imn, but not a subtype A virus, by the serum induced by the UG A peptide. 
There was, however, a very loose correlation between the breadths of the 
serological and neutralization responses: for example, antibodies induced by the 
MN peptide reacted with more peptides than the other peptide immunogens 
and also neutralized more viruses, possibly indicating that it was the most 
effective immunogen in these experiments.
3.8 Correlations between Clinical and Virus Neutralization Data
One of the main objectives of this study was to determine if the rate of disease 
progression in members of the Natural History cohort in rural SW Uganda 
could be linked with the presence of neutralizing antibodies in their plasma. 
This cohort is recruited from the General Population cohort, which is tested in 
yearly serosurveys. Hence, the Natural History cohort is ideal for this type of 
study as the dates of seroconversion in incident cases are known to within 12 
months and details of their age, sex and home village, etc are also known. At 3- 
monthly intervals after recruitment, cohort members are examined clinically 
and their blood monitored for T cell subset numbers and ratios by 
FACSCOUNT analysis.
Personal, clinical and T cell subset data and the estimated dates of 
seroconversion for 13 persons, supplied by Dr J Whitw^orth and Dr D Morgan of
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the MRCPA in Uganda, together with the neutralization and genotype data for 
the corresponding viruses, are summarised in Table 14 and Figure 20. Figure 20 
shows the CD4+ and CD8+ cells per pi against time in months since 
seroconversion for each person. With the exception of one person (listed as 
3032 in table 14) who died during the study period and whose sequential T cell 
subset data was not available, the data for the other subjects covers between 4 
and 7 visits to the clinic over a 2-3 year period, in most cases starting about 2-3 
years after their first seropositive blood sample: however, for subject 3052 this 
period was about 18 months. The results of the clinical examinations are shown 
as WHO clinical stagings, as defined in the World Health Organisation 
proposed clinical staging system for HIV infection and disease, a copy of which 
is included in Appendix V. Briefly, stage 1 is asymptomatic and stages 2 and 3 
are intermediate stages in the progression to AIDS, the stage 4 disease condition. 
The virus neutralization data shown in Table 14 gives the neutralization titres 
against the autologous virus and an indication of the range of neutralizing titres 
against heterologous viruses from the cohort, using data summarised in Table 
10. The data in Table 14 was somewhat incomplete for some of the subjects; 
some plasma were not tested against the autologous viruses due to low viral 
titres on PBMCs, and in the case of the several 3029 plasma, against 
heterologous viruses due to low plasma volumes. Subjects with incomplete data 
are shown with an "ND" in their scores.
This study included seven persons (3004, 3012, 3021, 3025, 3029, 3032 and 3048) 
who were recorded by early 1997 as WHO Stage 3 patients (Table 14) and who 
were probably progressing towards AIDS. Subject 3032 died during the course 
of the study after developing a very low CD4 count of 50 cells/ pi. Three subjects 
(3021, 3029 and 3049) showed a marked decline in their CD4 counts and 
CD4/CD8 ratios during the study period. It was not possible to test the 
neutralizing activity for the autologous virus of sample 3021, obtained from a 
person whose CD4+ cell counts fell to a very low level (<50 cells/ pi), but this 
serum sample neutralized 8/10 heterologous isolates with neutralization titres 
ranging from 30 to >640. However most of the plasma and viruses used in the
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Table 14. Serum Data for Samples.
Sample
3004
(D)
3011 
(A)
3012
(A)
3013
(C) 
3018
(D) 
3021 
(A) 
3025 
(D) 
3029 
(D) 
3032 
(D) 
3046 
(D)
3048 
(D)
3049 
(D) 
3052 
(A)
ND = Neutralization Titre not determined.
Seroconversion dates were estimated from the time of the first positive and the time of 
last negative results.
WHO Stage -  World Health Organisation hierarchical stage at time of examination, as 
defined in Appendix V.
All of the clinical data came from the MRCPA.
Date of
serum
sample
Seroconversion
Date
Autologous
Neutraliza­
tion
Titre
Heterologous 
Titre Range
Heterologous 
isolates 
Neutralized / 
Assayed
WHO
Stage
18.11.93 21.04.92 320 >640 1 /9 3
18.01.94 09.09.93 >640 30 to >640 9 /9 2
18.01.94 24.03.91 ND 20 to >640 6 / 1 0 2 / 3
18.01.94 08.09.92 ND 40 to >640 9 /9 2
18.01.94 13.06.92 ND 30 to >640 10/10 2
22.02.94 02.07.92 ND 30 to >640 8 / 1 0 3
22.02.94 09.01.92 80 60 to >640 8 /9 3
22.02.94 09.12.91 >640 ND 0 /0 2 /3
13.04.94 23.04.91 80 160 to >640 8 /8 3
26.05.94 19.11.91 ND ND 0 /0 1 /2
26.05.94 27.01.93 160 480 to >640 8 /8 3
26.05.94 01.06.92 40 60 to >640 8 /8 2
13.07.94 06.02.93 200 240 to >640 8 /8 2
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Figure 20. CD4+ and CD8+ Cell Counts.
For each HIV-1+ person the CD4+ and CD8+ cells/pi in the 
peripheral blood are plotted against time in months since 
seroconversion.
Each plot is labelled with the sample number. The CD4+ cells are 
shown in blue and the CD8+ cells are shown in red. Virus isolations 
are indicated on the time axis by red arrows.
Person 3032 had only one set of clinical data sampled on 12.02.94 (2 
months before the virus and plasma samples were taken). At this 
time the CD4+ count was 50 cells/pi and CD8+ count was 914 
cells/ pi.
All data came from the MRCPA.
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Figure 20. CD4+ and CD8+ Cell Counts
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neutralization assays were obtained at an early, asymptomatic, stage. The 
exceptions 3029 and 3049 where sequential isolates were tested (Table 11) and 
plasma were obtained at about the time of CD4 cell decline.
For eight subjects (3004, 3011, 3025, 3029, 3032, 3048, 3049 and 3052) there were 
autologous neutralization and clinical data. These data were examined in more 
detail to see if there was a relationship between the autologous virus 
neutralizing titres and the change in the CD4+ cell count.
In four of these persons (3004, 3011, 3048 and 3052) the CD4+ cell counts 
remained relatively high (>500 cells/ pi) over the study period. In one person 
(3025) the counts varied between 200 and 500 cells/ pi and in 3 persons (3029, 
3032 and 3049) had, or developed, low CD4+ counts (<130 cells/ pi) during the 
study period. The samples from the 4 persons with the high CD4+ counts and 
CD4+: CD8+ ratios all had relatively high neutralizing antibody titres against 
the autologous viruses. With the exception of sample 3029, which neutralized 
the autologous virus at a titre of >640, the four persons with low or intermediate 
CD4+ counts had relatively low neutralizing titres (between 40 and 80) against 
their autologous viruses.
So with this small number of samples it was not possible to determine any 
relationship between the neutralization data and the clinical data.
Clearly, additional data would be required from earlier and later matched 
plasma and virus samples for a more meaningful test of the possible correlation 
between disease progression and the presence of neutralizing antibodies.
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4. DISCUSSION
The H IV /AIDS epidemic is the major cause of adult morbidity in Uganda and 
the surrounding countries, although there have been indications that the 
seroprevalence of HIV infection may be dropping in women attending ante­
natal clinics in Kampala (UNAIDS and WHO, 2002a). Further indications of a 
decrease in seroprevalence have come from the most recent reports from the 
general population cohort in rural south western Uganda (Whitworth et ah, 
2002). The falling seroprevalence indicates that the government's AIDS 
awareness and sex education programmes are having an effect. However, the 
prevalence of HIV in young adults living in urban communities is still about 
10% and the major impact of AIDS on the community is probably yet to come 
(UNAIDS and WHO, 2002a).
Even if the educational programmes are having some success in reducing the 
transmission of HIV in Uganda, there is an urgent need to develop a vaccine 
which will be effective against African variants of HIV. It is also important that 
methods should be developed to assess the effectiveness of vaccines against HIV 
and to monitor the spread of different virus variants or subtypes in the 
community. My work has been concerned with these two aspects of the 
HIV/  AIDS epidemic in Uganda.
4.1 Serology
My first objective was to develop an enzyme-linked immunosorbent assay 
(ELISA) which could be used in sero-surveys to determine the distribution of 
different viral subtypes (clades) in different parts of Uganda and surrounding 
countries and to show if the pattern was changing with time. My approach was 
to develop a serological assay rather than more complex molecular biological 
methods since whereas the former can be used with plasma or sera, the latter 
requires a source of viral RNA or pro viral DNA, which would be much less 
readily available in developing countries.
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There were two main phases to this section of the work. Firstly, the 
characterization of Ugandan sera using a panel of synthetic peptides 
corresponding to North American and African V3 loop epitopes. This was 
followed by the vaccination of rabbits with whole V3 loop peptides and the 
analysis of antibodies induced by peptides of known structure.
Comparison of the peptide-binding specificities of FllV-positive Ugandan sera 
showed that there was no obvious correlation between the V3 loop sequence of 
a provirus and the specificity of the autologous serum. Thus, several sera 
reacted more strongly with the HIV-Imn peptide than with peptides encoded by 
the autologous virus isolate. Furthermore, as the majority of the Ugandan sera 
were cross reactive with V3 loop peptides based on HIV-Imn subtype and 
consensus Ugandan subtype A and D sequences, it seems unlikely that the 
subtype of the infecting virus could be distinguished by relatively simple 
peptide-based assays. It was obviously a serious problem that a very high 
proportion of the sera reacted strongly with the HIV-Imn peptide, and also with 
peptides encoded by some other subtype B viruses. Other groups had 
previously reported that many HIV-positive African sera react strongly with V3 
loop peptides encoded by subtype B viruses (Carrow et al., 1991; Warren et ah, 
1992; Blomberg et ah, 1993). However, with few exceptions, the majority of 
Africans are infected with viruses in other subtypes. Several hypotheses have 
been put forward to account for this paradox. A possible explanation is that 
most people were infected with a virus with an HIV-lMN-Iike V3 loop epitope 
which subsequently evolved to a virus with a different epitope, similar to either 
the Ugandan subtype A or D consensus sequences. However, no HIV-lMN-like 
viruses have been isolated from infected Ugandans and several studies (Oram et 
ah, 1991; Albert et ah, 1992; WHO network for HIV isolation and 
characterization, 1994) have shown that the amino acid sequences around the 
V3 loop apex of most Ugandan variants are not similar to that of HIV-Imn. An
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alternative explanation is that most variants induce antibodies which cross-react 
with a number of peptides, including that of HIV-Imn.
Kohler et ah (1992) proposed a concept of "clonal dominance" to account for the 
restricted B-cell response to V3 loop epitopes described by Goudsmit et ah (1989) 
and Zwart et al. (1992). They proposed that during the primary viraemic stage of 
infection the epitope presented by the genotypically homogeneous fast- 
replicating viral population saturates the antigen presenting cells in the 
germinal centres; subsequent genetic variants contain cross-reactive dominant 
epitopes which re-boost the primary response. They proposed that this led to 
"repertoire freeze" which limited the recruitment or maturation of other 
uncommitted B-cells to other variants of the epitope (Kohler et al., 1992). The 
high degree of sequence diversity of the V3 loop region of the gpl20 (Oram et 
al., 1991; Albert et al., 1992; Myers et al., 1993) within the provirus populations of 
infected Africans leads to the production of antibodies with broad, cross­
reactive V3 loop peptide binding patterns. Within an infected individual 
evolution of the provirus V3 loop epitopes may lead to a further broadening of 
the specificities of V3-loop reactive antibodies (as seen in the AIDS patients in 
this study). This may result in the production of antibodies reactive towards a 
very diverse range of V3 loop epitopes, which in some cases, do not cross-react 
with the epitopes of the initial infecting virus population. Formation of these 
antibodies may well be due to re-boosting of the original B cell clones, primed 
during seroconversion to initial HIV infection rather than to the recruitment of 
uncommitted B cells.
I have shown that it is possible to separate, by affinity chromatography, 
antibodies which react with different V3 loop peptides. This indicates that many 
infected Ugandans produce antibodies against distinct variants of the V3 loop 
epitope. For example, HIV-Imn and HIV-lusi have very different sequences, 
KRIHIGPGRAFYTT and RQRTPIGLGQALYTT, respectively, around the apex 
of the V3 loop. The peptides used in this work were based on these sequences 
which differ at 8/14 positions: the differences at the loop apex, GPGR and 
GLGQ, respectively, may be especially important as it has been proposed (Bruce
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et ah, 1993) that the presence of a leucine residue instead of the proline at the 
apex would not favour the formation of a type II p-turn, predicted from the 
algorithm of Wilmot and Thornton (Wilmot & Thornton, 1988) for the classic 
GPGR tip motif which is present in many Ugandan variants as well as in 
subtype B viruses, but could allow the formation a distorted type I p-turn which 
would impart a different secondary structure to the V3 loop. Many Ugandan 
viruses have a V3 loop without a proline residue at the apex (Oram et al., 1991; 
Albert et al., 1992; Myers et al., 1993) and these would be expected to induce 
antibodies which are not recognized by peptides based on consensus sequences: 
I found that 7% of the 1985/6 sera and a surprisingly high 20% of the 1990/2 
sera did not react with any of the peptides used in the assays; the difference was 
statistically significant (p<0.05). These data indicate that a relatively high 
proportion of seropositive persons were infected by viruses with V3 loop 
sequences which were either poorly immunogenic or not closely related to the 
consensus sequences.
The effect of geographical factors on antibody specificity was examined by 
comparing the reactivities of sera from Entebbe/Kampala with those from the 
Masaka area, which is 80 miles southwest of Kampala. There were no significant 
differences in the reactivities of the two groups of sera (data not shown).
My data also shows that the V3-specific antibody repertoire is greater in AIDS 
patients than in asymptomatic persons. A relatively high proportion (25%) of 
the latter appeared to react with only one the peptides used in the assays and 
most of these sera reacted with either the MN or UG A consensus peptides. In a 
sub-group of 54 asymptomatic mothers 18 (33.3%) were singly-reactive and 12 
(two thirds) of these reacted with the UG A consensus. However, DNA 
sequence data (personal communications from D Yirrell, P Kaleebu and JD 
Oram) show that almost two thirds of Ugandan virus are in subtype D and only 
about a third are subtype A viruses. Obviously, the two sets of data, serological
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and nucleotide sequence, lead to very different conclusions about the 
distribution of viral subtypes in Uganda.
Using sequential samples from the Natural History cohort in rural SW Uganda,
I found that the peptide binding activity of plasma samples from an individual 
showed gradual decreases with time in peptide binding activity to one or more 
of the V3 loop peptides. In some cases this resulted in a marked reduction in the 
reactivity with the MN loop peptide from the (presumably) high sero­
conversion level. These results do not explain the high reactivity of Ugandan 
sera with the MN loop peptide but do show that the length of the post infection 
period can strongly influence this kind of serological data and thus reduce its 
diagnostic value. More direct data about MN loop reactivities were obtained by 
injecting rabbits with V3 loop peptides and these results are discussed later.
I attempted to improve the specificities of the peptide-based ELISA by the use of 
competitive inhibition assays, in which the sera were pre-incubated with 
peptides before reaction with peptide-coated assay plates. Although these 
assays would be more complex and time consuming than the simple ELISA, 
they should be well within the technical capacity of experienced and well 
managed laboratories in developing countries.
This was reasonably successful for some sera - for example, results obtained 
with sera U5055 (subtype D) showed that antibody binding to the MN or UG D 
peptides was specifically inhibited by pre-incubation of the sera with relatively 
low concentrations of the MN or UG D peptides, respectively: similarly, 
antibody binding to the U31 peptide was specifically inhibited by pre­
incubation with that peptide (data not shown). However, more ambiguous 
results were obtained with other sera. Thus, the peptide binding activities of 
serum AGP 37026 (subtype A), which reacted with all the peptides tested, were 
all inhibited by pre-incubation with the autologous peptide and were also 
strongly but non-specifically inhibited by pre-incubation with the UG A
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peptide. Hence, it appears from these data that although competitive peptide 
binding assays might enhance the reaction specificities of some sera, they would 
not be of practical use for many other cross-reactive sera.
Since these results were published (Smith et al., 1994), Kaleebu and his 
colleagues attempted to improve the discrimination between sera which cross­
reacted with V3 loop peptides encoded by the main HIV-1 subtypes (A, B, C 
and D) then thought to be present in Uganda although we now know that B and 
C subtype viruses are extremely rare in Uganda (personal communications from 
D Yirrell, P Kaleebu and JD Oram). Kaleebu (1995) found considerable cross­
reactivities in binding to subtype A and C peptides and also between the 
subtype B and D peptides. The competitive ELISA gave some improvement in 
subtype discrimination but it was still doubtful whether it could be used as a 
routine method for sero-surveillance. Barin et al. found that by introducing a 
peptide blocking stage, m a competitive inhibition assay, they were able to give 
a more specific EIA which could be used at different disease stages. However, 
sera from the Central African Republic were still cross-reactive with V3 loop 
peptides, including subtype B, which led to inaccurate serological subtyping 
(Barin et al., 1996).
One of the problems in the use of V3 loop peptides in serological assays is the 
lack of knowledge about the epitopes recognized by human antibodies. The V3 
loop region varies in length between about 35 and about 39 amino acid residues 
and appears to encompass several epitopes recognized by monoclonal 
antibodies derived from humans and animals (Korber et al., 1995). Hence, it is 
probable that the position and length of the peptide used in assays could be just 
as important as its' composition. A further problem is that short peptides 
adsorbed or coupled to a solid surface may adopt a very different conformation 
than that presented in vivo. This is especially true in the case of the V3 loop 
which is thought to adopt a hairpin structure facilitated by the apical p-tum 
between the disulpliide bridge.
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I addressed this question by comparing data obtained by reacting sera with 
peptides spanning the whole loop of the UG D consensus sequence with three 
sub-regions - the N-terminus, the apex and the C-terminus. It was intended 
make a similar comparison using equivalent peptides derived from the MN 
peptide but, due to technical problems (referred to in Section 3.2.4), it was not 
possible to obtain the C-terminal peptide.
In a rather limited study containing 13 sera, I found that whereas nearly all 
Ugandan sera reacted with the whole loop MN, UG A and UG D peptides, only 
one serum reacted with the whole loop U31 peptide and one serum which 
reacted with the apex 16-mer peptide did not bind to the whole loop peptide. 
There were also discrepancies between the binding of other sera to the whole 
loop MN, UG A and UG D peptides, some binding to the whole loop peptide 
and not to the 16-17-mer apical peptides and vice versa. Further discrepancies 
were found between binding to 8-mer and 16-17-mer peptides: not surprisingly, 
many more sera bound to the larger than to the shorter MN and UG D apical 
peptides (100% versus 30% and 70% versus 15%, respectively).
Almost all the sera reacted with the UG D C-terminal peptide, indicating that 
this region accounted for most of the reactivity observed for the whole loop 
peptide. Since these sera gave similar reaction patterns with the MN and UG A 
whole loop peptides, it is probable that most of these reactions were with an 
epitope in the C-terminal part of the loop.
The C-terminal regions of the whole V3 loop used were:
MN: GRAFYTTKNIIGTIRQAHC
UG A: GQTFYATGEIIGDIRQAHC
UG D: GQALYTTNIIGDIRQAHC
U31: GQALYTTKGRGTTKVIGQAHC
The MN and UG D peptides have very similar C-terminal amino acid sequences 
and the UG A peptide shares the last 10 amino acid residues with the UG D 
peptide.
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MN: YTTKNIIGTIRQAHC
I_JCj D: — .—U------
UG A: -A-GE—D------
The U31 loop contains a three residue (Ti'K) insertion near its C-terminus, 
which would be expected to give a different conformation to this part of the 
loop.
Hence, it seems possible that part of the cross-reactions observed between some 
Ugandan sera and the MN peptide could be due to shared C-terminal epitopes. 
However, much of the work presented in this Thesis was done using shorter 
(16-19mer) peptides which included only 8-11 amino acid residues C-terminal to 
the loop apex so it seems probable that there must be at least one shared or 
cross-reactive epitope fairly close to the apex. This is consistent with data 
obtained in other studies including, for example, the demonstration by Meleon 
et al. that many HIV-reactive human and chimpanzee sera recognized a 9-mer 
peptide spanning the apex and that the sequences immediately C-terminal to 
the apex were important for the specificity of antibody binding (Meleon et ah, 
1989). Several monoclonal antibodies have also been found to bind to this region 
(Korber et ah, 1995).
These data draw attention to some of the problems associated with the use of 
simple peptides in serological assays and emphasize the crucial importance of 
the selection of the peptides and the standardization of the assays in different 
laboratories, for which there seems to be little enthusiasm, at present.
One of the major problems in the interpretation of ELISA data for sera from 
HIV-infected persons is that, except in exceedingly rare cases, the exact 
sequence of the immunogen is unknown. Under these conditions it is not 
possible to determine whether cross-reactive antibodies against an epitope 
reflects a range of antibodies induced by sequential variants of that present in
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the infecting virus or whether it is due to the induction of antibodies against 
shared epitopes or with a relatively low specificity. The data I obtained by 
vaccinating rabbits with whole V3 loop peptides is relevant to these questions. 
The data showed that whereas the MN peptide was a very good immunogen, 
inducing high binding titres towards the autologous peptide, it also induced 
relatively high titres against the UG A and UG D peptides; a very low titre of 
reactivity towards the U31 peptide was obtained in one rabbit vaccinated with 
the MN peptide. Competitive inhibition assays indicated that the MN, UG A 
and UG D reactive antibodies were specific for the MN and UG A peptides.
The U31 peptide was a relatively good immunogen, producing high titre U31- 
specific antibodies in 2 out of 4 rabbits. However, both the UG A and UG D 
peptides were poorly or non-immunogenic in 7 out of 8 rabbits. I conclude from 
these peptide-binding data that the two consensus peptides were not very 
immunogenic but this is contradicted by the virus neutralization data for these 
sera (see below).
It appears from these results that an immunogenic peptide such as the MN 
whole loop peptide can induce high titres of antibodies which cross-react with 
similar loop structures but not with those with less conserved structures like, for 
example, the U31 loop. By extrapolation to infected humans, it would seem 
likely that the virus, which would probably have a relatively invariant V3 loop 
structure at the sero-conversion stage (Zhang et al., 1993) would also induce 
antibodies with a wide spectrum of specificities, including cross-clade 
reactivities. This would make it very difficult to develop a subtype or sequence 
specific V3 loop peptide-based assay which would be of general use. However, 
it might be possible to develop a more specific assay for use in restricted 
situations, for example, with incident cases in a small community or cohort 
where the viruses may have a relatively narrow range of V3 loop sequences. 
Further, peptides based on common sequence motifs may show less cross­
reactivity than those derived from consensus sequences. However, this is far 
from certain, in view of the wide cross-reactivities I found in sera induced by 
single well defined peptides in rabbits.
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4.2 Virus Isolation and Characterization
The second main objective of my work was to investigate the neutralization of 
Ugandan viruses by autologous and heterologous sera, including those from 
persons infected with viruses in other subtypes. At the time (1992) when this 
work was started most laboratories were studying the neutralization of cell line 
adapted viruses which seemed to have little relevance to virus control or 
protection in vivo. Although many cell line adapted Ugandan viruses were 
available in the CAMR Repository, which also contained many HIV-infected 
primary PBMC samples, these were all taken in 1985/6 and it was felt that 1 
should work with more recent primary isolates. With the help of Dr B Tegume, 
Dr B Biryahawaho and Dr JD Oram, blood samples were obtained from persons 
attending the UVRl AIDS clinic in 1992. These samples were fractionated at 
UVRl and the plasma and leucocyte fractions dispatched in liquid nitrogen to 
CAMR, where 1 attempted to isolate viruses by co-cultures in PBMC.
The rate of virus isolation was relatively low -14 out of 30 samples, i.e. 44%, but 
an even lower isolation rate (21%) was also obtained for Ugandan viruses by the 
WHO Network for HIV Isolation and Characterization (1994). This group 
blamed operational and logistical difficulties in collection and shipment of blood 
samples to collaborating laboratories but this was not a problem in the samples 1 
received. They also quoted a personal report from Dr Leitner and Dr Albert that 
they were only able to isolate 2/11 viruses from Ugandans living in Sweden. 
Much better isolation rates were obtained by Dr Desselberger and his colleagues 
at the Cambridge Public Health Laboratory for samples obtained from the MRC 
in Uganda: many of these isolates were subsequently used in this investigation.
The majority of the viruses isolated from the UVRl clinic samples had the 81 
phenotype although, as far as is known, the majority of the persons bled were 
either asymptomatic or had only minor disease symptoms. Unfortunately, many 
of the persons attending the clinic do not re-appear for further sampling or 
counselling and their clinical and serological records are somewhat
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fragmentary. As evidenced by the differences in phenotypes of three isolates in 
PBMC and in cell lines, several of the blood samples appeared to contain a 
mixture of NSI and SI viruses, possibly indicating a phenotypic transition of the 
viruses in the infected persons concerned. A similar high proportion of SI 
viruses in primary isolates was described by Simmons et al. (1996). 1 also found 
that one of the viruses which had the SI phenotype in PBMC did not produce 
syncytia in the T cell lines and that some NSI variants can grow quite well in T 
cell lines and may even be selected in the presence of SI variants.
1 found that many of the isolates gave rather low titres, mostly between 10  ^and 
1Q3, in both PBMC and MT-2 cells. These titres are very similar to those since 
reported by Simmons et al. (1996) for primary SI and NSI isolates and 1 found 
that for some isolates the amounts of virus were sufficient for virus 
neutralization assays.
Whilst there is at present little data to indicate that neutralizing antibodies have 
a protective role against HIV infection, it would be very unwise to ignore their 
possible importance. It is unlikely to be a co-incidence that the huge decrease in 
plasma virus occurs post seroconversion at a time of maximum anti-HIV 
antibody production and when the HIV-specific CMl responses are also well 
developed. Therefore, it is not possible to define the separate roles of CMl and 
neutralizing antibodies in the control of virus and the maintenance of the 
virus/host equilibrium during the asymptomatic phase of infection. This virus- 
induced "immunity" can persist for many years or perhaps, in a few individuals, 
for life. Hence, it is important to characterize both the cellular and humoral 
immune responses to infection by HIV and to harness our understanding of the 
combined protective responses towards the production of effective vaccines 
against HIV. In view of the urgent need for a vaccine for HIV in Uganda and the 
surrounding countries, it is especially important to investigate immune 
responses in Africans infected with locally dominant subtypes of virus.
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4.3 Virus Neutralization
The main objectives of the virus neutralization studies which formed the larger 
part of my work were:
Firstly, to produce quantitative data, including neutralizing antibody titres and 
specificities, of human sera against primary Ugandan isolates.
Secondly, to determine whether neutralizing antibodies were effective against 
viruses from different subtypes.
Thirdly, to investigate possible correlations between peptide binding reactivities 
and neutralizing activities in human sera.
Fourthly, to measure the neutralizing titres and specificities of antibodies 
produced in rabbits vaccinated with whole V3 loop peptides.
Finally, to examine the possible protective role of neutralizing antibodies in a 
Ugandan cohort.
My initial neutralization experiments were done using viruses isolated from 
patients attending the UVRl clinic in Entebbe. However, as described above, it 
was difficult to obtain follow up samples and data from most of these patients 
and therefore the main part of this work was done with primary virus isolates 
from the Natural History cohort in rural SW Uganda, as these became available 
from the MRC AIDS Reagent Project in 1993/4. The availability of the blood 
samples from this cohort enabled me to isolate viruses and antisera as paired 
samples. The samples with sufficient quantity of antiserum to allow replication 
of experiments were used for neutralization studies. This cohort has been 
intensely studied over the past eight years by the MRCPA in Uganda 
Programme and a large body of clinical, serological and T cell sub-set data has 
been produced. This cohort seemed an obvious choice for studies on 
neutralization specificities both within and between virus subtypes and the role 
of neutralizing antibodies on the rate of disease progression.
These viruses were available as low passage (some were also low titre) isolates 
with matching plasma. In addition, the viruses had been phenotyped using 
PBMC and T cell line cultures by Gill Carnegie and most had been genotyped 
for both gag and the gp41 region cnv gene sequences by Catriona Baker, both
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working in Dr Desselberger's Laboratory in Cambridge. I am very grateful to Dr 
Desselberger and his colleagues for making their data available prior to 
publication. A further advantage was that it was possible to obtain sequential 
serum samples and to obtain fresh blood samples for sequential virus isolation 
work. I am very grateful to Mr Amato Ojwiya for supplying serum samples 
from the MRCPA Repository in Entebbe, to Dr Dilys Morgan for arranging the 
collection and transport of the fresh blood samples from the Natural History 
cohort in rural SW Uganda and to Dr Benon Biryahawaho for allowing me to 
use the UVRl Virology laboratories to fractionate these blood samples in 
Entebbe.
My first neutralization experiments were done using MT-2 cell adapted viruses, 
since the assays were technically easier than those using primary isolates. The 
main problem with assays using primary isolates was the maintenance of viable 
cultures of PBMC in microtitre plates over a 10 day period. However, with the 
kind help of Dr Pontiano Kaleebu, this problem was solved within a fairly short 
time and I was then able to compare neutralization data obtained with MT-2 cell 
adapted and primary isolates. This was done for three Ugandan viruses, 
obtained from the UVRl clinic, and also for two different preparations of HIV- 
I mn; back-adapted to grow in PBMC and adapted to grow in MT-2 cell culture. 
Whereas there was a reasonable correlation between neutralization titres 
obtained with the two H IV -Imn viruses, the correlation was much worse for the 
Ugandan isolates: the primary isolate of one of these was neutralized by all 
seven human sera tested but the corresponding MT-2 cell adapted virus was 
only neutralized by two of these sera with titres >20. These results raise a 
question about the validity of neutralization data obtained with cell line adapted 
viruses - which are still being used to monitor immune responses in some 
vaccine trials. One may also question the validity of neutralization assays done 
with primary isolates (selected by culture in vitro); however these experiments 
are at least one stage closer to the in vivo situation. In vivo assay systems, using 
unselected plasma virus or virus infected cells possibly within the patient, have
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yet to be developed and would in all probability be either completely 
impracticable or unethical.
The main conclusions from my studies on the neutralization of primary isolates 
is the majority of sera from infected persons neutralized a fairly large number of 
viruses, and many had relatively high neutralization titres - over 640 m many of 
the Natural History cohort plasma. These results were unexpected as most of 
the previous studies with primary isolates reported relatively low titre 
neutralizing antibodies which in some cases were effective against a restricted 
number of viruses (Trkola et ah, 1995; Kostrikis et ah, 1996; Mascola et ah, 1996a; 
Moore et ah, 1996). However comparison of my results with some work by 
Kaleebu with Ugandan isolates revealed similar levels of p24 and neutralizing 
antibody titres (Kaleebu, 1995). The neutralizing antibody titres found by Moore 
et ah (1996) for Ugandan subtype A and D isolates were shown in many cases as 
>128, where 1:128 was his highest serum dilution. The neutralizing antibody 
titres found by Kostrikis et ah (1996) for subtype A isolates were very similar to 
my titres against primary isolates. Only two (C24 and UG92001) out of the 18 
viruses that I tested were not neutralized by their autologous serum: 
unfortunately, due to the very small volume of serum available, it was not 
possible to test this serum C24 against a range of viruses so this atypical result 
could not be proved rigorously. Serum UG92001 neutralized 4 other Ugandan 
subtype D viruses with titres ranging from 40 to >320 and HIV-Imn subtype B 
with a titre of >320.
Many of the sera neutralized all the primary isolates tested, i.e., 8 /8 , 9 /9 , 
10/10, etc, and several others neutralized all but one or two of the viruses 
tested. However, a few sera neutralized only one or two viruses: for example, 
serum UG92001, from Entebbe/  Kampala, neutralized only 4 out of 7 viruses 
tested and serum 3004, from the Natural History cohort neutralized only 2 out 
of 10 viruses isolated from the cohort. A similar correlation between primary 
isolates' susceptibility to neutralization by autologous and heterologous 
antisera has been reported by Bongertz et ah (1997).
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The viruses used in this work, especially those obtained from the Natural 
History cohort in rural SW Uganda, were not positively selected and are 
reasonably representative of those circulating within the local population. 
Therefore, these neutralization data show that most infected persons mount 
an antibody response which is able to neutralize many of the viruses which 
are circulating in their community. This has good implications for the 
prospective protective effects of neutralizing antibody responses which could 
be induced in the majority of vaccinees especially if the vaccine included 
immunogens from several different viruses.
Although most of the primary isolates were very sensitive to neutralization by 
one or more of the sera tested, being neutralized by dilutions of sera typically 
between 1:10 and 1:320 or 1:640, one or two were more resistant. For example, 
the neutralization titres against virus UG93070, from the Entebbe/Kampala 
area, ranged between <10 to 40, in marked contrast to those obtained with 
other isolates. The reasons for this variation in sensitivity are not known. Von- 
Gegerfelt et al. (1991) observed that some viruses isolated a year or two after 
seroconversion were no longer neutralized by sera taken previously and 
argued that this showed that new, neutralization-resistant variants had arisen 
in the interval between sampling. It was therefore of interest to compare the 
susceptibilities of sequential isolates from the Natural History cohort in rural 
SW Uganda, taken about 2 years apart, to neutralization by sera taken over 
the same period. The two isolates of virus 3049 were almost equally sensitive 
to neutralization by the four autologous plasma: these sequential plasma also 
had essentially the same titres against several other virus isolates, indicating 
that there was little qualitative or quantitative change in virus sensitivity or 
neutralizing activity over the two year period. The two virus 3029 isolates 
were equally sensitive to neutralization by autologous sera, but the later virus 
was much more resistant towards heterologous sera. Hence, although I found 
no evidence for the appearance of resistance towards autologous sera, one of 
the two viruses appeared to have become much more resistant to other sera. 
Clearly, more data involving more viruses for a much longer period is
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required to show if this is a general rather than isolated phenomenon and to 
assess its biological/immunological importance, if any.
These neutralization studies were started in 1993 when it was not known 
whether viruses neutralization would be subtype specific. Since then there 
have been a few reports that neutralization of isolates by hum an or animal 
sera is not subtype specific (Trkola et ah, 1995; Mascola et al., 1996a; Moore et 
al., 1996). An extensive study involving primary isolates from all of the 9 
subtypes of the major group of HIV-1 identified five neutralization 
"serotypes" which, with the exception of the subtype E isolates from Thailand, 
did not correlate with the genotypes of the isolates (Kostrikis et al., 1996).
My data shows that Ugandan isolates in subtypes A and D are cross 
neutralized by sera induced by virus of either subtype, indicating a set of 
shared immunogenic epitopes which is potentially valuable in vaccine 
development. However, sera GB8 from a subtype B virus, obtained from an 
AIDS patient in the UK, neutralized only 3 out of 8 Ugandan isolates (2 
subtype D's and 1 of unknown subtype) and had very low titres (<15) against 
two of those. Moreover, a monoclonal antibody induced by a V3 loop peptide 
encoded by H IV -Imn (Gorny et al., 1991) neutralized only one out of 8 
Ugandan isolates. Hence, in view of the low level cross neutralization of some 
subtype B sera for subtype A or D viruses, it could be very im portant that a 
vaccine for use in Uganda should be based on subtype A and D viruses and 
not, as is the case for a vaccine currently undergoing trial in Uganda, on an 
American subtype B virus. However, the converse situation, that a vaccine 
based on subtype A and D viruses may not be effective against viruses in 
other subtypes, would probably not be of concern in Uganda. Although there 
have been reports (Bruce et al., 1993; Kaleebu et al., 1995 and G Baker, MA 
Thesis, University of Cambridge) of the presence of subtype B, C and G 
viruses in Uganda, only subtype A and D pro viruses were detected by gag 
sequence analyses of over 120 proviruses from the MRC cohorts (Yirrell et al. - 
Submitted for publication (1997) and Kaleebu et al, 2000).
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A possible complication in the development of vaccines for HIV is that the 
vaccine may induce virus-enhancing antibodies which could accelerate the 
rate of virus replication. I found some evidence for enhanced virus production 
in six out of 25 Ugandan isolates. For example, in one experiment with 
UG92001, a virus isolated from a UVRl clinic blood sample, virus yield was 
increased by 28% by antiserum C971 at 1/80 dilution. The yield of another 
virus, 3050 from the Natural History cohort in rural SW Uganda, was 
enhanced by between 20% and 70% by relatively high dilutions (1/80 to 
1/320) of four antisera. Since all sera were routinely heat-treated before use, it 
is unlikely that these effects would have been due to the kind of complement- 
dependant enhancement effect reported by (Robinson et al., 1988a). As I did 
not investigate the effect of added complement on virus neutralization, my 
data does not show whether enhancing antibodies were widespread in the 
Ugandan sera.
Comparison of the serological data with the corresponding virus 
neutralization patterns indicated that there was no clear cut relationship 
between the two types of reactivity. For example, several of the plasmas 
obtained from the UVRl clinic did not react with the U31 V3 loop peptide but 
neutralized the HIV-lusi primary isolate, with neutralization titres which 
were not significantly higher than that obtained with plasma which reacted 
strongly with the U31 peptide. Further, plasma UG92035, which did not react 
with any of the V3 loop peptides tested, neutralized 6 out of the 8 viruses 
tested. Data obtained with plasm a/virus samples obtained from the natural 
history cohort in rural SW Uganda also showed there was no correlation 
between serotype and neutralization phenotype. Hence, my data indicates 
that, for many of the plasm a/virus interactions, at least part (and possibly a 
major part) of the neutralizing activity was not directed against the linear V3 
loop epitopes.
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I also attempted to correlate the virus neutralizing activities of antisera 
produced by vaccinating rabbits with whole V3 loop antibodies with data 
obtained in peptide-based ELISA. The MN peptide induced the highest titred 
antibodies in both the serological and virus neutralization assays. However, 
the U31 peptide induced a relatively good peptide-specific serological 
response but only a very weak neutralizing activity and did not neutralize the 
autologous virus. The sera induced by the UG A consensus peptide reacted 
strongly w ith the MN peptide and neutralized the back-adapted H IV -Imn and 
2 /8  Ugandan isolates. However, the UG D consensus peptide induced sera 
which reacted poorly with peptide antigens but neutralized several Ugandan 
isolates. Hence, these experiments gave conflicting results, ranging from a 
good correlation for the MN peptide and a very poor one for the U31 peptide. 
Taking these uncertainties and those obtained in studies with hum an sera into 
account, it would probably be unwise to base predictions of virus neutralizing 
specificities or titres on data obtained in peptide binding assays with V3 linear 
epitopes.
4.4 Correlation of Clinical and Virus Neutralization Data
One of the main objectives of this study was to determine whether the 
presence of neutralizing antibodies could influence the rate of disease 
progression in the MRC Natural History cohort in Uganda.
As discussed earlier, persons in the cohort are tested at 3 monthly intervals 
making it ideal for this type of study, especially since much work on virus 
isolation and characterization had been done in UVRl at Entebbe and in the 
Public Health Laboratory at Cambridge. However, there were a num ber of 
problems in attempting to correlate the clinical, virological and virus 
neutralization data. For example, it was only possible to study a fairly limited 
number of viruses. I worked with 14 out of the 32 viruses isolated at 
Cambridge, but 4 of these grew very poorly in PBMC: hence, it was not 
possible to get neutralization data for these viruses. In addition, relatively few 
persons infected with these viruses developed AIDS, by which disease stage
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the immune system would be impaired and unable to maintain humoral and 
cellular immunity. Although the exact date of seroconversion is not known, 
two of the persons included in my study were infected in late 1990/ early 1991 
and the other 12 between early 1992 and early/m id 1993. Clinical data was 
obtained for the 3 year period up to early 1997, by which time most of the 
people had been infected for between 4 and 6 years. At that time Morgan et al. 
(1997) reported that in this cohort the mean time from infection to AIDS was
4.4 years and to death was 6 years. From their data it would be expected that 
the majority of the subjects included in my study would have developed 
AIDS but, in fact, only two of the 14 persons had progressed beyond WHO 
stage 3. Both of these persons died - one about 3-4 years after infection; 
unfortunately, it was not possible to obtain clinical data for the other person 
who died. Although six of the other 11 persons had progressed to WHO stage 
3 within the study period, it would not be expected that they would have 
shown a marked loss of virus neutralizing activities at this stage.
Excluding the one person who died for whom clinical data was available, 
three others showed a marked decrease in their CD4 counts, two of whom 
were at WHO disease stage 3 and one at stage 2. As one of the viruses from 
the stage 3 patients was not tested w ith the autologous plasma and the other 
was not tested with heterologous plasma, full neutralization data was 
obtained only for the latter, whose plasma had a relatively low titre against 
the autologous virus and high titres against heterologous viruses.
A further problem was that, w ith two exceptions, the viruses tested were 
isolated relatively soon after infection, i.e. within two years. Since there is 
good evidence (Von-Gegerfelt et al., 1991) that sequential virus isolates may 
not be neutralized by preceding sera, it would have been more relevant to 
have studied viruses from later samples from the Natural History cohort in 
rural SW Uganda. I was able to do this for two viruses, which I isolated two 
years after their first isolation at Cambridge. Both of these were from persons 
who showed a marked decline in their CD4 cell counts; however the two 
isolates gave rather conflicting data. All but one of the sequential plasma
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samples (taken over the same two year period) gave similar titres against the 
early and late isolates of the two autologous viruses. However, although one 
of the later isolates was much more resistant to neutralization by heterologous 
plasma, the other was still fairly strongly neutralized by those plasma which 
neutralized the early isolate. Hence, there were no clear cut differences 
between the early and late isolates that could be correlated to change in 
disease status, as shown by the drop in CD4 cell counts. In summary, I 
obtained insufficient data in this rather limited study to test thoroughly the 
possible correlation between the clinical and neutralization data.
It might be expected that the development of a strong virus neutralizing 
antibody response to HIV infection would help protect against disease and 
death. I attempted to see if there was any evidence that neutralizing 
antibodies have a protective effect from the comparison of neutralization data 
and the clinical data available from samples from the Natural History cohort. 
Analysis of the change in the CD4+ cell count with the autologous virus 
neutralizing titres for 8 samples for which both data were available (as shown in 
Table 14 and Figure 20) was insufficient to determine a relationship between the 
presence of autologous virus neutralizing antibodies and disease progression.
Clearly, additional neutralization data obtained from sequential plasma and, 
if possible, later virus isolates, would be required to extend these studies in 
future for a more meaningful test of the possible correlations between disease 
progression and the presence of neutralizing antibodies. These data would be 
especially useful in cases where individuals have progressed to AIDS.
I hope that these preliminary studies may be extended, especially as the 
cohort is still being followed and the MRCPA and UVRl have all the 
necessary facilities and expertise.
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Appendix III
HIV prevalence among women attending antenatal clinics in Africa. (Adapted from the 
UNAIDS and World Health Organization HIV/AIDS Epidemiological Surveillance 
Update for the WHO African Region 2002.)
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APPENDIX IV 
Materials List
Antisera, plasmas, viruses and peptides were as described in the Materials and Methods 
text.
A ll chemicals mentioned in the text, but not listed below  were obtained from The Sigma 
Chemical Company.
Antibody binding assay 96 well plates - Nunc, Maxisorb (high affinity binding).
Dilution 96 well plates - Coming, Delta (low  affinity binding).
Foetal C alf Serum - ICN Flow.
Anti-human IgG-horse radish peroxidase conjugate - Sigma.
Anti-rabbit IgG-horse radish peroxidase conjugate - Jackson Immuno Research 
Laboratories Inc..
3,3',5,5'-tetramethylbenzidine dihydrochloride tablets - Sigma.
Activated CH-Sepharose - Pharmacia.
Keyhole Limpet Haemocyanin - Sigma.
PDIO column (Sephadex G-25 medium column) - Pharmacia.
Sephadex G-50 fine column (1.6 x30cm ) - Pharmacia.
Freund's Incomplete Adjuvant - ICN Flow.
Dutch modified R P M I1640 cell medium - ICN Flow.
Ficoll-Paque - Pharmacia.
Centrifuge tubes (50ml and 15ml) - Coming.
W ide bore pastettes - Elky Eireann.
Kanamycin - Sigma.
Phytohaemagglutinin (PHA) - Sigma.
Interleukin-2 (IL-2) - MRC-ARP.
EDTA Vacutaner tubes - Becton Dickinson Vacutaner Systems.
Cell culture flasks (25 cm^) - Coming.
Empigen detergent - Calbiochem N ova Biochem  UK  LTD.
P24 Antigen assay kit - Coulter.
Cryotubes - Nunc.
96 w ell round bottomed plates, tissue culture treated - Coming.
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APPENDIX V
Definition of the WHO Clinical staging:
Clinical Stage 1 -
1. Asymptomatic.
2. Generalized lymphadenopathy.
Performance Scale 1: Asymptomatic, normal activity.
Clinical Stage 2 -
3. Weight loss <  10% body weight and >5% .
4. Minor mucocutaneous manifestations.
5. Herpes zoster within the last 5 years.
6. Recurrent upper respiratory tract infections.
And/or Performance Scale 2: Symptomatic, normal activity.
Clinical Stage 3 -
7. Weight loss >  10% body weight.
8. Unexplained chroitic diarrhoea >  1 month.
9. Unexplained prolonged fever >  1 month.
10. Oral candidiasis.
11. Oral hairy leukoplakia.
12. Pulmonary TB within 1 year.
13. Severe bacterial infections.
And/or Performance Scale 3: Bed-ridden <  50% o f  day during last month. 
Clinical Stage 4 -
14. HIV wasting syndrome.
15. Pneumocystis pneumonia.
16. Toxoplasmosis o f  brain.
17. Cryptosporidiosis with diarrhoea >  1 month.
18. Cryptococcus extra-pulmonary.
19. CMV o f  an organ oÂer than the liver, spleen or lymph nodes.
20. HSV infection, mucocutaneous >  1 month, or visceral.
21. Progressive multifocal leukoencephalopathy.
22. Disseminated endemic mycosis.
23. Candidiasis o f  oesophagus, trachea, bronchi or lungs.
24. Atypical, disseminated mycobacteriosis.
25. Non-typhoid, salmonella septicaemia.
26. Extra-pulmonary TB.
27. Lymphoma.
28. Kaposis sarcoma.
29. HTV encephalopathy.
And/or Performance Scale 4: Bed-ridden >  50% o f  day.
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A PPE N D IX  VI
BIN D IN G  O F A N TIBO DIES TO V 3 L O O P SPECIFIC PEPTID ES.
SERA
(SU BTY PE)
PEPTIDES U SED  IN  ASSAYS
M N
(USA)
U G A
(UGANDA)
U G D
(UGANDA)
U31
(UGANDA)
U 455 (A) 2000 375 - 6000
1 .3 9 /1 .3 8 0.7/0.78 - 1.4
U 4 1 3 3 (D ) 5000 - 4000 4000
1 .8 7 /1 .6 8 - 1 .0 /0 .8 7 0.9/0.92
U 1685(D ) 6000 800 6400 8000
1 .2 /1 .1 2 0 .7 /0 .6 1 1 .3 /1 .1 4 1 .9 /2 .0
U653 (D) 4000 500 4800 5000
1 .0 6 /1 .1 5 0.6 /  0.63 1.4/1.29 1 .4 /1 .3 6
U 4 6 2 (D ) 60000 2900 1600 3000
1:400
1.65/1.52
1.1 / 1 . 1 0 .8 2 /0 .8 4 1 .0 5 /1 .1 2
U 2999 (D) 20000 - 5500 3000
1:400
1.38/1.36
- 1 .7 /1 .7 8 0 .5 /0 .4 3
U4132 (D) 20000 - - 5000
1:400
1 .6 /1 .7 4
- - 1 .1 /0 .9 7
U 1 6 65(D ) 5 0 0 0 /4 7 0 0 1 0 0 0 /9 8 0 1 1 0 0 /1 1 0 0 4000 /  4100
1.28/1.39 0.8/0.74 0 .8 /0 .8 6 1 .2 /1 .1 6
U 5 0 5 5 (D ) 20000 2000 10000 2000
1:400
1 .9 3 /1 .8 6
0.8/0.84 1:400
1 .8 /1 .7 7
1 .2 6 /1 .1 3
A CP37024 1 0 0 0 /1 1 0 0 200 /  220 1000 /1000 -
(D) 0.94 /  0.82 0 .3 /0 .3 6 1 .0 8 /1 .2 4
A CP37025 4500 /  4700 400 /  420 - -
(A) 1 .2 5 /1 .1 7 0 .4 /0 .4 6
ACP37026 45000 7500 7000 2000
(A) 2.08/2.15 1 .9 /1 .8 2 1 .7 /1 .5 6 1 .2 9 /1 .2 4
A CP37027 3 2 0 0 /3 0 0 0 - 3 0 0 /3 2 0 -
1 .3 /1 .2 4 - 0 .2 2 /0 .2 6 -
ACP38051 1 8 0 0 /1 7 0 0 - - -
1 .0 7 /1 .1 5
Titres (som e shown in duplicate) are reciprocals o f  serum dilutions giving an EIA  
reading o f  0.5 CD units and duplicate absorbancy readings at 1:200 serum dilution are 
shown below  these. Where indicated som e absorbancy readings are at 1:400 serum  
dilution.
- =  titre <  100 or that the absorbancy reading at 1:200 serum dilution was not 
significantly above the negative control.
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Appendix VI continued:
Figure showing the correlation between Antiserum Dilution at 0.5 OD units and 
the Absorbance at a single 1:200 Antiserum dilution for a range of antisera with 
the 4 peptides MN, UG A, UG D and U31.
Each point represents the intersection of the 2 readings for one antiserum.
The lines represent the correlation for the 4 peptides.
2
1
0
83 75 62 40
Reciprocal of Antiserum Dilution (x 1000) at 0.5 OD units
■MN
Peptide 
UG D ▼UG A #U 31
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APPENDIX VII
This com bination o f  data illustrates w hy I decided to  use 75%  inhibition o f  p24 production as my 
neutralization cu t o ff  point. The 2 graphs show  that the 90% and 50% cut o ff points (indicated here by red 
horizontal lines) do not cross as m any data hnes as the 75%  cut o ff  point would. (To view  these graphs in  
detail see Figures 16ii c/ and 16v a/.) This is backed up  by the data in the table showing the antisera titres 
at the 3 inhibition levels for the 2 isolates. H ere you can see that 90%  inhibition m isses the antisera that 
do not neutralize the isolates to th is degree (show n by and that 50% inhibition m isses the antisera 
w bich are still inhibiting the viral p24 production to this degree at the m axim um  dilution (show n by 
“>n”). 75% inhibition o f  p24 production gave a  varying range o f  titres across a broad range o f  antisera for 
many o f  the viral isolates.
Isolate 3025 Isolate 3049 (26.05.94)
50%
90%'
90%
PtesTO OMai (King 2 scat)
•  3021 A3025 HOCOS
-O K  HiUon —50* WOAm ■  3011 ■  3013 ■  30B •  3021
A302S ■  3028 •  3032 V3048
■  3 0 «  (260554) A  3045 (210256) •  3049 (290196) Y  3049 (280596)
T3052 ■jSjCortral —90% Mtdian — 60% IrtiSon
NEUTRALIZATION OF UGANDAN HIV-1 ISOLATES IN PBMC CULTURES.
Plasma
(Subtype)
Virus Isolate (Subtype) 
% Neutralization
3025 (D) 
50%
3025 (D) 
75%
3025 (D) 
90%
3049 (D) 
50%
3049 (D) 
75%
3049(D) 
90%
3011 (A) >320 160 - 80 30 -
3013 (C) >320 120 - 340 200 -
3018 (D) 80 40 - 420 80 -
3021 (A) 120 60 100 60 20
3025 (D) >320 80 1 160 60 -
3028 {AID) >320 15 ! 320 200 -
3029 (D) ND ND ND >640 ND 100
3032 (D) ND ND ND >640 640 320
3048 (D) ND ND ND >640 >640 380
3049 (D) ND ND ND 80 40 -
3050 (D) ND ND ND 640 - -
3052 (A) ND ND ND 640 320 200
Figures shown as reciprocal of plasma dilution giving 50%, 75% or 90% inhibition as determined by p24 detection. 
ND = Assay not done. - = Inhibition < 50%, 75% or 90%. * = gag subtype A and env  subtype D.
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